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Abstract: Flavonoids are a large family of compounds associated with a broad range of biologically
useful properties. In recent years, synthetic compounds that contain two flavonoid units linked
together have attracted attention in drug discovery and development projects. Numerous flavonoid
dimer systems, incorporating a range of monomers attached via different linkers, have been reported
to exhibit interesting bioactivities. From a medicinal chemistry perspective, the 1,2,3-triazole ring
system has been identified as a particularly attractive linker moiety in dimeric derivatives (owing to
several favourable attributes including proven biological relevance and metabolic stability) and
triazole-bridged flavonoid dimers possessing anticancer and antimalarial activities have recently
been reported. However, there are relatively few examples of libraries of triazole-bridged flavonoid
dimers and the diversity of flavonoid subunits present within these is typically limited. Thus, this
compound type arguably remains underexplored within drug discovery. Herein, we report a modular
strategy for the synthesis of novel and biologically interesting triazole-bridged flavonoid heterodimers
and also very rare heterotrimers from readily available starting materials. Application of this strategy
has enabled step-efficient and systematic access to a library of structurally diverse compounds of this
sort, with a variety of monomer units belonging to six different structural subclasses of flavonoid
successfully incorporated.
Keywords: flavonoid; triazole; dimer; trimer; hybridization; structural diversity
1. Introduction
Flavonoids are a large family of polyphenolic compounds that represent dietary constituents
of importance to good health as well as a potentially important new class of pharmaceutical lead
substrates [1–3]. There are several subclasses of flavonoids, including aurones, chalcones, coumarins,
flavones and isoflavones, which serve as the core structural units of numerous biologically active
molecules [4–7]. In recent years, synthetic compounds that contain two such flavonoid units linked
together (so-called flavonoid dimers) have garnered attention from the synthetic and medicinal
chemistry communities [8–17]. The generation of species that integrate two pharmacophoric entities
(both homo- and hetero-dimers) is a common strategy in drug discovery [18,19] and numerous
flavonoid dimer systems, incorporating a range of monomers linked in a variety of ways, have been
reported to exhibit biologically useful properties [8–17]. From a medicinal chemistry perspective,
the 1,2,3-triazole ring system has been identified as a particularly attractive linker moiety owing to
various favourable properties including ease of synthesis, proven biological relevance and metabolic
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stability [11,18,20]; indeed, triazole-bridged flavonoid dimers possessing anticancer [10,11] and
antimalarial [11] activities have recently been reported (Figure 1). However, there are relatively
few examples of libraries of triazole-bridged flavonoid dimers, and the diversity of flavonoid subunits
present within these is typically limited. Thus, the triazole-bridged flavonoid dimer compound
type arguably remains underexplored within drug discovery. We were interested in investigating
the biological potential of triazole-bridged flavonoid dimers further and so sought access to a more
structurally diverse collection of such compounds incorporating a wide range of flavonoid units.
In addition, we were also interested in accessing triazole-bridged trimeric derivatives, which are
also expected to have interesting biological properties. Though the synthesis of triazole-bridged
flavonoid trimers has previously been reported [10], compounds of this sort are very rare and they
have received relatively little attention from synthetic and medicinal chemists. Herein, we report the
development of a modular strategy for the synthesis of novel triazole-bridged flavonoid heterodimers
and heterotrimers. Application of this strategy has enabled concise and systematic access to a library
of 46 structurally diverse compounds of this sort (41 dimers and five trimers) from readily available
starting materials.
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2. Results and Discussion 
2.1. Outline of the Synthetic Strategy 
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envisaged a branching-type strategy to access triazole-bridged flavonoid dimers and trimers, based 
around the use of iterative copper-catalysed “click”-type alkyne-azide 1,3-dipolar cycloadditions 
(Scheme 1) [21]. It was anticipated that flavonoid monomer units bearing a terminal alkyne group 
(“alkyne-flavonoid” building blocks) could be reacted with a range of flavonoid monomer units 
bearing a terminal azide group (“azido-flavonoid” building blocks) to furnish diverse and novel 
triazole-bridged flavonoid homo- and hetero-dimers (of the general structure A, Scheme 1). The 
presence of a free hydroxyl functionality in either monomer unit would allow for post-cyclisation 
introduction of a terminal alkyne group in the dimers, thus providing the necessary synthetic handle 
for a further cycloaddition with varied alkyne-flavonoids to furnish structurally diverse triflavonoid 
derivatives of the general forms B and C (Scheme 1). The presence of additional synthetic handles in 
any given monomer unit should also allow for further elaboration of the dimers and trimers. Overall, 
it was anticipated that this modular strategy would enable step-efficient and facile access to a 
structurally diverse library of triazole-bridged flavonoid dimers and trimers through the use of a 
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Figure 1. Three examples of biologically active triazole-linked flavonoid dimers. The flavonoid
subunits in each example are highlighted in colours. (a) A modulator of multidrug resistance in some
cancers [10]; (b) A modulator of multidrug resistance in some cancers [10]; (c) A compound with
anticancer activity and antimalarial activity [11].
2. Results and Discussio
2.1. Outline of the Synthetic Strategy
Inspired by previous studies on the synthesis of triazole-linked flavonoid libraries [10,11] we
envisaged a branching-type strategy to access triazole-bridged flavonoid dimers and trimers, based
around the use of iterative copper-catalysed “cl ck”-type alkyne-azide 1,3-dipolar cycloadditions
(Scheme 1) [21]. It was anticipated that flavonoid monomer units bearing a terminal alkyne
group (“alkyne-flavonoid” building blocks) could be reacted with a range of flavonoid monomer
units bearing a terminal azide group (“azido-flavonoid” building blocks) to furnish diverse and
novel triazole-bridged flavonoid homo- and hetero-dimers (of the ge eral stru ture A, Scheme 1).
The presence of a free hydroxyl functionality in either monomer unit would allow for post-cyclisation
introduction of a terminal alkyne group in the dimers, thus providing the necessary synthetic handle
for a further cycloaddition with varie alkyne-flavonoids to furnish structurally diverse triflavonoid
derivatives of the general forms B and C (Scheme 1). The presence of additional synthetic handles in
any given monomer unit should also allow for further elaboration of the dimers and trimers. Overall, it
was anticipated that this modular strategy would enable step-efficient and facile access to a structurally
diverse library of triazole-bridged flavonoid dimers and trimers through the use of a variety of different
flavonoid building blocks belonging to different flavonoid structural subclasses.
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Scheme 1. Overview of the branching-type strategy towards structurally diverse triazole-bridged
flavonoid heterodimers and heterotrimers. It was anticipated that homo- dimers and trimers could
also be accessed through the use of appropriate building blocks.
2.2. Building Block Design and Synthesis
In order t facilitate the generati n of structural diversity in the final c mpound c ll ction,
building blocks belonging to a variety of flavonoid structural subclasses (chalcone, coumarin,
flavone, aurone, flavonol and isoflavone, see Scheme 1) and derivatives thereof were targeted.
Structural diversity, including functional group diversity, within building blocks of some subclasses
was also sought in order to further increase the overall structural diversity of the final library
(as well as providing a means of introducing additional biomolecular-interacting elements into the
library compounds, for example, additional bio-relevant heterocyclic motifs and hydrogen-bonding
functi naliti s). Variation in the position of the key alkyne/azid ligation handles round the flavonoid
structures was also envisaged as a strategy to further increase library structural div sity, since this
would enable access to different structural isomers of any given dimers/trimers. On the basis
of synthetic tractability, various alkyne-chalcones, flavones and isoflavones and azido-chalcone,
flavonols and flavones were targeted. Hydroxyl-substituted building blocks were also required
in order to allow access to trimeric species (as outlined in Scheme 1). Based on predicted synthetic
accessibility, the syntheses of a hydroxyl-substituted alkyne-chalcone, alkyne-flavonol, azido-chalcone
and azido-flavonol were targeted.
2.2.1. Synthesis of the Alkyne-Flavonoid Building-Blocks
Alkyne-Chalcones
Hydroxyl-substituted alkyne-chalcone 4 was accessed from phenol 1 via a two-step sequence:
alkylation with propargyl bromide proceeded smoothly to yield aldehyde 2 and subsequent
Claisen-Schmidt aldol reaction with acetophenone 3 yielded the target compound 4 (Scheme 2) [22].
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Scheme 2. Synthesis of hydroxyl-substituted alkyne-chalcone building block 4.
Structu lly divers alkyne-chalcone building blocks 20–26, including chalconoid derivatives
incorp rating a range of heteroaromatic caffolds and an unusual ferrocenyl motif, were generated
from aldehydes 5–9 respectively b Claisen-Schmidt aldol condensation with various acetophenone
derivatives followed by propargylation (Scheme 3).
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Scheme 3. Synthesis of alkyne-chalcone building blocks 20–26.
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Alkyne-Flavones
Propargylation of commercially available flavones 27–29 proceeded smoothly to furnish
alkyne-flavones 30–32 with the alkyne synthetic handle appended at various positions on the flavone
core unit (Scheme 4) [23,24].
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Alkyne-Flavonol
The preparation of alkyne-flavonol 36 commenced with the synthesis of chalcone 35 via the
Claisen-Schmidt reaction of the alkyne-substituted benzaldehyde 34 with acetophenone 10. Subsequent
Algar-Flynn-Oyamada (AFO) oxidation [22] of the chalcone 35 proceeded smoothly to furnish 36
(Scheme 5).
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Alkyne-Isoflavones
The preparation of the alkyne-isoflavone building blocks 45 and 46 commenced with the acylation
of commercially available substituted phenols 37 and 38 with phenylacetic acids 39 and 40 to afford
the deoxyb nz ins 41 and 42 [25]. Sub equent cyclization of 41 and 42 in methanesulfonyl chloride
afforded the corresponding isoflavones 43 and 44 which then underwent propargylation to yield the
desired alkyne-isoflavones 45 and 46 (Scheme 6) [25].
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Alkyne-Coumarin
Alkyne-coumarin 48 was synthesised by propargylation of hydroxycoumarin 47 in the presence
of anhydrous potassium carbonate (Scheme 7) [11].
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Alkyne-Aurone
Alkyne-aurone 56 was prepared from commercially available phloroglucinol 49 (Scheme 8).
Condensation with chloroacetonitrile in the presence of ZnCl2 furnished imine 50 [26]. Subsequent
hydrolysis under acidic conditions afforded ketone 51 which was then treated with methanolic sodium
methoxide to give hydroxybenzofuranone 52 [26]. Methyl protection of the free hydroxyl groups
afforded benzofuranone 53 which was then condensed with 3-hydroxybenzaldehyde 54 under basic
conditions to yield hydroxyaurone 55. Subsequent propargylation gave the desired alkyne-aurone 56
in an excellent yield (Scheme 8).
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2.2.2. Synthesis of the Azido-Flavonoid Building Blocks
Azido-Cou arin
Azido-cou arin 58 was prepared from readily available hydroxycoumarin 47 by alkylation
(to form 57) followed by reaction with sodium azide (Scheme 9) [27].
olecules 2016, 21, 1230 6 of 56 
 
lkyne- ou arin 
lkyne-cou arin 48 as synthesised by propargylation of hydroxycou arin 47 in the presence 
of anhydrous potassiu  carbonate (Sche e 7) [11]. 
 
Sche e 7. Synthesis of alkyne-cou arin 48. 
Alkyne-Aurone 
Alkyne-aurone 56 was prepared from commercially available phloroglucinol 49 (Scheme 8). 
Condensation with chloroacetonitrile in the presence of ZnCl2 furnished imine 50 [26]. Subsequent 
hydrolysis under acidic conditions afforded ketone 51 hich as then treated ith ethanolic 
sodiu  ethoxide to give hydroxybenzofuranone 52 [26]. ethyl protection of the free hydroxyl 
groups afforded benzofuranone 53 hich as then condensed ith 3-hydroxybenzaldehyde 54 
under basic conditions to yield hydroxyaurone 55. Subsequent propargylation gave the desired 
alkyne-aurone 56 in an excellent yield (Sche e 8). 
 
 . t i  f l - r  . 
2.2.2. Synthesis of the zido-Flavonoid Building Blocks 
 
i  58 as prepared fro  readily available hydroxycou arin 47 by alky ation (to 
for  57) follo ed by reaction ith sodiu  azide (Sche  9) [27]. 
 
Sche e 9. Synthesis of azido-cou arin 58. 
  
Br
K2 3
Ac tone
eflux
47 48; 58
l
Zn l2, l l l
a 3
e
eflux
K , 2
50; 20 51; 25
52; 7153; 79
Br
K2 3
Ac tone
eflux
49
55; 78
56; 96
54
1  l
l
e , rt F, 80 o
Et2               
0 o  to rt
eflux
3I 
K2 3
Br 3Br Br
Acetone, eflux
K2 3
47 57; 16 58; 98
F, 100 o
a 3
Scheme 9. Synthesis of azido-coumarin 58.
Molecules 2016, 21, 1230 7 of 59
Azido-Chalcones
Hydroxyl-substituted azido-chalcone 61 was prepared by a three step sequence from
phenolic aldehyde 33 (Scheme 10). Reaction with 1,2-dibromoethane generated aldehyde 59 and
subsequent nucleophilic substitution with sodium azide produced azide 60 in an excellent yield.
Claisen-Schmidt aldol condensation with ketone 10b then yielded the target compound 61 [22].
Alternatively, Claisen-Schmidt aldol condensation of aldehydes 64–66 and 7 with readily-prepared
azido-ketone 63 furnished azido-chalcone building blocks 67–70 respectively (Scheme 11) [22].
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Azido-Flavonols
Aldehydes 59 and 72 nd 73, generated by alkylatio of 33, 71 and 1 respectively with
1,2-dibromoethane, were r acted with sodium azide to form 60 and 74 and 75 espectively (Scheme 12).
Subsequent aldol condensation with acetophenones 10 or 3 (see Scheme 12) fur ished chalc nes 61
and 76–78 and AFO proceeded smoothly in all cases to furnish azido-flavonols 79 and 80–82 in good
yields [22].
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Azido-Flavones
Azido-flavones 85 and 86 were readily accessed from commercially available hydroxyflavones 28
and 29 by reaction with 1,2-dibromoethane to forge 83 and 84 followed by nucleophilic substitution
with sodium azide (Scheme 13) [10,28]. Azido-flavone 87 was prepared in an excellent yield from
chalcone 76 by an iodine-mediated oxidative cyclization (Scheme 14).
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Azido-Aurones
Mercury(II) acetate-mediated oxidative cyclization of chalcones 61 and 76 furnished azido-aurones
88 and 89 respectively in excellent yields (Scheme 15) [29].Molecules 2016, 21, 1230 9 of 56 
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2.2.3. Synthesis of Triazole-Bridged Flavonoid Dimers
With the alkyne- and azido-flavonoid building blocks in hand, we were ready to forge a series of
dimeric combinations via triazole formation. Thus, various pairs of building blocks were subjected
to standard copper-mediated “click” cycloaddition conditions to generate 41 distinct and diverse
triazole-bridged flavonoid dimers (compounds 90–130, Schemes 16–20). The reactions generally
proceeded smoothly and with high levels of regioselectivity and isolated yields of the target compounds
were typically moderate-to-good. Six different biologically-relevant flavonoid structural subclasses
(chalcone, flavonol, aurone, flavone, coumarin and isoflavone) were successfully incorporated into
the dimer library together with other biologically-relevant features, and variation within building
blocks belonging to certain subclasses allowed for the generation of additional structural diversity
in the library and the concomitant introduction of additional biomolecule-interacting elements
(for example, the varied heterocyclic motifs exhibited by the chalcone-chalcone dimers 90–97).
Several compounds also featured groups that could provide synthetic handles for further elaboration or
diversification (for example, compounds 96 and 97 and 105 and 106 contain a hydroxyl group and the
aryl-bromide group present in 107 and 108 could conceivably be exploited in various metal-catalysed
cross-coupling processes).
2.2.4. Synthesis of Triazole-Bridged Flavonoid Trimers
Propargylation of the free phenolic hydroxyl groups of triazole-bridged flavonoid dimers 126, 122,
92 and 110 and 106 led to the formation of alkyne-capped derivatives 131–135 respectively. These were
successfully coupled with three azido-flavonoid building blocks (86 for 131 and 132; 87 for 133;
and 89 for 134 and 135) via copper-catalysed triazole formation to furnish five structurally diverse
triazole-bridged flavonoid trimers 136–140 (Scheme 21).
2.3. Preliminary Biological Screening
A representative sample of 13 final triazole-bridged dimers (90–93, 112–114, 122, 123, 125, 126, 129
and 130) was screened for inhibitory activity against the aggregation of amyloid beta (1–42) (Aβ42), a
pathological hallmark of Alzheimer’s disease [30]. Aggregation of the mono eric form of the peptide
into oligomeric and fibrillar species is associated with disease onset and progression. As such, the
identification of compounds capable of inhibiting the aggregation process holds great potential for
the development of therapeutic agents [31]. Flavonoid and chalcone derivatives have previously
shown activity in perturbing the aggregation of Aβ, with compounds such as EGCG myricetin and
morin displaying inhibitory activity in a variety of biophysical and in vivo tests [32–35]. It has also
been shown that dimeric flavonoids can display enhanced inhibitory activity than their monomeric
counterparts [36], suggesting that the libraries synthesised may be effective at targeting this peptide
aggregation pathway. The ability of the triazole-linked dimers to inhibit the Aβ42 aggregation was
assessed using a thioflavin T (THT) assay (Figure 2). Three of the compounds screened were found
Molecules 2016, 21, 1230 10 of 59
to have moderate inhibitory activity, with 92 found to be the most potent and comparable to the
inhibitor morin.
It is difficult to draw any firm conclusions at this time regarding structure-activity relationships
in the triazole-bridged dimer compound class due to the relatively small sample size and some
issues with the solubility and fluorescence behaviour of some compounds under the assay conditions.
Nevertheless, this preliminary screen has identified structurally novel Aβ42 aggregation inhibitors
which could represent interesting scaffolds for further study in this regard.
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subclasses (chalcone, flavonol, aurone, flavone, coumarin and isoflavone) were successfully 
incorporated into the dimer library together with other biologically-relevant features, and variation 
within building blocks belonging to certain subclasses allowed for the generation of additional 
structural diversity in the library and the concomitant introduction of additional biomolecule-
interacting elements (for example, the varied heterocyclic motifs exhibited by the chalcone-chalcone 
dimers 90–97). Several co pounds also featured groups that could provide synthetic handles for 
furth r elaborati n or diversification (for example, compounds 96 and 97 and 105 and 106 contain a 
hydroxyl group and the aryl-bromide group present in 107 and 108 could conceivably be exploited 
in various metal-catalysed cross-coupling processes). 
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2.3. Preliminary Biological Screening 
A representative sample of 13 final triazole-bridged dimers (90–93, 112–114, 122, 123, 125, 126, 
129 and 130) was screened for inhibitory activity against the aggregation of amyloid beta (1–42) 
(Aβ42), a pathological hallmark of Alzheimer’s disease [30]. Aggregation of the monomeric form of 
the peptide into oligomeric and fibrillar species is associated with disease onset and progression. As 
such, the identification of compounds capable of inhibiting the aggregation process holds great 
potential for the development of therapeutic agents [31]. Flavonoid and chalcone derivatives have 
previously shown activity in perturbing the aggregation of Aβ, with compounds such as EGCG 
myricetin and morin displaying inhibitory activity in a variety of biophysical and in vivo tests [32–35]. 
It has also been shown that dimeric flavonoids can display enhanced inhibitory activity than their 
monomeric counterparts [36], suggesting that the libraries synthesised may be effective at targeting this 
peptide aggregation pathway. The ability of the triazole-linked dimers to inhibit the Aβ42 aggregation 
was assessed using a thioflavin T (THT) assay (Figure 2). Three of the compounds screened were found 
to have moderate inhibitory activity, with 92 found to be the most potent and comparable to the 
inhibitor morin. 
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Figure 2. Percentage inhibition of Aβ42 aggregation achieved by compounds 92, 122 and 126 (50 μM 
concentration) relative to that of Aβ42 alone (10 μM), where 100% represents complete aggregation 
inhibition and 0% shows no inhibition. The data represents the averages and standard error from the 
results of three independent biological repeats. Inhibitory effect of morin determined under identical 
assay conditions. 
It is difficult to draw any firm conclusions at this time regarding structure-activity relationships 
in the triazole-bridged dimer compound class due to the relatively small sample size and some issues 
with the solubility and fluorescence behaviour of some compounds under the assay conditions. 
Nevertheless, this preliminary screen has identified structurally novel Aβ42 aggregation inhibitors 
which could represent interesting scaffolds for further study in this regard. 
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Temperatures of 0 °C were maintained using an ice-water bath. Petroleum ether was distilled before 
use. Ethyl acetate and methanol were distilled from calcium hydride. Melting points were measured 
using a Büchi B545 melting point apparatus and are uncorrected. Thin layer chromatography (TLC) 
was performed on pre-coated silica gel GF254 plates (Merck, Kenilworth, NJ, USA). Infrared (IR) 
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Figure 2. Percentage inhibition of Aβ42 aggregation achieved by compounds 92, 122 and 126 (50 µM
concentration) relative to that of Aβ42 alone (10 µM), where 100% represents complete aggregation
inhibition and 0% shows no inhibition. The data represents the averages and standard error from the
results of three independent biological repeats. Inhibitory effect of morin determined under identical
assay conditions.
3. Materials and Methods
3.1. Chemica Synthesis
3.1.1. General Information
All non-aqueous reactions were performed under a constant stream of dry nitrogen using
oven-dried glassware. Standard practices were employed when handling moisture and air-sensitive
materials. All reagents and solvents were purchased from commercial sources and used without further
purification unless otherwise stated. Room temperature refers to ambient temperature. Temperatures
of 0 ◦C were maintained using an ice-water bath. Petroleum ether was distilled before use. Ethyl acetate
and methanol were distilled from calcium hydride. Melting points were measured using a Büchi B545
melting p int apparatus and are unco rected. Thin l yer chromatography (TLC) was performed
on pre-coated silica gel GF254 plates (M rck, Kenilworth, NJ, USA). Infrared (IR) spectra wer
recorded on a Spectrum One (FT-IR) spectrophotometer (Perkin-Elmer, Waltham, MA, USA) with
internal referencing. Absorption maxima (νmax) are reported in wavenumbers (cm−1). Flash column
chromatography was perfor ed on silica gel (230–400 mesh). 1H-NMR and 13C-NMR were recorded
on an Avance 500 MHz instrument (Bruker, Billerica, MA, USA) in CDCl3 or (CD3)2CO. Chemical hifts
(δ) are quoted in pp , to the nearest 0.01 ppm (1H-NMR) or 0.1 ppm (13C-NMR) and are referenced
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to the residual non-deuterated solvent peak. 1H-NMR and 13C-NMR data for all compounds can be
found in Supplementary Materials. LCMS analysis was performed on an ACQUITY H-Class UPLC
(Waters, Milford, MA, USA) with an ESCi Multi-Mode Ionisation Waters SQ Detector 2 spectrometer
using MassLynx 4.1 software. LC system: solvent A: 2 mM NH4OAc in H2O/MeCN (95:5); solvent B:
MeCN; solvent C: 2% aqueous formic acid; gradient: 5%–95% B with constant 5% C over 1 min at flow
rate of 0.6 mL/min. High resolution mass spectrometry (HRMS) measurements were recorded on a
Q-TOF mass spectrometer (Micromass, Cary, NC, USA) or a Waters LCT Premier Time of Flight mass
spectrometer. Mass values are quoted within the error limits of ±5 ppm mass units. ESI+ refers to the
mass ionisation technique.
3.1.2. General Synthetic Procedures
General Procedure A: Synthesis of Biflavonoid Triazole Hybrids (GP-A). To a stirred solution of
alkyne flavonoid (1.0 equiv.) and azide flavonoid (1.0 equiv.) in t-BuOH/H2O (1:1, 40 mL) were
added CuSO4·5H2O (1.1 equiv.) and sodium ascorbate (2.5 equiv.). The reaction mixture was stirred
at room temperature for 24 h or until TLC analysis indicated complete consumption of starting
material. The resulting mixture was poured into H2O (100 mL) and the aqueous solution was extracted
with CHCl3 (3 × 100 mL). The combined organic layer was washed with H2O (2 × 100 mL), brine
(2 × 100 mL), dried over anhydrous MgSO4, filtered and the solvent removed under reduced pressure.
The crude residue was purified by flash column chromatography over silica and recrystallized from
MeOH to afford the corresponding biflavonoid triazole hybrids.
General Procedure B: Synthesis of Alkyne Biflavonoid Triazole Hybrids (GP-B). To a stirred solution
of the corresponding biflavonoid triazole hybrid (1.0 equiv.) in dry acetone (50 mL) were added
propargyl bromide (3.0 equiv.) and anhydrous K2CO3 (3.0 equiv.). The reaction mixture was heated at
reflux with stirring for 24 h under a nitrogen atmosphere or until TLC analysis indicated complete
consumption of starting material. The resulting mixture was allowed to cool to room temperature and
the solvent removed in vacuo. The crude residue was re-suspended in CHCl3 (50 mL) and the organic
layer was washed with H2O (2 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO4, filtered
and evaporated to dryness. The crude residue was purified by flash column chromatography over
silica to afford the corresponding propynyloxy biflavonoid triazole hybrid.
General Procedure C: Synthesis of Propynyloxy flavonoids or benzaldehydes (GP-C). To a stirred
solution of the corresponding flavonoid or benzaldehyde (1.0 equiv.) in dry acetone (50 mL) were added
anhydrous K2CO3 (3.0 equiv.) and propargyl bromide (3.0 equiv.). The reaction mixture was heated at
reflux with stirring for 24 h under a nitrogen atmosphere or until TLC analysis indicated complete
consumption of starting material. The resulting mixture was allowed to cool to room temperature
and the solvent removed in vacuo. The crude residue was re-suspended in CHCl3 (100 mL) and the
organic layer was washed with H2O (2 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO4,
filtered and evaporated to dryness. The crude residue was purified by flash column chromatography
over silica to afford the corresponding propynyloxy flavonoids or benzaldehydes.
General Procedure D: Synthesis of Chalcones (GP-D). To a stirred solution of KOH (12.0 equiv.)
in absolute EtOH (100 mL) cooled to 0 ◦C in an ice-bath were added dropwise a solution of the
corresponding acetophenone (1.0 equiv.) and aldehyde (1.0 equiv.) in EtOH (20 mL). The reaction
mixture was stirred at 0 ◦C for 1 h and then at room temperature for 72 h under a nitrogen atmosphere
or until TLC analysis indicated complete consumption of starting material. The resulting mixture was
then poured into ice-water (100 mL) and acidified to pH 3–4 with 3 M HCl. The aqueous solution was
extracted with CHCl3 (3 × 100 mL) and the combined organic layer was washed with satd NaHCO3
(2 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO4, filtered and the solvent removed
under reduced pressure. The crude residue was purified by flash column chromatography over silica
and/or recrystallized from MeOH or absolute EtOH to afford the corresponding chalcones.
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General Procedure E: Synthesis of Indole or Pyrrole 2-hydroxychalcones (GP-E). To a stirred solution
of indole or pyrrole aldehyde (1.0 equiv.) and the corresponding 2-hydroxyacetophenone (1.0 equiv.)
in absolute EtOH (100 mL) was added piperidine (1.0 equiv.). The reaction mixture was heated at
reflux for 24 h under a nitrogen atmosphere or until TLC analysis indicated complete consumption of
starting material. The reaction mixture was allowed to cool to room temperature, poured into ice-water
(100 mL) and then acidified to pH 3–4 with 3 M HCl. The resulting suspension was filtered and the
precipitate washed with ice-water (2 × 100 mL), suction-dried and recrystallized from MeOH to afford
the corresponding indole or pyrrole chalcones.
General Procedure F: Synthesis of Flavonols (GP-F). To a stirred solution of the corresponding chalcone
(0.30 mmol) in MeOH (20 mL) were added 16% NaOH (aq) (0.60 mL) and 15% H2O2 (0.30 mL).
The reaction mixture was stirred at room temperature for 24 h under a nitrogen atmosphere or until
TLC analysis indicated complete consumption of starting material. The resulting mixture was then
poured into ice-water (50 mL) and acidified to pH 3–4 with 3 M HCl. The aqueous solution was
extracted with CHCl3 (3 × 50 mL) and the combined organic layer was washed with satd NaHCO3
(2 × 50 mL), brine (2 × 50 mL), dried over anhydrous MgSO4, filtered and the solvent removed under
reduced pressure. The crude residue was purified by flash column chromatography over silica to
afford the corresponding flavonols.
General Procedure G: Synthesis of Phenylethanones (GP-G). To a stirred solution of substituted phenol
(1.2 equiv.) in BF3·OEt2 (50 mL) was added the corresponding phenylacetic acid (1.0 equiv.) and the
reaction mixture was heated at 80 ◦C for 8 h under a nitrogen atmosphere. The resulting dark solution
was allowed to cool to room temperature and slowly poured into ice-water (100 mL). The organic layer
was separated and the aqueous layer was extracted with EtOAc (3 × 100 mL). The combined organic
layer was washed with satd NaHCO3 (2 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO4,
filtered and evaporated to dryness. The crude residue was purified by flash column chromatography
over silica to afford the corresponding phenylethanones.
General Procedure H: Synthesis of Isoflavones (GP-H). To a stirred solution of the corresponding
phenylethanone (1.0 equiv.) in dry DMF (15 mL) was carefully added BF3·OEt2 (4.0 equiv.) over 10 min
under a nitrogen atmosphere. To this mixture, methanesulfonyl chloride (3.0 equiv.) was added at
55 ◦C, stirred for 1 h and then heated at 80 ◦C for 24 h. The resulting dark solution was allowed to
cool to room temperature and then poured with rapid stirring into ice-water (100 mL). The resulting
precipitate was filtered, washed with H2O (2 × 100 mL), suction-dried and re-dissolved in EtOAc
(100 mL). The organic solution was washed with H2O (2 × 100 mL), brine (2 × 100 mL), dried over
anhydrous MgSO4, filtered and evaporated to dryness. The crude residue was purified by flash column
chromatography over silica to afford the corresponding isoflavones.
General Procedure I: Synthesis of Bromoalkylated flavonoids or benzaldehdyes (GP-I). To a stirred
solution of the corresponding flavonoid or benzaldehyde (1.0 equiv.) in dry acetone (50 mL) or
dry DMF (50 mL) were added anhydrous K2CO3 (3.0 equiv.) and 1,2-dibromoethane (3.0 equiv.).
The reaction mixture was heated at reflux with stirring for 24 h under a nitrogen atmosphere or until
TLC analysis indicated complete consumption of starting material. The resulting mixture was allowed
to cool to room temperature and the solvent removed in vacuo. The crude residue was re-suspended
in CHCl3 (100 mL) and the organic layer was washed with H2O (2 × 100 mL), brine (2 × 100 mL),
dried over anhydrous MgSO4, filtered and evaporated to dryness. The crude residue was purified
by flash column chromatography over silica to afford the corresponding bromoalkylated flavonoids
or benzaldehydes.
General Procedure J: Synthesis of Azido flavonoids or benzaldehydes (GP-J). To a stirred solution
of the corresponding bromoalkylated flavonoids or benzaldehydes (1.0 equiv.) in dry DMF (30 mL)
was added NaN3 (3.0 equiv.). The reaction mixture was heated at 100 ◦C with stirring for 3 h under
a nitrogen atmosphere. The resulting mixture was allowed to cool to room temperature and poured
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into H2O (100 mL). The aqueous solution was extracted with CHCl3 (3 × 100 mL) and the combined
organic layer was washed with H2O (2 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO4,
filtered and evaporated to dryness to afford the corresponding azido flavonoids or benzaldehydes and
were used without further purification.
General Procedure K: Synthesis of Aurones (GP-K). To a stirred solution of the corresponding chalcone
(1.0 equiv.) in pyridine (10 mL) was added Hg(OAc)2 (1.0 equiv.). The reaction mixture was heated
at 110 ◦C with stirring for 1 h under a nitrogen atmosphere. The resulting mixture was then poured
into ice-water (50 mL) and acidified to pH 3–4 with 3 M HCl. The aqueous solution was extracted
with CHCl3 (3 × 50 mL) and the combined organic layer was washed with H2O (2 × 50 mL),
brine (2 × 50 mL), dried over anhydrous MgSO4, filtered and the solvent removed under reduced
pressure. The crude residue was purified by flash column chromatography over silica to afford the
corresponding aurones.
3.2. Synthetic Procedures
3.2.1. Building Block Synthesis
4-Methoxy-3-(prop-2-yn-1-yloxy)benzaldehyde (2). A mixture of isovanillin (1, 10.0 g, 65.7 mmol),
propargyl bromide (8.78 mL, 98.6 mmol) and anhydrous K2CO3 (18.2 g, 131 mmol) in dry
acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column
chromatography (SiO2, CH2Cl2) to afford benzaldehyde 2 (9.23 g, 74%) as a white fluffy solid.
m.p. 78–80 ◦C. TLC Rf = 0.21 (CH2Cl2). IR νmax (neat)/cm−1: 3229m (C≡C-H str), 3096w (C-H str),
2839w (C-H str), 2124w (C≡C str), 1671s (C=O str), 1599s (C=C str), 1586s (C=C str), 1508s (C=C str),
1436m, 1407m, 1387m, 1261s, 1229s, 1161s, 1129s, 1012s. 1H-NMR (500 MHz, CDCl3): δ 2.55 (1H, t,
J = 2.4 Hz, -OCH2C≡CH), 3.97 (3H, s, -OCH3), 4.83 (2H, d, J = 2.4 Hz, -OCH2C≡CH), 7.01 (1H, d,
J = 8.0 Hz, ArH), 7.53 (1H, dd, J = 8.0, 1.6 H z, ArH), 7.55 (1H, d, J = 1.6 Hz, ArH), 9.87 (1H, s, CHO).
13C-NMR (500 MHz, CDCl3): δ 56.2, 56.6, 76.4, 77.7, 110.9, 112.0, 127.3, 129.9, 147.3, 154.9, 190.7. LCMS
(ES+) m/z = 191.2 ([M + H]+, tR = 3.09 min). These characterisation data are in accordance with that
previously reported in the literature [37].
(E)-1-(2-Hydroxy-4-methoxyphenyl)-3-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (4). A mixture
of benzaldehyde 2 (2.05 g, 10.8 mmol), acetophenone 3 (1.80 g, 10.8 mmol) and KOH (3.02 g, 53.8 mmol)
in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash
column chromatography (SiO2, PE/EtOAc; 5:1) and recrystallized from MeOH to afford chalcone 4
(1.42 g, 39%) as a bright yellow-orange fluffy solid. m.p. 144–146 ◦C. TLC Rf = 0.37 (PE/EtOAc; 2:1).
IR νmax (neat)/cm−1: 3506w (br) (O-H str), 3229 m (C≡C-H str), 3081w (C-H str), 2973w (C-H str),
2111w (C≡C str), 1633m (C=O str), 1572 m (C=C str), 1556s (C=C str), 1507s (C=C str), 1466 m, 1440s,
1361s, 1339s, 1260s, 1206s, 1170m, 1126s, 1018s. 1H-NMR (500 MHz, CDCl3): δ 2.58 (1H, t, J = 2.0 Hz,
-OCH2C≡CH), 3.87 (3H, s, -OCH3), 3.94 (3H, s, -OCH3), 4.85 (2H, d, J = 2.4 Hz, -OCH2C≡CH),
6.49–6.52 (2H, m, ArH), 6.94 (1H, d, J = 8.4 Hz, ArH), 7.32 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.35 (1H, d,
J = 1.2 Hz, ArH), 7.45 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.83 (1H, d, J = 8.4 Hz, ArH), 7.85 (1H, d,
J = 15.6 Hz, -CH=CHCO-), 13.53 (1H, s, OH). 13C-NMR (500 MHz, CDCl3): δ 55.6, 56.0, 56.9, 76.3, 78.1,
101.0, 107.7, 111.7, 113.8, 114.1, 118.3, 124.3, 127.7, 131.1, 144.3, 146.9, 152.2, 166.1, 166.6, 191.7. LCMS
(ES+) m/z = 339.2 ([M + H]+, tR = 1.70 min). HRMS (ESI+) m/z = 339.1224 [M + H]+ found, C20H19O5+
required 339.1227.
(E)-1-(4-Hydroxy-3-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (13). A mixture of aldehyde 5
(7.40 mL, 60.8 mmol), acetophenone 11 (10.0 g, 60.3 mmol) and KOH (16.9 g, 302 mmol) in absolute
EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash column
chromatography (SiO2, PE/EtOAc; 5:1) to afford chalcone 13 (10.7 g, 63%) as a bright yellow-orange
powdery solid. m.p. 148–150 ◦C. TLC Rf = 0.40 (PE/EtOAc; 1:1). IR νmax (neat)/cm−1: 3180m (br)
(O-H str), 2991w (C-H str), 2836w (C-H str), 1643m (C=O str), 1602m (C=C str), 1560s (C=C str), 1508s
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(C=C str), 1461w, 1424s, 1338m, 1296s, 1278s, 1248s, 1166s, 1048m, 1026s. 1H-NMR (500 MHz, CDCl3):
δ 3.86 (3H, s, -OCH3), 3.98 (3H, s, -OCH3), 6.23 (1H, s, OH), 6.94 (2H, d, J = 9.0 Hz, ArH), 7.00 (1H,
d, J = 8.0 Hz, ArH), 7.45 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.61 (2H, d, J = 8.5 Hz, ArH), 7.64–7.66
(2H, m, ArH), 7.79 (1H, d, J = 16.0 Hz, -CH=CHCO-). 13C-NMR (500 MHz, CDCl3): δ 55.4, 56.1, 110.5,
113.7, 114.3, 119.3, 123.5, 127.8, 130.1, 131.2, 143.8, 146.8, 150.2, 161.5, 188.6. LCMS (ES+) m/z = 285.2
([M + H]+, tR = 1.75 min). These characterisation data are in accordance with that previously reported
in the literature [38].
(E)-1-(5-Bromo-2-hydroxyphenyl)-3-(1-methyl-1H-indol-3-yl)prop-2-en-1-one (14). A mixture of indole
aldehyde 6 (1.03 g, 6.47 mmol), acetophenone 12 (1.38 g, 6.42 mmol) and piperidine (0.62 mL,
6.28 mmol) in absolute EtOH (100 mL) was reacted according to GP-E. The crude residue was purified
by recrystallization from MeOH to afford chalcone 14 (2.15 g, 94%) as a bright orange fluffy solid.
m.p. 250–252 ◦C. TLC Rf = 0.45 (PE/EtOAc 2:1). IR νmax (neat)/cm−1: 3101w (C-H str), 2885w
(C-H str), 1626s (C=O str), 1541m (C=C str), 1513s (C=C str), 1462m, 1387m, 1375m, 1344m, 1295m,
1252s, 1177s, 1126s, 1074s, 1028s, 1014m. 1H-NMR (500 MHz, CDCl3): δ 3.88 (3H, s, -NCH3), 6.93
(1H, d, J = 8.8 Hz, ArH), 7.38–7.40 (3H, m, ArH), 7.49–7.56 (2H, m, ArH), 7.55 (1H, d, J = 15.6 Hz,
-CH=CHCO-), 8.00–8.03 (2H, m, ArH), 8.23 (1H, d, J = 15.2 Hz, -CH=CHCO-), 13.25 (1H, br s, OH).
13C-NMR (500 MHz, CDCl3): δ 33.5, 110.2, 110.3, 113.1, 113.6, 120.5, 120.8, 121.7, 122.1, 123.6, 126.1,
131.5, 135.6, 138.1, 138.4, 140.4, 162.4, 192.5. LCMS (ES+) m/z = 358.0 ([M + H]+, tR = 4.96 min). HRMS
(ESI+) m/z = 356.0279 [M + H]+ found, C18H15O2NBr+ required 356.0281.
(E)-1-(2-Hydroxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (15). A mixture of pyrrole aldehyde
7 (4.00 mL, 37.2 mmol), acetophenone 10 (4.50 mL, 37.4 mmol) and piperidine (3.80 mL, 38.5 mmol)
in absolute EtOH (100 mL) was reacted according to GP-E. The crude residue was purified by
recrystallization from MeOH to afford chalcone 15 (2.28 g, 27%) as a bright yellow-orange powdery
solid. m.p. 98–100 ◦C. TLC Rf = 0.45 (PE/EtOAc; 3:1). IR νmax (neat)/cm−1: 3112w (C-H str), 2937w
(C-H str), 1627s (C=O str), 1579w (C=C str), 1549s (C=C str), 1479s, 1440m, 1412m, 1384m, 1356w,
1338m, 1290m, 1260s, 1249s, 1203s, 1182w, 1155s, 1092w, 1061s, 1025s. 1H-NMR (500 MHz, CDCl3):
δ 3.81 (3H, s, -NCH3), 6.26–6.27 (1H, m, ArH), 6.87 (1H, t, J = 2.0 Hz, ArH), 6.91–6.96 (2H, m, ArH),
7.02 (1H, dd, J = 8.4, 0.8 Hz, ArH), 7.40 (1H, d, J = 14.8 Hz, -CH=CHCO-), 7.48 (1H, t, J = 8.4 Hz, ArH),
7.89 (1H, dd, J = 8.0, 2.0 Hz, ArH), 7.92 (1H, d, J = 14.8 Hz, -CH=CHCO-), 13.14 (1H, s, OH). 13C-NMR
(500 MHz, CDCl3): δ 34.4, 110.2, 113.3, 114.5, 118.5, 118.7, 120.2, 128.6, 129.2, 130.2, 132.8, 135.8, 163.4,
193.1. LCMS (ES+) m/z = 228.1 ([M + H]+, tR = 1.68 min). HRMS (ESI+) m/z = 228.1020 [M + H]+
found, C14H14O2N+ required 228.1019.
(E)-1-(4-Hydroxy-3-methoxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (16). A mixture of pyrrole
aldehyde 7 (3.30 mL, 30.7 mmol), acetophenone 11 (5.02 g, 30.2 mmol) and KOH (10.2 g, 182 mmol)
in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash
column chromatography (SiO2, PE/EtOAc; 5:1) and recrystallized from absolute EtOH to afford
chalcone 16 (4.28 g, 55%) as a dark red-brown powdery solid. m.p. 150–152 ◦C. TLC Rf = 0.31
(PE/EtOAc; 1:1). IR νmax (neat)/cm−1: 3177m(br) (O-H str), 2958w (C-H str), 2930w (C-H str), 1630m
(C=O str), 1600m (C=C str), 1587m (C=C str), 1543s (C=C str), 1508s (C=C str), 1478m, 1380w, 1333m,
1270s, 1218m, 1196s, 1169s, 1052s, 1031s. 1H-NMR (500 MHz, CDCl3): δ 3.77 (3H, s, -NCH3), 3.99
(3H, s, -OCH3), 6.18 (1H, s, OH), 6.23 (1H, t, J = 3.2 Hz, ArH), 6.81 (1H, t, J = 2.0 Hz, ArH), 6.84
(1H, dd, J = 4.0, 1.6 Hz, ArH), 6.99 (1H, d, J = 8.8 Hz, ArH), 7.32 (1H, d, J = 15.2 Hz, -CH=CHCO-),
7.62–7.64 (2H, m, ArH), 7.81 (1H, d, J = 14.8 Hz, -CH=CHCO-). 13C-NMR (500 MHz, CDCl3): δ 34.3,
56.1, 109.6, 110.4, 112.0, 113.7, 116.4, 123.1, 127.5, 130.3, 131.5, 131.5, 146.8, 150.0, 188.1. LCMS (ES+)
m/z = 258.1 ([M + H]+, tR = 1.40 min). HRMS (ESI+) m/z =280.0935 [M + Na]+ found, C15H15O3NNa+
required 280.0944.
(E)-1-(5-Bromo-2-hydroxyphenyl)-3-(furan-2-yl)prop-2-en-1-one (17). A mixture of furan aldehyde 8
(1.20 mL, 14.5 mmol), acetophenone 12 (3.06 g, 14.2 mmol) and KOH (4.70 g, 83.8 mmol) in absolute
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EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization
from MeOH to afford chalcone 17 (1.97 g, 47%) as a bright yellow-orange fluffy solid. m.p. 80–82 ◦C.
TLC Rf = 0.50 (PE/EtOAc; 3:1). IR νmax (neat)/cm−1: 3128w (C-H str), 3046w (C-H str), 2868w
(C-H str), 1638m (C=O str), 1567s (C=C str), 1548s (C=C str), 1467s, 1364m, 1335s, 1296m, 1258s, 1202s,
1177s, 1077w, 1013s. 1H-NMR (500 MHz, CDCl3): δ 6.56–6.57 (1H, m, ArH), 6.82 (1H, d, J = 3.6 Hz,
ArH), 6.93 (1H, d, J = 8.8 Hz, ArH), 7.45 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.56 (1H, dd, J = 9.2,
2.4 Hz, ArH), 7.60 (1H, d, J = 0.8 Hz, ArH), 7.70 (1H, d, J = 15.2 Hz, -CH=CHCO-), 8.00 (1H, d,
J = 2.4 Hz, ArH), 12.83 (1H, s, OH). 13C-NMR (500 MHz, CDCl3): δ 110.4, 113.0, 116.8, 117.8, 120.5,
121.2, 131.8, 131.9, 138.8, 145.8, 151.3, 162.4, 192.3. LCMS (ES+) m/z = 293.1 ([M + H]+, tR = 1.85 min).
These characterisation data are in accordance with that previously reported in the literature [39].
(E)-3-(Ferrocenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (18). A mixture of ferrocene aldehyde 9 (4.77 g,
22.3 mmol), acetophenone 10 (2.70 mL, 22.4 mmol) and KOH (7.63 g, 136 mmol) in absolute EtOH
(100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization from
MeOH to afford chalcone 18 (4.99 g, 67%) as a dark purple microcrystalline solid. m.p. 162–164 ◦C.
TLC Rf = 0.43 (PE/EtOAc; 7:1). IR νmax (neat)/cm−1: 3315w(br) (O-H str), 3088w (C-H str), 1742w
(C=O str), 1627m, 1554s (C=C str), 1489s, 1440m, 1383w, 1347m, 1302s, 1271m, 1246m, 1206s, 1158m,
1104m, 1048w, 1023m, 1002w. 1H-NMR (500 MHz, CDCl3): δ 4.21 (5H, s, -C5H5), 4.55 (2H, t, J = 2.0 Hz,
-C5H4), 4.65 (2H, t, J = 2.0 Hz, -C5H4), 6.94 (1H, t, J = 8.0 Hz, ArH), 7.03 (1H, dd, J = 8.5, 1.0 Hz,
ArH), 7.26 (1H, d, J = 15.0 Hz, -CH=CHCO-, overlain by CDCl3), 7.49 (1H, t, J = 8.5 Hz, ArH), 7.87
(1H, dd, J = 8.0, 1.0 Hz, ArH), 7.91 (1H, d, J = 15.0 Hz, -CH=CHCO-), 13.07 (1H, s, OH). 13C-NMR
(500 MHz, CDCl3): δ 69.3, 69.9, 71.8, 78.8, 116.7, 118.6, 118.6, 120.0, 129.3, 135.9, 147.9, 163.6, 192.7.
LCMS (ES+) m/z = 333.1 ([M + H]+, tR = 1.87 min). These characterisation data are in accordance with
that previously reported in the literature [40].
(E)-3-(Ferrocenyl)-1-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one (19). A mixture of ferrocene aldehyde
9 (3.86 g, 18.0 mmol), acetophenone 11 (3.05 g, 18.4 mmol) and KOH (6.10 g, 109 mmol) in
absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash
column chromatography (SiO2, PE/EtOAc; 5:1) to afford chalcone 19 (5.61 g, 86%) as a dark purple
microcrystalline solid. m.p. 78–80 ◦C. TLC Rf = 0.29 (PE/EtOAc; 2:1). IR νmax (neat)/cm−1: 3098w(C-H
str), 2835w (C-H str), 1743w, 1642m, (C=O str) 1588s (C=C str), 1563s (C=C str), 1511s (C=C str), 1462m,
1424s, 1359m, 1347m, 1281s, 1264s, 1189s, 1162s, 1026s, 1001w. 1H-NMR (500 MHz, CDCl3): δ. 3.95
(3H, s, -OCH3), 4.17 (5H, s, -C5H5), 4.47 (2H, t, J = 2.0 Hz, -C5H4), 4.59 (2H, t, J = 2.0 Hz, -C5H4), 6.54
(1H, br s, OH), 7.00 (1H, d, J = 8.0 Hz, ArH), 7.16 (1H, d, J = 15.0 Hz, -CH=CHCO-), 7.60 (1H, dd,
J = 8.5, 1.5 Hz, ArH), 7.63 (1H, d, J = 1.5 Hz, ArH), 7.76 (1H, d, J = 15.5 Hz, -CH=CHCO-). 13C-NMR
(500 MHz, CDCl3): δ 56.0, 68.8, 69.7, 71.2, 79.3, 110.5, 113.8, 118.5, 123.2, 131.1, 145.8, 146.8, 150.1, 187.9.
LCMS (ES+) m/z = 363.1 ([M + H]+, tR = 1.66 min). HRMS (ESI+) m/z = 363.0595 [M + H]+ found,
C20H19O3Fe+ required 363.0600.
(E)-1-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (20). A mixture of
chalcone 13 (1.02 g, 3.57 mmol), propargyl bromide (0.63 mL, 7.07 mmol) and anhydrous K2CO3
(1.49 g, 10.8 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue was
purified by flash column chromatography (SiO2, CH2Cl2) to afford chalcone 20 (1.07 g, 93%) as a
pale yellow powdery solid. m.p. 168–170 ◦C. TLC Rf = 0.41 (CH2Cl2). IR νmax (neat)/cm−1: 3251w
(C≡C-H str), 2990w (C-H str), 2835w (C-H str), 2116w (C≡C str), 1651s (C=O str), 1598s (C=C str),
1577s (C=C str), 1508s (C=C str), 1466m, 1421s, 1382w, 1323m, 1257s, 1229s, 1165s, 1145s, 1056w, 1015s.
1H-NMR (500 MHz, CDCl3): δ 2.57 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 3.87 (3H, s, -OCH3), 3.98 (3H, s,
-OCH3), 4.87 (2H, d, J = 2.4 Hz, -OCH2C≡CH), 6.95 (2H, d, J = 8.8 Hz, ArH), 7.11 (2H, d, J = 8.4 Hz,
ArH), 7.44 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.62 (2H, d, J = 8.8 Hz, ArH), 7.65 (1H, d, J = 2.0 Hz,
ArH), 7.68 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.80 (1H, d, J = 15.6 Hz, -CH=CHCO-). 13C-NMR (500 MHz,
CDCl3): δ 55.4, 56.1, 56.6, 76.4, 77.8, 111.3, 112.3, 114.4, 119.3, 122.3, 127.7, 130.1, 132.6, 144.0, 149.7,
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150.7, 161.6, 188.7. LCMS (ES+) m/z = 323.2 ([M + H]+, tR = 1.56 min). HRMS (ESI+) m/z = 323.1265
[M + H]+ found, C20H19O4+ required 323.1278.
(E)-1-(5-Bromo-2-(prop-2-yn-1-yloxy)phenyl)-3-(1-methyl-1H-indol-3-yl)prop-2-en-1-one (21). A mixture
of indole chalcone 14 (2.07 g, 5.81 mmol), propargyl bromide (1.50 mL, 16.8 mmol) and anhydrous
K2CO3 (2.52 g, 18.2 mmol) in dry acetone (100 mL) was reacted according to GP-C. The crude residue
was purified by flash column chromatography (SiO2, CH2Cl2) to afford chalcone 21 (2.20 g, 96%)
as a bright yellow powdery solid. m.p. 126–128 ◦C. TLC Rf = 0.20 (CH2Cl2). IR νmax (neat)/cm−1:
3257w (C≡C-H str), 3070w (C-H str), 2942w (C-H str), 2114w (C≡C str), 1638s (C=O str), 1587m
(C=C str), 1544s (C=C str), 1524s (C=C str), 1473m, 1373s, 1269s, 1213m, 1176s, 1133m, 1073m, 1006s.
1H-NMR (500 MHz, CDCl3): δ 2.55 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 3.82 (3H, s, -NCH3), 4.79 (2H, d,
J = 2.4 Hz, -OCH2C≡CH), 7.03 (1H, d, J = 9.2 Hz, ArH), 7.26–7.38 (3H, m, ArH), 7.38 (1H, d, J = 16.0 Hz,
-CH=CHCO-), 7.41 (1H, s, ArH), 7.55 (1H, dd, J = 8.8, 2.4 Hz, ArH), 7.77 (1H, d, J = 2.4 Hz, ArH), 7.88
(1H, d, J = 15.6 Hz, -CH=CHCO-), 8.01 (1H, d, J = 8.0 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 33.3,
56.6, 76.4, 77.8, 110.0, 112.9, 114.3, 115.3, 121.0, 121.5, 121.6, 123.2, 126.0, 132.6, 132.9, 134.3, 134.8, 138.2,
138.6, 154.6, 191.0. LCMS (ES+) m/z = 396.1 ([M + H]+, tR = 1.98 min). HRMS (ESI+) m/z = 394.0425
[M + H]+ found, C21H17NO2Br+ required 394.0443.
(E)-1-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (22). A mixture
of pyrrole chalcone 16 (1.00 g, 3.89 mmol), propargyl bromide (0.70 mL, 7.86 mmol) and anhydrous
K2CO3 (1.61 g, 1.17 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue
was purified by flash column chromatography (SiO2, PE/EtOAc; 3:1) to afford chalcone 22 (1.06 g,
92%) as a bright yellow powdery solid. m.p. 164–166 ◦C. TLC Rf = 0.41 (PE/EtOAc; 1:1). IR νmax
(neat)/cm−1: 3234m (C≡C-H str), 2995w (C-H str), 2866w (C-H str), 1739m (C=O str), 1645m, 1598s,
(C=C str), 1561s (C=C str), 1515m (C=C str), 1483m, 1416w, 1374m, 1346s, 1272s, 1179m, 1129s, 1087w,
1042m, 1012m. 1H-NMR (500 MHz, CDCl3): δ 2.56 (1H, t, J = 2.5 Hz, -OCH2C≡CH), 3.78 (3H, s,
-NCH3), 3.98 (3H, s, -OCH3), 4.86 (1H, d, J = 2.5 Hz, -OCH2C≡CH), 6.23–6.24 (1H, m, ArH), 6.82
(1H, t, J = 2.0 Hz, ArH), 6.85 (1H, dd, J = 4.0, 1.0 Hz, ArH), 7.10 (1H, d, J = 8.0 Hz, ArH), 7.32 (1H, d,
J = 15.0 Hz, -CH=CHCO-), 7.64–7.67 (2H, m, ArH), 7.82 (1H, d, J = 15.0 Hz, -CH=CHCO-). 13C-NMR
(500 MHz, CDCl3): δ 34.4, 56.1, 56.6, 76.4, 77.8, 109.7, 111.2, 112.1, 112.4, 116.4, 122.0, 127.6, 130.3,
131.7, 132.9, 149.6, 150.5, 188.1. LCMS (ES+) m/z = 296.2 ([M + H]+, tR = 1.57 min). HRMS (ESI+)
m/z = 294.1119 [M − H]+ found, C18H16O3N+ required 294.1125.
(E)-3-(1-Methyl-1H-pyrrol-2-yl)-1-(2-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (23). A mixture of pyrrole
chalcone 15 (308 mg, 1.32 mmol), propargyl bromide (0.25 mL, 2.81 mmol) and anhydrous K2CO3
(568 mg, 4.11 mmol) in dry acetone (20 mL) was reacted according to GP-C. The crude residue was
purified by flash column chromatography (SiO2, PE/EtOAc; 3:1) to afford chalcone 23 (352 mg,
98%) as a bright yellow viscous oil. TLC Rf = 0.34 (PE/EtOAc; 2:1). IR νmax (neat)/cm−1: 3283w
(C≡C-H str), 3072w (C-H str), 2923w (C-H str), 2120w (C≡C str), 1698w (C=O str), 1647m, 1598s (C=C
str), 1580s (C=C str), 1564s (C=C str), 1480s, 1450m, 1330m, 1287s, 1217s, 1113w, 1057m, 1018s. 1H-NMR
(500 MHz, CDCl3): δ 2.54 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 3.74 (3H, s, -NCH3), 4.79 (2H, d, J = 2.4 Hz,
-OCH2C≡CH), 6.20–6.21 (1H, m, ArH), 6.78–6.80 (2H, m, ArH), 7.08–7.12 (2H, m, ArH), 7.19 (1H, d,
J = 15.2 Hz, -CH=CHCO-), 7.47 (1H, t, J = 8.8 Hz, ArH), 7.65 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.66
(1H, dd, J = 7.6, 2.0 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 34.5, 56.4, 75.9, 78.2, 109.6, 112.8, 113.3,
121.8, 121.9, 127.7, 130.2, 130.5, 130.5, 131.1, 132.2, 155.7, 191.9. LCMS (ES+) m/z = 266.1 ([M + H]+,
tR = 1.57 min). HRMS (ESI+) m/z = 266.1183 [M + H]+ found, C17H16NO2+ required 266.1181.
(E)-1-(5-Bromo-2-(prop-2-yn-1-yloxy)phenyl)-3-(furan-2-yl)prop-2-en-1-one (24). A mixture of furan
chalcone 17 (2.02 g, 6.89 mmol), propargyl bromide (1.30 mL, 14.6 mmol) and anhydrous K2CO3
(2.90 g, 21.0 mmol) in dry acetone (100 mL) was reacted according to GP-C. The crude residue was
purified by flash column chromatography (SiO2, CH2Cl2) to afford chalcone 24 (2.14 g, 94%) as a pale
yellow-brown powdery solid. m.p. 82–84 ◦C. TLC Rf = 0.21 (PE/CH2Cl2; 1:1). IR νmax (neat)/cm−1:
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3224m (C≡C-H str), 3118w (C-H str), 2118w (C≡C str), 1660m (C=O str), 1600s (C=C str), 1586m
(C=C str), 1554m (C=C str), 1476m, 1394m, 1313w, 1276m, 1211s, 1180m, 1131m, 1079w, 1048m,
1012s. 1H-NMR (500 MHz, CDCl3): δ 2.54 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 4.78 (2H, d, J = 2.4 Hz,
-OCH2C≡CH), 6.50–6.51 (1H, m, ArH), 6.70 (1H, d, J = 3.6 Hz, ArH), 7.03 (1H, d, J = 8.8 Hz, ArH),
7.21 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.40 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.52 (1H, d, J = 1.2 Hz,
ArH), 7.56 (1H, dd, J = 8.8, 2.4 Hz, ArH), 7.73 (1H, d, J = 2.4 Hz, ArH). 13C-NMR (500 MHz, CDCl3):
δ 56.6, 76.5, 77.6, 112.6, 114.3, 115.4, 116.2, 123.8, 130.4, 131.6, 133.0, 135.0, 145.1, 151.5, 154.8, 190.5.
LCMS (ES+) m/z = 333.0 ([M + H]+, tR = 1.89 min). HRMS (ESI+) m/z = 330.9973 [M + H]+ found,
C16H12O3Br+ required 330.9970.
(E)-3-(Ferrocenyl)-1-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (25). A mixture of ferrocene
chalcone 19 (1.01 g, 2.79 mmol), propargyl bromide (0.50 mL, 5.61 mmol) and anhydrous K2CO3
(1.18 g, 8.56 mmol) in dry acetone (50 mL) was reacted according to GP-C. The crude residue was
purified by flash column chromatography (SiO2, CH2Cl2) to afford chalcone 25 (1.01 g, 91%) as a dark
red-purple microcrystalline solid. m.p. 128–130 ◦C. TLC Rf = 0.47 (0.5% MeOH/CH2Cl2). IR νmax
(neat)/cm−1: 3225m (C≡C-H str), 3008w (C-H str), 2939w (C-H str), 2114w (C≡C str), 1646s (C=O
str), 1595m (C=C str), 1567s (C=C str), 1506m (C=C str), 1456m, 1413s, 1345w, 1295s, 1259s, 1194m,
1159s, 1136s, 1107m, 1060w, 1044m, 1020s. 1H-NMR (500 MHz, CDCl3): δ 2.56 (1H, t, J = 2.5 Hz,
-OCH2C≡CH), 3.96 (3H, s, -OCH3), 4.18 (5H, s, -C5H5), 4.48 (2H, t, J = 2.0 Hz, -C5H4), 4.60 (2H, t,
J = 2.0 Hz, -C5H4), 4.85 (2H, d, J = 2.0 Hz, -OCH2C≡CH), 7.09 (1H, d, J = 8.5 Hz, ArH), 7.15 (1H, d,
J = 15.5 Hz, -CH=CHCO-), 7.61–7.63 (2H, m, ArH), 7.75 (1H, d, J = 15.0 Hz, -CH=CHCO-). 13C-NMR
(500 MHz, CDCl3): δ 56.0, 56.5, 68.9, 69.7, 71.2, 76.3, 77.8, 79.3, 111.2, 112.3, 118.5, 122.1, 132.6, 146.0,
149.5, 150.4, 187.9. LCMS (ES+) m/z = 401.1 ([M + H]+, tR = 1.81 min). HRMS (ESI+) m/z = 401.0823
[M + H]+ found, C23H21O3Fe+ required 401.0840.
(E)-3-(Ferrocenyl)-1-(2-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (26). A mixture of chalcone 18 (1.02 g,
3.07 mmol), propargyl bromide (0.54 mL, 6.02 mmol) and anhydrous K2CO3 (1.20 g, 8.68 mmol) in
dry acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column
chromatography (SiO2, PE/CH2Cl2; 1:1) to afford chalcone 26 (919 mg, 81%) as a bright red powdery
solid. m.p. 90–92 ◦C. TLC Rf = 0.38 (CH2Cl2). IR νmax (neat)/cm−1: 3257m (C≡C-H str), 2924w
(C-H str), 2850w (C-H str), 2117w (C≡C str), 1654s (C=O str), 1587s (C=C str), 1480m, 1448m, 1356w,
1345w, 1289m, 1211s, 1159w, 1104m, 1058m, 1016s, 1001s. 1H-NMR (500 MHz, CDCl3): δ 2.56 (1H, t,
J = 2.5 Hz, -OCH2C≡CH), 4.19 (5H, s, -C5H5), 4.46 (2H, t, J = 2.0 Hz, -C5H4), 4.56 (2H, t, J = 2.0 Hz,
-C5H4), 4.79 (2H, d, J = 2.5 Hz, -OCH2C≡CH), 6.95 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.09–7.13 (2H,
m, ArH), 7.47 (1H, t, J = 9.0 Hz, ArH), 7.50 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.58 (1H, dd, J = 7.5,
1.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 56.3, 69.0, 69.8, 71.2, 76.0, 78.2, 79.0, 113.3, 121.7, 124.6,
130.1, 130.5, 131.9, 146.2, 155.4, 192.5. LCMS (ES+) m/z = 371.1 ([M + H]+, tR = 1.96 min). HRMS (ESI+)
m/z = 370.0639 [M]+ found, C22H18O2Fe+ required 370.0651.
3-(Prop-2-yn-1-yloxy)flavone (30). A mixture of 3-hydroxyflavone 27 (2.06 g, 8.65 mmol), propargyl
bromide (1.50 mL, 16.8 mmol) and anhydrous K2CO3 (3.48 g, 25.2 mmol) in dry acetone (100 mL) was
reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO2,
CH2Cl2) to afford flavone 30 (2.38 g, 99%) as a pale yellow-white powdery solid. m.p. 104–106 ◦C.
TLC Rf = 0.24 (CH2Cl2). IR νmax (neat)/cm−1: 3254m (C≡C-H str), 2946w (C-H str), 2114w (C≡C str),
1612s (C=O str), 1600s, 1557s (C=C str), 1468s, 1445m, 1399s, 1354m, 1345m, 1279w, 1234w, 1195s, 1185s,
1148s, 1110m, 1079w, 1036m. 1H-NMR (500 MHz, CDCl3): δ 2.33 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 5.00
(2H, d, J = 2.4 Hz, -OCH2C≡CH), 7.42 (1H, t, J = 8.0 Hz, ArH), 7.50–7.54 (3H, m, ArH), 7.56 (1H, d,
J = 8.4 Hz, ArH), 7.70 (1H, t, J = 8.4 Hz, ArH), 8.14–8.16 (2H, m, ArH), 8.27 (1H, dd, J = 8.0, 1.6 Hz, ArH).
13C-NMR (500 MHz, CDCl3): δ 59.1, 76.1, 78.5, 118.0, 123.9, 124.7, 125.7, 128.3, 128.9, 130.7, 130.9, 133.5,
138.5, 155.2, 156.7, 174.8. LCMS (ES+) m/z = 277.5 ([M + H]+, tR = 4.47 min). These characterisation
data are in accordance with that previously reported in the literature [23].
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6-(Prop-2-yn-1-yloxy)flavone (31). A mixture of 6-hydroxyflavone 28 (2.00 g, 8.39 mmol), propargyl
bromide (1.50 mL, 16.8 mmol) and anhydrous K2CO3 (3.50 g, 25.3 mmol) in dry acetone (100 mL) was
reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO2,
1% MeOH/CH2Cl2) to afford flavone 31 (2.03 g, 87%) as a white crystalline solid. m.p. 170–172 ◦C.
TLC Rf = 0.44 (1% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3266m (C≡C-H str), 3059w (C-H str),
2116w (C≡C str), 1623s (C=O str), 1606s, 1582s (C=C str), 1568s (C=C str), 1497m, 1482m, 1455s, 1365s,
1283m, 1259m, 1234m, 1186s, 1144s, 1075m, 1048m, 1007s. 1H-NMR (500 MHz, CDCl3): δ 2.57 (1H, t,
J = 2.4 Hz, -OCH2C≡CH), 4.76 (2H, d, J = 2.4 Hz, -OCH2C≡CH), 6.77 (1H, s, -C=CH), 7.31 (1H, dd,
J = 9.2, 3.2 Hz, ArH), 7.46–7.51 (4H, m, ArH), 7.65 (1H, d, J = 3.2 Hz, ArH), 7.86–7.88 (2H, m, ArH).
13C-NMR (500 MHz, CDCl3): δ 56.3, 76.0, 77.7, 106.4, 106.7, 119.6, 123.9, 124.4, 126.1, 128.9, 131.4, 131.6,
151.3, 154.7, 163.0, 177.9. LCMS (ES+) m/z = 277.0 ([M + H]+, tR = 1.56 min). These characterisation
data are in accordance with that previously reported in the literature [24].
7-(Prop-2-yn-1-yloxy)flavone (32). A mixture of 7-hydroxyflavone 29 (990 mg, 4.16 mmol), propargyl
bromide (0.748 mL, 8.39 mmol) and anhydrous K2CO3 (1.75 g, 12.7 mmol) and in dry acetone (100 mL)
was reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO2,
1% MeOH/CH2Cl2) to afford flavone 32 (1.10 g, 95%) as an off-white powdery solid. m.p. 216–218 ◦C.
TLC Rf = 0.44 (2% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3194w (C≡C-H str), 2921w (C-H str), 2115w
(C≡C str), 1619s (C=O str), 1591s (C=C str), 1568s (C=C str), 1496m, 1451s, 1435s, 1378s, 1350m, 1268m,
1229m, 1168s, 1135s, 1091s, 1017s. 1H-NMR (500 MHz, CDCl3): δ 2.62 (1H, t, J = 2.4 Hz, -OCH2C≡CH),
4.83 (2H, d, J = 2.4 Hz, -OCH2C≡CH), 6.77 (1H, s, -C=CH), 7.05 (1H, dd, J = 8.8, 2.4 Hz, ArH), 7.09
(1H, d, J = 2.4 Hz, ArH), 7.51–7.55 (3H, m, ArH), 7.90–7.93 (2H, m, ArH), 8.17 (1H, d, J = 8.8 Hz, ArH).
13C-NMR (500 MHz, CDCl3): δ 56.2, 76.6, 77.3, 101.8, 107.6, 114.7, 118.4, 126.2, 127.2, 129.0, 131.5, 131.8,
157.7, 161.9, 163.1, 177.7. LCMS (ES+) m/z = 277.0 ([M + H]+, tR = 1.54 min). These characterisation
data are in accordance with that previously reported in the literature [24].
4-(Prop-2-yn-1-yloxy)benzaldehyde (34). A mixture of benzaldehyde 33 (10.2 g, 83.7 mmol), propargyl
bromide (14.6 mL, 164 mmol) and anhydrous K2CO3 (22.7 g, 165 mmol) in dry acetone (200 mL)
was reacted according to GP-C. The crude residue was purified by flash column chromatography
(SiO2, CH2Cl2) to afford benzaldehyde 34 (12.2 g, 91%) as a white crystalline solid. m.p. 88–90 ◦C.
TLC Rf = 0.49 (CH2Cl2). IR νmax (neat)/cm−1: 3205m (C≡C-H str), 2971w (C-H str), 2837w (C-H str),
2123w (C≡C str), 1739s (C=O str), 1679s, 1601s, 1576s (C=C str), 1508m (C=C str), 1428w, 1384s, 1245s,
1217s, 1170s, 1009s. 1H-NMR (500 MHz, CDCl3): δ 2.58 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 4.77 (2H,
d, J = 2.4 Hz, -OCH2C≡CH), 7.08 (2H, d, J = 8.8 Hz, ArH), 7.85 (2H, d, J = 8.8 Hz, ArH), 9.89 (1H, s,
CHO). 13C-NMR (500 MHz, CDCl3): δ 55.9, 76.3, 77.5, 115.1, 130.5, 131.8, 162.3, 190.7. LCMS (ES+) m/z
= 161.1 ([M + H]+, tR = 1.65 min). These characterisation data are in accordance with that previously
reported in the literature [41].
(E)-1-(2-Hydroxyphenyl)-3-(4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (35). A mixture of benzaldehyde
34 (5.04 g, 31.5 mmol), acetophenone 10 (3.76 mL, 31.2 mmol), and KOH (10.6 g, 189 mmol) in absolute
EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization
from MeOH to afford chalcone 35 (6.67 g, 77%) as a bright yellow powdery solid. m.p. 144–146 ◦C.
TLC Rf = 0.45 (PE/EtOAc; 3:1). IR νmax (neat)/cm−1: 3487w (O-H str), 3240m (C≡C-H str), 2923w
(C-H str), 2124w (C≡C str), 1634s (C=O str), 1604m, 1559s (C=C str), 1509s (C=C str), 1488s, 1442m,
1368m, 1299s, 1270m, 1203m, 1177s, 1159s, 1027s. 1H-NMR (500 MHz, CDCl3): δ 2.58 (1H, t, J = 2.4 Hz,
-OCH2C≡CH), 4.75 (2H, d, J = 2.4 Hz, -OCH2C≡CH), 6.94 (1H, t, J = 7.6 Hz, ArH), 7.03 (3H, d,
J = 8.4 Hz, ArH), 7.49 (1H, t, J = 8.4 Hz, ArH), 7.54 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.63 (2H, d,
J = 8.8 Hz, ArH), 7.89 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.90–7.92 (1H, m, ArH), 12.93 (1H, s, OH).
13C-NMR (500 MHz, CDCl3): δ 55.8, 76.1, 77.9, 115.3, 118.0, 118.5, 118.7, 120.0, 128.0, 129.5, 130.4,
136.1, 145.0, 159.7, 163.5, 193.5. LCMS (ES+) m/z = 279.1 ([M + H]+, tR = 1.75 min). HRMS (ESI+)
m/z = 279.1005 [M + H]+ found, C18H15O3+ required 279.1016.
Molecules 2016, 21, 1230 25 of 59
3-Hydroxy-4′-(prop-2-yn-1-yloxy)flavone (36). A mixture of chalcone 35 (2.02 g, 7.26 mmol), 16% NaOH
(14.4 mL) and 15% H2O2 (7.19 mL) in MeOH (50 mL) was reacted according to GP-F. The crude residue
was purified by flash column chromatography (SiO2, 1% MeOH/CH2Cl2) to afford flavonol 36 (1.56 g,
73%) as a pale yellow-white powdery solid. m.p. 194–196 ◦C. TLC Rf = 0.44 (0.5% MeOH/CH2Cl2). IR
νmax (neat)/cm−1: 3271s (C≡C-H str), 3260w (O-H str), 2979w (C-H str), 2119w (C≡C str), 1599s (C=O
str), 1562s (C=C str), 1507m (C=C str), 1483m, 1470m, 1427m, 1411m, 1233s, 1216m, 1180s, 1120s, 1109s,
1017s. 1H-NMR (500 MHz, CDCl3): δ 2.58 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 4.79 (2H, d, J = 2.4 Hz,
-OCH2C≡CH), 7.00 (1H, br s, OH), 7.14 (2H, d, J = 9.2 Hz, ArH), 7.42 (1H, t, J = 8.0 Hz, ArH), 7.58
(1H, d, J = 8.4 Hz, ArH), 7.70 (1H, t, J = 8.4 Hz, ArH), 8.25–8.28 (3H, m, ArH). 13C-NMR (500 MHz,
CDCl3): δ 55.8, 76.0, 78.0, 115.0, 118.2, 120.7, 124.4, 124.4, 125.4, 129.5, 133.4, 137.8, 145.0, 155.3, 158.9,
173.2. LCMS (ES+) m/z = 293.1 ([M + H]+, tR = 1.62 min). HRMS (ESI+) m/z = 315.0618 [M + Na]+
found, C18H12O4Na+ required 315.0628.
1-(2-Hydroxy-4-methoxyphenyl)-2-(4-hydroxyphenyl)ethan-1-one (41). A mixture of phenol 37 (8.70 mL,
79.32 mmol) and phenylacetic acid 39 (10.1 g, 66.3 mmol) in BF3·OEt2 (85.0 mL, 677 mmol) was reacted
according to GP-G. The crude residue was purified by flash column chromatography (SiO2, CH2Cl2)
to afford phenylethanone 41 (13.2 g, 78%) as a white powdery solid. m.p. 158–160 ◦C. TLC Rf = 0.38
(1% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3469w(br) (O-H str), 3221w(br ) (O-H str), 2984w (C-H
str), 2904w (C-H str), 1706w (C=O str), 1613s (C=C str), 1518s (C=C str), 1450m, 1437s, 1381m, 1354s,
1291s, 1224s, 1202s, 1127s, 1021m. 1H-NMR (500 MHz, (CD3)2CO): δ 3.85 (3H, s, -OCH3), 4.19 (2H,
s, -COCH2), 6.42 (1H, d, J = 2.8 Hz, ArH), 6.49 (1H, dd, J = 8.8, 2.4 Hz, ArH), 6.80 (2H, d, J = 8.8 Hz,
ArH), 7.16 (2H, d, J = 8.4 Hz, ArH), 7.98 (1H, d, J = 9.2 Hz, ArH), 8.29 (1H, br s, OH), 12.80 (1H, s, OH).
13C-NMR (500 MHz, (CD3)2CO): δ 43.7, 55.4, 101.0, 107.5, 113.2, 115.6, 125.9, 130.6, 133.1, 156.6, 166.0,
166.5, 203.5. LCMS (ES+) m/z = 259.1 ([M + H]+, tR = 1.47 min). These characterisation data are in
accordance with that previously reported in the literature [42].
1-(2,4-Dihydroxyphenyl)-2-(4-methoxyphenyl)ethan-1-one (42). A mixture of phenol 38 (8.00 g, 72.7 mmol)
and phenylacetic acid 40 (10.2 g, 61.5 mmol) in BF3·OEt2 (70.0 mL, 557 mmol) was reacted according to
GP-G. The crude residue was purified by recrystallization from CHCl3 to afford phenylethanone
42 (5.67 g, 36%) as a pale yellow-white powdery solid. m.p. 168–170 ◦C. TLC Rf = 0.50 (1%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3349s(br) (O-H str), 2917w (C-H str), 2838w (C-H str), 1614s
(C=O str), 1607s (C=C str), 1590s (C=C str), 1510s (C=C str), 1500m (C=C str), 1436m, 1412w, 1351s,
1299m, 1239m, 1174s, 1129m, 1105w, 1023s. 1H-NMR (500 MHz, (CD3)2CO): δ 3.76 (3H, s, -OCH3),
4.22 (2H, s, -COCH2), 6.33 (1H, d, J = 2.0 Hz, ArH), 6.44 (1H, dd, J = 9.2, 2.4 Hz, ArH), 6.88 (2H, d,
J = 8.8 Hz, ArH), 7.26 (2H, d, J = 8.8 Hz, ArH), 7.96 (1H, d, J = 8.8 Hz, ArH), 9.46 (1H, s, OH), 12.73 (1H,
s, OH). 13C-NMR (500 MHz, (CD3)2CO): δ 43.6, 54.8, 103.0, 108.2, 112.8, 114.1, 127.3, 130.7, 133.7, 159.0,
165.0, 166.1, 203.1. LCMS (ES+) m/z = 259.1 ([M + H]+, tR = 1.52 min). These characterisation data are
in accordance with that previously reported in the literature [43].
4′-Hydroxy-7-methoxyisoflavone (43). A mixture of phenylethanone 41 (2.00 g, 7.74 mmol), BF3·OEt2
(3.90 mL, 31.1 mmol) and MeSO2Cl (1.80 mL, 23.3 mmol) in dry DMF (50 mL) was reacted according
to GP-H. The crude residue was purified by flash column chromatography (SiO2, PE/EtOAc; 2:1) to
afford isoflavone 43 (1.18 g, 57%) as a white powdery solid. m.p. 232–234 ◦C. TLC Rf = 0.39 (PE/EtOAc;
1:1). IR νmax (neat)/cm−1: 3210m(br) (O-H str), 3014w (C-H str), 1621s (C=O str), 1583s (C=C str),
1563m (C=C str), 1517s (C=C str), 1439s, 1373w, 1253s, 1205w, 1170w, 1095m, 1050m, 1019m. 1H-NMR
(500 MHz, (CD3)2CO): δ 3.97 (3H, s, -OCH3), 6.89 (2H, d, J = 8.4 Hz, ArH), 7.04–7.07 (2H, m, ArH), 7.48
(2H, d, J = 8.8 Hz, ArH), 8.10 (1H, d, J = 8.8 Hz, ArH), 8.19 (1H, s, -C=CH), 8.44 (1H, s, OH). 13C-NMR
(500 MHz, (CD3)2CO): δ 55.8, 100.4, 114.7, 115.2, 118.5, 123.7, 124.7, 127.4, 130.4, 152.7, 157.6, 158.2,
164.4, 175.1. LCMS (ES+) m/z = 269.1 ([M + H]+, tR = 1.41 min). These characterisation data are in
accordance with that previously reported in the literature [42].
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7-Hydroxy-4’-methoxyisoflavone (44). A mixture of phenylethanone 42 (2.02 g, 7.82 mmol), BF3·OEt2
(3.90 mL, 31.1 mmol) and MeSO2Cl (1.80 mL, 23.2 mmol) in dry DMF (50 mL) was reacted according
to GP-H. The crude residue was purified by flash column chromatography (SiO2, PE/EtOAc; 1:1) and
recrystallized from CHCl3 to afford isoflavone 44 (1.62 g, 77%) as a dark yellow powdery solid. m.p.
242–244 ◦C. TLC Rf = 0.26 (PE/EtOAc; 1:1). IR νmax (neat)/cm−1: 3126s(br) (O-H str), 2993w (C-H str),
2836w (C-H str), 1637m (C=O str), 1621m, 1594s (C=C str), 1568m (C=C str), 1512s (C=C str), 1451s,
1384m, 1273m, 1178s, 1099m, 1045m, 1025s. 1H-NMR (500 MHz, (CD3)2CO): δ 3.20 (1H, br s, OH),
3.83 (3H, s, -OCH3), 6.92 (1H, d, J = 2.0 Hz, ArH), 6.98 (2H, d, J = 9.2 Hz, ArH), 7.01 (1H, dd, J = 8.8,
2.4 Hz, ArH), 7.56 (2H, d, J = 8.8 Hz, ArH), 8.07 (1H, d, J = 8.4 Hz, ArH), 8.18 (1H, s, -C=CH). 13C-NMR
(500 MHz, (CD3)2CO): δ 54.9, 102.5, 113.7, 115.1, 117.9, 124.3, 124.9, 127.8, 130.4, 152.8, 158.2, 159.8,
162.6, 175.0. LCMS (ES+) m/z = 269.1 ([M + H]+, tR = 1.47 min). These characterisation data are in
accordance with that previously reported in the literature [44].
7-Methoxy-(4′-(prop-2-yn-1-yloxy)isoflavone (45). A mixture of isoflavone 43 (602 mg, 2.25 mmol),
propargyl bromide (0.50 mL, 5.61 mmol) and anhydrous K2CO3 (1.09 g, 7.91 mmol) in dry
acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column
chromatography (SiO2, 1% MeOH/CH2Cl2) to afford isoflavone 45 (641 mg, 93%) as a white powdery
solid. m.p. 162–164 ◦C. TLC Rf = 0.45 (1% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3289m (C≡C-H
str), 3083w (C-H str), 2953w (C-H str), 1645s (C=O str), 1624s, 1606s, 1579m (C=C str), 1513s (C=C str),
1456m, 1442s, 1378s, 1285m, 1262s, 1245s, 1192s, 1176s, 1103s, 1050w, 1017s. 1H-NMR (500 MHz,
CDCl3): δ 2.54 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 3.92 (3H, s, -OCH3), 4.73 (2H, d, J = 2.4 Hz,
-OCH2C≡CH), 6.86 (2H, d, J = 2.0 Hz, ArH), 7.00 (1H, dd, J = 8.8, 2.0 Hz, ArH), 7.05 (2H, d, J = 8.8 Hz,
ArH), 7.52 (2H, d, J = 8.8 Hz, ArH), 7.93 (1H, s, -C=CH), 8.21 (2H, d, J = 8.8 Hz, ArH). 13C-NMR
(500 MHz, CDCl3): δ 55.8, 75.6, 78.5, 100.1, 114.5, 114.9, 118.4, 124.7, 125.2, 127.8, 130.1, 152.1, 157.5,
157.9, 164.0, 175.7. LCMS (ES+) m/z = 307.1 ([M + H]+, tR = 1.59 min). HRMS (ESI+) m/z =307.0959
[M + H]+ found, C19H15O4+ required 307.0965.
4′-Methoxy-7-(prop-2-yn-1-yloxy)isoflavone (46). A mixture of isoflavone 44 (810 mg, 3.02 mmol),
propargyl bromide (0.55 mL, 6.17 mmol) and anhydrous K2CO3 (1.25 g, 9.01 mmol) in dry
acetone (50 mL) was reacted according to GP-C. The crude residue was purified by flash column
chromatography (SiO2, CH2Cl2) to afford isoflavone 46 (550 mg, 60%) as a white powdery solid. m.p.
150–152 ◦C. TLC Rf = 0.32 (0.5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3281m (C≡C-H str), 3259m,
3078w (C-H str), 2950w (C-H str), 2116w (C≡C str), 1624s (C=O str), 1608s, 1597s (C=C str), 1565m
(C=C str), 1513s (C=C str), 1440s, 1373m, 1326w, 1295m, 1271s, 1237s, 1176s, 1109w, 1095s, 1052m,
1033s, 1016s. 1H-NMR (500 MHz, CDCl3): δ 2.61 (1H, t, J = 2.0 Hz, -OCH2C≡CH), 3.85 (3H, s, -OCH3),
4.81 (1H, d, J = 2.4 Hz, -OCH2C≡CH), 6.98 (2H, d, J = 8.4 Hz, ArH), 6.98 (1H, d, J = 2.4 Hz, ArH),
7.05 (1H, dd, J = 8.8, 2.4 Hz, ArH), 7.51 (2H, d, J = 8.8 Hz, ArH), 7.93 (1H, s, -C=CH), 8.24 (1H, d,
J = 8.8 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 55.3, 56.2, 76.6, 77.3, 101.5, 113.9, 114.8, 119.0, 124.1,
124.9, 127.9, 130.1, 152.1, 157.6, 159.6, 161.6, 175.8. LCMS (ES+) m/z = 307.1 ([M + H]+, tR = 1.62 min).
These characterisation data are in accordance with that previously reported in the literature [45].
4-(Prop-2-yn-1-yloxy)-2H-chromen-2-one (48). A mixture of 4-hydroxycoumarin 47 (5.06 g, 31.2 mmol),
propargyl bromide (6.20 mL, 69.6 mmol) and anhydrous K2CO3 (8.74 g, 63.2 mmol) in dry
acetone (100 mL) was reacted according to GP-C. The crude residue was purified by flash column
chromatography (SiO2, CH2Cl2) to afford coumarin 48 (3.60 g, 58%) as a white fluffy solid. m.p.
154–156 ◦C. TLC Rf = 0.24 (CH2Cl2). IR νmax (neat)/cm−1: 3281m (C≡C-H str), 3240m, 3078w (C-H
str), 2131w (C≡C str), 1714s (C=O str), 1688m, 1622s, 1610m (C=C str), 1568m (C=C str), 1493m, 1453m,
1409m, 1361m, 1329w, 1274s, 1248s, 1194w, 1179m, 1155w, 1145m, 1107s, 1032w. 1H-NMR (500 MHz,
CDCl3): δ 2.68 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 4.88 (2H, d, J = 2.4 Hz, -OCH2C≡CH), 5.84 (1H, s,
-C=CH), 7.29–7.34 (2H, m, ArH), 7.57 (1H, t, J = 8.4 Hz, ArH), 7.84 (1H, dd, J = 8.0, 1.2 Hz, ArH).
13C-NMR (500 MHz, CDCl3): δ 56.8, 75.7, 77.9, 91.7, 115.4, 116.8, 123.1, 124.0, 132.6, 153.3, 162.4, 164.2.
Molecules 2016, 21, 1230 27 of 59
LCMS (ES+) m/z = 201.1 ([M + H]+, tR = 1.47 min). These characterisation data are in accordance with
that previously reported in the literature [46].
2-(2-Chloro-1-iminoethyl)-1,3,5-benzentriol hydrochloride (50). To a stirred solution of phloroglucinol 49
(5.02 g, 39.8 mmol) and chloroacetonitrile (2.50 mL, 39.5 mmol) in Et2O (100 mL) was added anhydrous
ZnCl2 (0.558 g, 4.09 mmol). The reaction mixture was cooled to 0 ◦C and HCl gas was bubbled through
the solution for 30 min. The resulting mixture was stirred at 0 ◦C for 3 h and further 24 h at room
temperature. The resulting suspension was filtered and the precipitate was washed with ice-cold
Et2O (2 × 50 mL) and suction-dried to afford hydrochloric salt 50 (1.87 g, 20%) as a pale yellow-white
powdery solid and was used without further purification in the next step. m.p. 240–242 ◦C. IR νmax
(neat)/cm−1: 3389m (N-H str), 3257m(br) (O-H str), 3184s(br) (O-H str), 2968w (C-H str), 1646m, 1616s
(C=C str), 1591s (C =C str), 1531w (C=C str), 1457m, 1383m, 1366s, 1291m, 1248s, 1175s, 1128w, 1065m,
1050s, 1024w. 1H-NMR (500 MHz, DMSO-d6): δ 5.46 (2H, s, -CH2-), 6.07 (1H, d, J = 1.2 Hz, ArH), 6.26
(1H, d, J = 1.2 Hz, ArH), 9.90 (1H, s, OH), 10.84 (1H, s, OH), 11.80 (1H, br s, NH), 12.54 (1H, s, OH).
13C-NMR (500 MHz, DMSO-d6): δ 75.3, 90.1, 96.9, 99.3, 160.4, 172.8, 173.7, 176.0. These characterisation
data are in accordance with that previously reported in the literature [47].
2,4,6-Trihydroxy-2-chloroacetophenone (51). A mixture of imine salt 50 (1.80 g, 7.56 mmol) and 1 M HCl
(100 mL) were heated at reflux with stirring for 1 h. The resulting red solution was blown under a
steady stream of nitrogen and the residual solid was re-suspended in H2O (50 mL). The precipitate
was filtered, washed with ice-water (2 × 50 mL), suction-dried and re-dissolved in EtOAc (50 mL). The
organic solution was washed with H2O (2 × 50 mL), brine (2 × 50 mL), dried over anhydrous Na2SO4,
filtered and evaporated to dryness. The crude residue was purified by flash column chromatography
(SiO2, PE/EtOAc; 1:1) to afford acetophenone 51 (389 mg, 25%) as a white powdery solid. m.p.
236–238 ◦C. TLC Rf = 0.32 (PE/EtOAc; 1:1). IR νmax (neat)/cm−1: 3422m (br) (O-H str), 3372s(br)
(O-H str), 3068w (C-H str), 2962w (C-H str), 1640m (C=O str), 1598s (C=C str), 1521m (C=C str),
1456s, 1376s, 1331w, 1279m, 1213s, 1164s, 1073s, 1017m. 1H-NMR (500 MHz, DMSO-d6): δ 4.98 (2H,
s, -COCH2-), 5.84 (2H, s, ArH), 10.55 (1H, s, OH), 12.07 (2H, s, OH). 13C-NMR (500 MHz, DMSO-d6):
δ 51.0, 94.7, 102.5, 163.9, 165.5, 194.7. LCMS (ES+) m/z = 203.0 ([M + H]+, tR = 1.26 min). These
characterisation data are in accordance with that previously reported in the literature [26].
Dihydroxybenzofuran-3(2H)-one (52). To a stirred solution of acetophenone 51 (5.00 g, 24.7 mmol) in
MeOH (100 mL) was added NaOMe (4.88 g, 90.3 mmol) and the mixture was heated at reflux for 2 h
under nitrogen. The reaction mixture was allowed to cool to room temperature, acidified with 1 M HCl
and the solvent removed under reduced pressure. The resulting dark residue was then re-dissolved in
EtOAc (100 mL). The organic solution was washed with H2O (2 × 100 mL), brine (2 × 100 mL), dried
over anhydrous MgSO4, filtered and evaporated to dryness. The crude residue was purified by flash
column chromatography (SiO2, PE/EtOAc; 1:1) to afford benzofuranone 52 (2.90 g, 71%) as a pale
brown-white powdery solid. m.p. 280–282 ◦C. TLC Rf = 0.16 (PE/EtOAc; 1:1). IR νmax (neat)/cm−1:
3331s(br) (O-H str), 3164m(br) (O-H str), 3062w (C-H str), 1671m (C=O str), 1607s (C=C str), 1533w
(C=C str), 1457m, 1422w, 1399m, 1369m, 1336m, 1261w, 1227m, 1157s, 1064s, 1042m, 1012m. 1H-NMR
(500 MHz, DMSO-d6): δ 4.55 (2H, s, -OCH2CO-), 5.91 (2H, s, ArH), 10.59 (2H, br s, OH). 13C-NMR
(500 MHz, DMSO-d6): δ 74.9, 90.1, 96.2, 102.7, 157.5, 167.6, 175.6, 194.0. LCMS (ES+) m/z = 167.1
([M + H]+, tR = 1.27 min). These characterisation data are in accordance with that previously reported
in the literature [26].
4,6-Dimethoxybenzofuran-3(2H)-one (53). To a stirred solution of dihydroxybenzofuranone 52 (2.02 g,
12.2 mmol) in dry DMF (50 mL) were added CH3I (2.30 mL, 37.0 mmol) and anhydrous K2CO3 (3.35 g,
24.2 mmol). The resulting dark red-brown suspension was heated at 80 ◦C for 1 h under a nitrogen
atmosphere. The reaction mixture was then allowed to cool to room temperature, poured into ice-water
(100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layer was washed with H2O
(3 × 100 mL), brine (2 × 100 mL), dried over anhydrous MgSO4, filtered and evaporated to dryness.
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The crude residue was purified by flash column chromatography (SiO2, PE/EtOAc; 1:1) to afford
benzofuranone 53 (1.87 g, 79%) as a pale yellow-white powdery solid. m.p. 148–150 ◦C. TLC Rf = 0.23
(PE/EtOAc; 1:1). IR νmax (neat)/cm−1: 2979w (C-H str), 2949w (C-H str), 1699s (C=O str), 1616s
(C=C str), 1585s (C=C str), 1500m (C=C str), 1463m, 1431m, 1366m, 1342m, 1288m, 1217s, 1186s, 1160s,
1099s, 1052m, 1021m. 1H-NMR (500 MHz, CDCl3): δ 3.83 (3H, s, -OCH3), 3.87 (3H, s, -OCH3), 4.55
(2H, s, -OCH2CO-), 5.97 (1H, d, J = 1.6 Hz, ArH), 6.11 (1H, d, J = 2.0 Hz, ArH). 13C-NMR (500 MHz,
CDCl3): δ 55.9, 55.9, 75.4, 88.8, 92.9, 104.7, 158.7, 169.7, 177.0, 194.9. LCMS (ES+) m/z = 195.1 ([M + H]+,
tR = 1.52 min). These characterisation data are in accordance with that previously reported in the
literature [26].
4,6-Dimethoxy-3′-hydroxyaurone (55). To a stirred solution of benzofuranone 53 (1.01 g, 5.20 mmol) in
MeOH (20 mL) was added 3-hydroxybenzaldehyde 54 (0.760 g, 6.22 mmol) followed by the addition
of KOH (1.50 g, 26.6 mmol) in H2O (20 mL). The reaction mixture was stirred at room temperature
for 2 h and then poured into H2O (2 × 100 mL). The resulting suspension was neutralized to pH 7
with 3 M HCl and extracted with CHCl3 (3 × 50 mL). The combined organic layer was washed with
H2O (3 × 100 mL), brine (100 mL), dried over anhydrous MgSO4, filtered and evaporated to dryness
under reduced pressure. The crude residue was purified by flash column chromatography (SiO2,
PE/EtOAc; 1:1) and recrystallized from MeOH to afford aurone 55 (1.21 g, 78%) as a bright yellow
powdery solid. m.p. 178–180 ◦C. TLC Rf = 0.35 (PE/EtOAc; 1:2). IR νmax (neat)/cm−1: 3254m(br)
(O-H str), 2944w (C-H str), 2842w (C-H str), 1688m (C=O str), 1649m, 1612s (C=C str), 1586s (C=C str),
1501m (C=C str), 1447s, 1430w, 1338m, 1303m, 1249m, 1214s, 1153s, 1138m, 1087s, 1038w. 1H-NMR
(500 MHz, (CD3)2CO): δ 3.94 (3H, s, -OCH3), 3.98 (3H, s, -OCH3), 6.32 (1H, d, J = 2.0 Hz, ArH), 6.56 (1H,
d, J = 1.6 Hz, ArH), 6.56 (1H, s, -C=CH), 6.91 (1H, ddd, J = 8.0, 2.4, 0.8 Hz, ArH), 7.30 (1H, t, J = 8.0 Hz,
ArH), 7.40 (1H, d, J = 7.6 Hz, ArH), 7.47 (1H, t, J = 2.0 Hz, ArH), 8.57 (1H, s, OH). 13C-NMR (500 MHz,
(CD3)2CO): δ 55.9, 56.2, 89.7, 94.4, 104.8, 109.4, 116.8, 117.5, 122.8, 130.0, 134.1, 148.1, 157.9, 159.7, 169.2,
169.5, 179.4. LCMS (ES+) m/z = 299.2 ([M + H]+, tR = 1.71 min). These characterisation data are in
accordance with that previously reported in the literature [48].
4,6-Dimethoxy-3′-(prop-2-yn-1-yloxy)aurone (56). A mixture of aurone 55 (505 mg, 1.69 mmol), propargyl
bromide (0.30 mL, 3.37 mmol) and anhydrous K2CO3 (701 mg, 5.07 mmol) in dry acetone (30 mL) was
reacted according to GP-C. The crude residue was purified by flash column chromatography (SiO2,
0.5% MeOH/CH2Cl2) to afford aurone 56 (545 mg, 96%) as a pale yellow-white powdery solid. m.p.
152–154 ◦C. TLC Rf = 0.46 (1% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3219m (C≡C-H str), 3007w
(C-H str), 2940w (C-H str), 2110w (C≡C str), 1686s (C=O str), 1654m, 1612s (C=C str), 1589s (C=C str),
1504s (C=C str), 1454m, 1423m, 1347m, 1313m, 1266m, 1215s, 1154m, 1094s, 1040m, 1019w. 1H-NMR
(500 MHz, CDCl3): δ 2.57 (1H, t, J = 2.5 Hz, -OCH2C≡CH), 3.91 (3H, s, -OCH3), 3.95 (3H, s, -OCH3),
4.75 (2H, d, J = 2.5 Hz, -OCH2C≡CH), 6.12 (1H, d, J = 2.0 Hz, ArH), 6.37 (1H, d, J = 2.0 Hz, ArH),
6.72 (1H, s, -C=CH), 6.99 (1H, ddd, J = 8.0, 2.5, 1.0 Hz, ArH), 7.35 (1H, t, J = 8.0 Hz, ArH), 7.46 (1H,
d, J = 7.5 Hz, ArH), 7.54 (1H, t, J = 1.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 55.9, 56.1, 56.2, 75.7,
78.3, 89.2, 94.0, 105.1, 110.3, 115.9, 117.1, 124.6, 129.7, 133.9, 148.0, 157.6, 159.4, 169.0, 180.6. LCMS
(ES+) m/z = 337.2 ([M + H]+, tR = 1.83 min). HRMS (ESI+) m/z = 337.1062 [M + H]+ found, C20H17O5+
required 337.1071.
4-(2-Bromoethoxy)-2H-chromen-2-one (57). A mixture of 4-hydroxycoumarin 47 (5.14 g, 31.7 mmol),
1,2-dibromoethane (3.19 mL, 37.0 mmol) and anhydrous K2CO3 (8.56 g, 61.9 mmol) in dry
acetone (100 mL) was reacted according to GP-I. The crude residue was purified by flash column
chromatography (SiO2, CH2Cl2) to afford coumarin 57 (1.33g, 16%) as a white powdery solid. m.p.
176–178 ◦C. TLC Rf = 0.41 (PE/EtOAc 1:1). IR νmax (neat)/cm−1: 3044w (C-H str), 2982w (C-H str),
1716s (C=O str), 1627s, 1607s, 1566m (C=C str), 1496m, 1454m, 1407s, 1369s, 1330m, 1272m, 1246s,
1225s, 1184s, 1147m, 1111s, 1067w, 1034s. 1H-NMR (500 MHz, CDCl3): δ 3.77 (2H, t, J = 6.0 Hz,
-OCH2CH2Br), 4.46 (2H, t, J = 6.0 Hz, -OCH2CH2Br), 5.68 (1H, s, -C=CH), 7.31 (1H, t, J = 8.0 Hz, ArH),
7.34 (1H, dd, J = 8.5, 0.5 Hz, ArH), 7.58 (1H, t, J = 8.5 Hz, ArH), 7.88 (1H, dd, J = 7.5, 1.5 Hz, ArH).
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13C-NMR (500 MHz, CDCl3): δ 27.6, 68.4, 90.9, 115.3, 116.8, 123.1, 124.0, 132.7, 153.3, 162.5, 164.9. LCMS
(ES+) m/z = 271.0 ([M + H]+, tR = 1.53 min). These characterisation data are in accordance with that
previously reported in the literature [49].
4-(2-Azidoethoxy)-2H-chromen-2-one (58). A mixture of coumarin 57 (679 mg, 2.52 mmol) and NaN3
(370 mg, 5.69 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture was
worked up to afford coumarin 58 (571 mg, 98%) as an off-white powdery solid and was used without
further purification. m.p. 150–152 ◦C. TLC Rf = 0.40 (1% MeOH/CH2Cl2). IR νmax (neat)/cm−1:
3075w (C-H str), 2947w (C-H str), 2125s (N3 str), 1732s (C=O str), 1623s, 1609s, 1566s (C=C str), 1495s,
1453m, 1417s, 1371s, 1277m, 1236s, 1180s, 1147s, 1109s, 1032s. 1H-NMR (500 MHz, CDCl3): δ 3.75 (2H,
t, J = 5.0 Hz, -OCH2CH2N3), 4.32 (2H, t, J = 5.0 Hz, -OCH2CH2N3), 5.70 (1H, s, -C=CH), 7.31 (1H, t,
J = 8.0 Hz, ArH), 7.34 (1H, dd, J = 8.5, 0.5 Hz, ArH), 7.58 (1H, t, J = 8.5 Hz, ArH), 7.84 (1H, dd, J = 8.0,
1.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.6, 68.2, 90.9, 115.2, 116.8, 123.0, 124.1, 132.7, 153.3,
162.5, 165.1. LCMS (ES+) m/z = 232.1 ([M + H]+, tR = 1.70 min). These characterisation data are in
accordance with that previously reported in the literature [27].
4-(2-Bomoethoxy)benzaldehyde (59). A mixture of benzaldehyde 33 (20.0 g, 164 mmol), 1,2-dibromoethane
(28.5 mL, 331 mmol) and anhydrous K2CO3 (46.0 g, 333 mmol) in dry acetone (100 mL) was reacted
according to GP-I. The crude residue was purified by flash column chromatography (SiO2, CH2Cl2)
to afford benzaldehyde 59 (13.2 g, 35%) as a white powdery solid. m.p. 56–58 ◦C. TLC Rf = 0.41
(CH2Cl2). IR νmax (neat)/cm−1: 2967w (C-H str), 1679s (C=O str), 1601s (C=C str), 1577s (C=C str),
1508m (C=C str), 1458m, 1422m, 1392m, 1317w, 1300m, 1282m, 1249s, 1229s, 1211s, 1160s, 1107w, 1068s,
1008s. 1H-NMR (500 MHz, CDCl3): δ 3.68 (2H, t, J = 6.4 Hz, -OCH2CH2Br), 4.39 (2H, t, J = 6.4 Hz,
-OCH2CH2Br), 7.03 (2H, d, J = 8.8 Hz, ArH), 7.86 (2H, d, J = 8.8 Hz, ArH), 9.91 (1H, s, CHO). 13C-NMR
(500 MHz, CDCl3): δ 28.4, 67.9, 114.8, 130.5, 132.0, 163.0, 190.7. LCMS (ES+) m/z = 231.0 ([M + H]+,
tR = 1.56 min). These characterisation data are in accordance with that previously reported in the
literature [50].
4-(2-Azidoethoxy)benzaldehyde (60). A mixture of benzaldehyde 59 (12.8 g, 56.0 mmol) and NaN3 (7.36 g,
113 mmol) in dry DMF (100 mL) was reacted according to GP-J. The reaction mixture was worked
up to afford benzaldehyde 60 (10.6 g, 99%) as a pale yellow viscous oil and was used without further
purification. TLC Rf = 0.38 (CH2Cl2). IR νmax (neat)/cm−1: 2942w (C-H str), 2837w (C-H str), 2100s
(N3 str), 1682s (C=O str), 1598s (C=C str), 1578s (C=C str), 1508s (C=C str), 1427w, 1395w, 1304m,
1247s, 1213s, 1157s, 1110m, 1052m, 1008w. 1H-NMR (500 MHz, CDCl3): δ 3.64 (2H, t, J = 5.0 Hz,
-OCH2CH2N3), 4.22 (2H, t, J = 5.0 Hz, -OCH2CH2N3), 7.02 (2H, d, J = 8.5 Hz, ArH), 7.84 (2H, d,
J = 9.0 Hz, ArH), 9.88 (1H, s, CHO). 13C-NMR (500 MHz, CDCl3): δ 49.9, 67.1, 114.7, 130.3, 131.9, 163.0,
190.7. LCMS (ES+) m/z = 193.2 ([M + H]+, tR = 1.62 min). These characterisation data are in accordance
with that previously reported in the literature [50].
(E)-3-(4-(2-Azidoethoxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (61). A mixture of benzaldehyde 60
(4.90 g, 25.6 mmol), acetophenone 10 (3.09 mL, 25.7 mmol) and KOH (8.70 g, 155 mmol) in absolute
EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by recrystallization
from MeOH to afford chalcone 61 (6.13 g, 77%) as a bright yellow powdery solid. m.p. 142–144 ◦C.
TLC Rf = 0.48 (PE/EtOAc; 2:1). IR νmax (neat)/cm−1: 2932w (C-H str), 2874w (C-H str), 2107m (N3 str),
2070m, 1636s (C=O str), 1602s, 1575s (C=C str), 1560s (C=C str), 1508s (C=C str), 1488s, 1424m, 1345m,
1299m, 1271m, 1244m, 1201m, 1059m, 1031m. 1H-NMR (500 MHz, CDCl3): δ 3.63 (2H, t, J = 5.0 Hz,
-OCH2CH2N3), 4.19 (2H, t, J = 5.0 Hz, -OCH2CH2N3), 6.93–6.98 (3H, m, ArH), 7.03 (1H, dd, J = 8.5,
1.0 Hz, ArH), 7.49 (1H, t, J = 8.5 Hz, ArH), 7.54 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.63 (2H, d, J = 8.5 Hz,
ArH), 7.89 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.92 (1H, dd, J = 8.5, 2.0 Hz, ArH), 12.94 (1H, s, OH).
13C-NMR (500 MHz, CDCl3): δ 50.0, 67.0, 115.0, 117.9, 118.5, 118.7, 120.0, 127.9, 129.5, 130.5, 136.2,
145.0, 160.5, 163.5, 193.5. LCMS (ES+) m/z = 310.1 ([M + H]+, tR = 1.80 min). These characterisation
data are in accordance with that previously reported in the literature [51].
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1-(4-(2-Bromoethoxy)-3-methoxyphenyl)ethan-1-one (62). A mixture of acetophenone 11 (10.0 g, 60.3 mmol),
1,2-dibromoethane (10.5 mL, 122 mmol) and anhydrous K2CO3 (12.6, 91.5 mmol) in dry DMF (100 mL)
was reacted according to GP-I. The crude residue was purified by flash column chromatography (SiO2,
CH2Cl2) to afford acetophenone 62 (3.90 g, 24%) as a white powdery solid. m.p. 98–100 ◦C. TLC
Rf = 0.16 (CH2Cl2). IR νmax (neat)/cm−1: 3075w (C-H str), 2971w (C-H str), 1760w, 1671s (C=O str),
1585s (C=C str), 1507s (C=C str), 1460m, 1412s, 1385w, 1359m, 1263s, 1220s, 1171m, 1144s, 1076s, 1030s,
1008s. 1H-NMR (500 MHz, CDCl3): δ 2.58 (3H, s, -COCH3), 3.70 (2H, t, J = 6.8 Hz, -OCH2CH2Br), 3.94
(3H, s, -OCH3), 4.41 (2H, t, J = 6.8 Hz, -OCH2CH2Br), 6.91 (1H, d, J = 8.8 Hz, ArH), 7.55–7.57 (2H, m,
ArH). 13C-NMR (500 MHz, CDCl3): δ 26.3, 28.2, 56.1, 68.7, 111.0, 112.2, 123.0, 131.4, 149.5, 151.7, 196.7.
LCMS (ES+) m/z = 275.0 ([M + H]+, tR = 1.43 min). These characterisation data are in accordance with
that previously reported in the literature [52].
1-(4-(2-Azidoethoxy)-3-methoxyphenyl)ethan-1-one (63). A mixture of acetophenone 62 (3.50 g, 12.8 mmol)
and NaN3 (1.25 g, 19.2 mol) in DMF (30 mL) was reacted according to GP-J. The reaction mixture was
worked up to afford phenylethanone 63 (2.94 g, 98%) as a pale brown residual oil which solidified
upon standing to give a pale brown crystalline solid and used without further purification. m.p.
58–60 ◦C. TLC Rf = 0.30 (0.5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3088w (C-H str), 2956w (C-H
str), 2110s (N3 str), 2067m, 1742w, 1671s (C=O str), 1589s (C=C str), 1508s (C=C str), 1471m, 1419s,
1355m, 1270s, 1216s, 1177m, 1151s, 1080m, 1036s. 1H-NMR (500 MHz, CDCl3): δ 2.56 (3H, s, -COCH3),
3.68 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.91 (3H, s, -OCH3), 4.23 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 6.89
(1H, d, J = 8.0 Hz, ArH), 7.53–7.55 (2H, m, ArH). 13C-NMR (500 MHz, CDCl3): δ 26.2, 50.0, 56.0, 67.7,
110.7, 111.9, 122.9, 131.2, 149.4, 151.9, 196.7. LCMS (ES+) m/z = 236.0 ([M + H]+, tR = 1.45 min). These
characterisation data are in accordance with that previously reported in the literature [52].
(E)-1-(4-(2-Azidoethoxy)-3-methoxyphenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one (67). A mixture of
benzaldehyde 64 (1.48 g, 8.91 mmol), acetophenone 63 (2.04 g, 8.67 mmol) and KOH (2.41 g, 43.0 mmol)
in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash
column chromatography (SiO2, PE/EtOAc; 5:1) and recrystallized from MeOH to afford chalcone
67 (2.61 g, 79%) as a pale yellow-green powdery solid. m.p. 106–108 ◦C. TLC Rf = 0.28 (PE/EtOAc;
1:1). IR νmax (neat)/cm−1: 2940w (C-H str), 2838w (C-H str), 2112s (N3 str), 2068m, 1648s (C=O str),
1595s (C=C str), 1568s (C=C str), 1509s (C=C str), 1458m, 1419m, 1355w, 1312m, 1261s, 1242s, 1199m,
1159m, 1139s, 1036s, 1021s. 1H-NMR (500 MHz, CDCl3): δ 3.67 (2H, t, J = 5.2 Hz, -OCH2CH2N3),
3.91 (3H, s, -OCH3), 3.93 (3H, s, -OCH3), 3.94 (3H, s, -OCH3), 4.23 (2H, t, J = 5.2 Hz, -OCH2CH2N3),
6.88 (1H, d, J = 8.4 Hz, ArH), 6.92 (1H, d, J = 8.0 Hz, ArH), 7.15 (1H, d, J = 2.0 Hz, ArH), 7.22 (1H,
dd, J = 8.4, 2.0 Hz, ArH), 7.39 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.61–7.65 (2H, m, ArH), 7.75 (1H, d,
J = 15.2 Hz, -CH=CHCO-). 13C-NMR (500 MHz, CDCl3): δ 49.9, 55.8, 56.0, 67.7, 110.1, 111.0, 111.4,
111.9, 119.4, 122.4, 122.8, 127.8, 132.2, 144.2, 149.1, 149.6, 151.2, 151.7, 188.5. LCMS (ES+) m/z = 384.2
([M + H]+, tR = 3.98 min). These characterisation data are in accordance with that previously reported
in the literature [52].
(E)-1-(4-(2-Azidoethoxy)-3-methoxyphenyl)-3-(2,3,4-trimethoxyphenyl)prop-2-en-1-one (68). A mixture of
benzaldehyde 65 (1.70 g, 8.66 mmol), acetophenone 63 (2.02 g, 8.59 mmol) and KOH (2.39 g, 42.6 mmol)
in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by flash
column chromatography (SiO2, PE/EtOAc; 5:1) and recrystallized from MeOH to afford chalcone 68
(2.61 g, 74%) as a pale yellow-green powdery solid. m.p. 114–116 ◦C. TLC Rf = 0.35 (PE/EtOAc; 1:1).
IR νmax (neat)/cm−1: 2945w (C-H str), 2836w (C-H str), 2119s (N3 str), 2072m, 1743w, 1644m (C=O
str), 1588m (C=C str), 1560s (C=C str), 1519m (C=C str), 1494s, 1466m, 1420s, 1246s, 1149s, 1093s, 1042s.
1H-NMR (500 MHz, CDCl3): δ 3.66 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.87 (3H, s, -OCH3), 3.88 (3H, s,
-OCH3), 3.92 (3H, s, -OCH3), 3.93 (3H, s, -OCH3), 4.23 (2H, t, J = 5.0 Hz, -OCH2CH2N3), 6.70 (1H, d,
J = 8.8 Hz, ArH), 6.91 (1H, d, J = 8.8 Hz, ArH), 7.37 (1H, d, J = 8.8 Hz, ArH), 7.55 (1H, d, J = 16.0 Hz,
-CH=CHCO-), 7.61–7.63 (2H, m, ArH), 7.97 (1H, d, J = 15.6 Hz, -CH=CHCO-). 13C-NMR (500 MHz,
CDCl3): δ 49.9, 55.9, 60.8, 61.2, 67.7, 107.5, 111.5, 112.0, 120.8, 121.9, 122.4, 123.7, 132.4, 139.3, 142.3,
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149.6, 151.6, 153.6, 155.6, 188.9. LCMS (ES+) m/z = 414.1 ([M + H]+, tR = 1.64 min). HRMS (ESI+)
m/z = 414.1653 [M + H]+ found, C21H24O6N3+ required 414.1660.
(E)-1-(4-(2-Azidoethoxy)-3-methoxyphenyl)-3-(2,4,6-trimethoxyphenyl)prop-2-en-1-one (69). A mixture of
benzaldehyde 66 (1.69 g, 8.61 mmol), acetophenone 63 (2.06 g, 8.76 mmol) and KOH (2.44 g, 43.5 mmol)
in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by
recrystallization from MeOH to afford chalcone 69 (2.91 g, 82%) as a pale yellow-green powdery
solid. m.p. 132–134 ◦C. TLC Rf = 0.29 (PE/EtOAc; 1:1). IR νmax (neat)/cm−1: 3005w (C-H str), 2939w
(C-H str), 2840w (C-H str), 2112m (N3 str), 1647m (C=O str), 1596m (C=C str), 1567s (C=C str), 1518m
(C=C str), 1493w, 1451m, 1417m, 1320s, 1266m, 1213s, 1147s, 1119s, 1026s. 1H-NMR (500 MHz, CDCl3):
δ 3.70 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.87 (3H, s, -OCH3), 3.92 (6H, s, 2 × -OCH3), 3.96 (3H, s,
-OCH3), 4.27 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 6.16 (2H, s, ArH), 6.95 (1H, d, J = 8.4 Hz, ArH), 7.62–7.65
(2H, m, ArH), 7.88 (1H, d, J = 16.0 Hz, -CH=CHCO-), 8.24 (1H, d, J = 16.0 Hz, -CH=CHCO-). 13C-NMR
(500 MHz, CDCl3): δ 50.1, 55.4, 55.8, 56.1, 67.8, 90.5, 106.6, 111.8, 112.2, 121.8, 122.4, 133.3, 135.4, 149.6,
151.2, 161.6, 163.0, 190.5. LCMS (ES+) m/z = 414.1 ([M + H]+, tR = 1.67 min). HRMS (ESI+) m/z =
414.1654 [M + H]+ found, C21H24O6N3+ required 414.1660.
(E)-1-(4-(2-Azidoethoxy)-3-methoxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (70). A mixture of
pyrrole aldehyde 7 (1.40 mL, 13.0 mmol), acetophenone 63 (3.03 g, 12.9 mmol) and KOH (4.33 g,
77.2 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude product was purified
by flash column chromatography (SiO2, PE/EtOAc; 5:1) and recrystallized from MeOH to afford
chalcone 70 as a bright yellow powdery solid (1.56 g, 37%). m.p. 124–126 ◦C. TLC Rf = 0.32 (PE/EtOAc;
1:1). IR νmax (neat)/cm−1: 2946w (C-H str), 2107m (N3 str), 2064w, 1739w, 1644m (C=O str), 1595s (C=C
str), 1562s (C=C str), 1515m (C=C str), 1485m, 1342s, 1272s, 1238s, 1196s, 1174s, 1125s, 1059m, 1034s.
1H-NMR (500 MHz, CDCl3): δ 3.70 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.78 (3H, s, -NCH3), 3.96 (3H, s,
-OCH3), 4.27 (2H, t, J = 4.8 Hz, -OCH2CH2N3), 6.23–6.24 (1H, m, ArH), 6.82 (1H, t, J = 1.6 Hz, ArH),
6.85 (1H, dd, J = 4.0, 1.6 Hz, ArH), 6.94 (1H, d, J = 8.8 Hz, ArH), 7.31 (1H, d, J = 14.8 Hz, -CH=CHCO-),
7.62–7.64 (2H, m, ArH), 7.81 (1H, d, J = 15.2 Hz, -CH=CHCO-). 13C-NMR (500 MHz, CDCl3): δ 34.4,
50.1, 56.1, 67.8, 109.7, 111.5, 112.1, 112.1, 116.4, 122.2, 127.6, 130.3, 131.7, 132.7, 149.7, 151.6, 188.1.
LCMS (ES+) m/z = 327.2 ([M + H]+, tR = 1.82 min). HRMS (ESI+) m/z = 327.1447 [M + H]+ found,
C17H19O3N4+ required 327.1452.
4-(2-Bromoethoxy)-3-methoxy benzaldehyde (72). A mixture of benzaldehyde 71 (10.0 g, 65.9 mmol),
1,2-dibromoethane (7.40 mL, 85.9 mmol) and anhydrous K2CO3 (11.8 g, 85.5 mmol) in dry
acetone (100 mL) was reacted according to GP-I. The crude residue was purified by flash column
chromatography (SiO2, CH2Cl2) to afford benzaldehyde 72 (4.24 g, 25%) as a white crystalline solid.
m.p. 84–86 ◦C. TLC Rf = 0.37 (CH2Cl2). IR νmax (neat)/cm−1: 2967w (C-H str), 2849w (C-H str),
1697m (C=O str), 1682s, 1672s, 1585s (C=C str), 1508s (C=C str), 1459m, 1444m, 1427m, 1397m, 1349w,
1279m, 1266s, 1233s, 1215w, 1159w, 1134s, 1015s, 1003m. 1H-NMR (500 MHz, CDCl3): δ 3.70 (2H,
t, J = 6.5 Hz, -OCH2CH2Br), 3.94 (3H, s, -OCH3), 4.42 (2H, t, J = 6.5 Hz, -OCH2CH2Br), 6.99 (1H, d,
J = 8.0 Hz, ArH), 7.43–7.46 (2H, m, ArH), 9.87 (1H, s, CHO). 13C-NMR (500 MHz, CDCl3): δ 28.1, 56.1,
68.7, 109.8, 112.4, 126.4, 130.8, 150.0, 152.9, 190.8. LCMS (ES+) m/z = 261.0 ([M + H]+, tR = 1.49 min).
These characterisation data are in accordance with that previously reported in the literature [53].
3-(2-Bromoethoxy)-4-methoxy benzaldehyde (73). A mixture of isovanillin 1 (10.3 g, 68.0 mmol),
1,2-dibromoethane (7.36 mL, 85.4 mmol) and anhydrous K2CO3 (11.8 g, 85.7 mmol) in dry
acetone (100 mL) was reacted according to GP-I. The crude residue was purified by flash column
chromatography (SiO2, CH2Cl2) to afford benzaldehyde 73 (3.81 g, 22%) as a white powdery solid.
m.p. 88–90 ◦C. TLC Rf = 0.38 (CH2Cl2). IR νmax (neat)/cm−1: 2978w (C-H str), 2840w (C-H str), 1677s
(C=O str), 1595m (C=C str), 1582s (C=C str), 1509s (C=C str), 1462w, 1434s, 1392m, 1259s, 1238s, 1162s,
1131s, 1072w, 1013s. 1H-NMR (500 MHz, CDCl3): δ 3.69 (2H, t, J = 6.4 Hz, -OCH2CH2Br), 3.96 (3H, s,
-OCH3), 4.39 (2H, t, J = 6.4 Hz, -OCH2CH2Br), 7.00 (1H, d, J = 8.0 Hz, ArH), 7.41 (1H, d, J = 1.6 Hz,
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ArH), 7.50 (1H, dd, J = 8.0, 1.6 Hz, ArH), 9.84 (1H, s, CHO). 13C-NMR (500 MHz, CDCl3): δ 28.5, 56.2,
68.8, 111.1, 111.6, 127.4, 130.0, 148.0, 155.0, 190.6. LCMS (ES+) m/z = 261.0 ([M + H]+, tR = 1.47 min).
These characterisation data are in accordance with that previously reported in the literature [53].
4-(2-Azidoethoxy)-3-methoxybenzaldehyde (74). A mixture of benzaldehyde 72 (3.40 g, 13.1 mmol) and
NaN3 (1.74 g, 26.8 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture
was worked up to afford benzaldehyde 74 (2.84 g, 98%) as a pale yellow viscous oil and was used
without further purification. TLC Rf = 0.21 (CH2Cl2). IR νmax (neat)/cm−1: 2938w (C-H str), 2831w
(C-H str), 2106s (N3 str), 1679s (C=O str), 1586s (C=C str), 1507s (C=C str), 1457m, 1424m, 1396w,
1339w, 1263s, 1236m, 1194w, 1158w, 1134s, 1051w, 1030m. 1H-NMR (500 MHz, CDCl3): δ 3.66 (2H,
t, J = 5.2 Hz, -OCH2CH2N3), 3.88 (3H, s, -OCH3), 4.22 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 6.95 (1H, d,
J = 8.0 Hz, ArH), 7.38–7.41 (2H, m, ArH), 9.81 (1H, s, CHO). 13C-NMR (500 MHz, CDCl3): δ 49.8, 55.8,
67.7, 109.5, 112.0, 126.1, 130.6, 149.9, 153.0, 190.7. LCMS (ES+) m/z = 222.0 ([M + H]+, tR = 1.66 min).
HRMS (ESI+) m/z = 222.0863 [M + H]+ found, C10H12O3N3+ required 222.0834.
3-(2-Azidoethoxy)-4-methoxybenzaldehyde (75). A mixture of benzaldehyde 73 (3.63 g, 14.0 mmol) and
NaN3 (1.80 g, 27.7 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture
was worked up to afford benzaldehyde 75 (3.03 g, 98%) as a pale yellow viscous oil and was used
without further purification. TLC Rf = 0.26 (CH2Cl2). IR νmax (neat)/cm−1: 2940w (C-H str), 2838w
(C-H str), 2094s (N3 str), 1682s (C=O str), 1596s (C=C str), 1583s (C=C str), 1508s (C=C str), 1435s,
1397w, 1339w, 1261s, 1236s, 1161m, 1134s, 1125s, 1051w, 1019s. 1H-NMR (500 MHz, CDCl3): δ 3.68
(2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.96 (3H, s, -OCH3), 4.25 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 7.00
(1H, d, J = 8.0 Hz, ArH), 7.42 (1H, d, J = 2.0 Hz, ArH), 7.50 (1H, dd, J = 8.4, 2.0 Hz, ArH), 9.85 (1H, s,
CHO). 13C-NMR (500 MHz, CDCl3): δ 50.0, 56.1, 67.9, 110.9, 111.1, 127.5, 129.9, 148.3, 155.1, 190.7.
LCMS (ES+) m/z = 222.3 ([M + H]+, tR = 1.69 min). HRMS (ESI+) m/z = 244.0683 [M + Na]+ found,
C10H11O3N3Na+ required 244.0693.
(E)-3-(4-(2-Azidoethoxy)phenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one (76). A mixture of
benzaldehyde 60 (5.00 g, 26.2 mmol), acetophenone 3 (4.39 g, 26.4 mmol) and KOH (9.42 g, 168 mmol)
in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified by
recrystallization from MeOH to afford chalcone 76 (5.72 g, 64%) as a bright yellow-orange powdery
solid. m.p. 124–126 ◦C. TLC Rf = 0.36 (PE/EtOAc; 2:1). IR νmax (neat)/cm−1: 2940w (C-H str),
2873w (C-H str), 2109m (N3 str), 2073m, 1634m (C=O str), 1604m, 1573s (C=C str), 1513s (C=C str),
1445m, 1426m, 1361s, 1328m, 1307w, 1279s, 1250w, 1209s, 1184s, 1119s, 1057m, 1015s. 1H-NMR
(500 MHz, CDCl3): δ 3.65 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.87 (3H, s, -OCH3), 4.22 (2H, t, J = 5.2 Hz,
-OCH2CH2N3), 6.49–6.51 (2H, m, ArH), 6.98 (2H, d, J = 8.8 Hz, ArH), 7.48 (1H, d, J = 15.2 Hz,
-CH=CHCO-), 7.63 (2H, d, J = 8.8 Hz, ArH), 7.84 (1H, d, J = 9.2 Hz, ArH), 7.87 (1H, d, J = 15.6 Hz,
-CH=CHCO-), 13.52 (1H, s, OH). 13C-NMR (500 MHz, CDCl3): δ 50.6, 55.6, 67.1, 101.0, 107.7, 114.1,
115.0, 118.3, 128.2, 130.4, 131.1, 144.0, 160.3, 166.1, 166.6, 191.8. LCMS (ES+) m/z = 340.2 ([M + H]+,
tR = 1.74 min). HRMS (ESI+) m/z = 340.1295 [M + H]+ found, C18H18N3O4+ required 340.1297.
(E)-3-(4-(2-Azidoethoxy)-3-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (77). A mixture of
benzaldehyde 74 (2.70 g, 12.2 mmol), acetophenone 10 (1.50 mL, 12.5 mmol) and KOH (4.30 g,
76.6 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified
by flash column chromatography (SiO2, PE/EtOAc; 5:1) to afford chalcone 77 (1.91 g, 46%) as a bright
yellow-orange powdery solid. m.p. 84–86 ◦C. TLC Rf = 0.25 (PE/EtOAc; 3:1). IR νmax (neat)/cm−1:
2935w (C-H str), 2876w (C-H str), 2106s (N3 str), 1635s (C=O str), 1580m (C=C str), 1562s (C=C str),
1508s (C=C str), 1489s, 1462w, 1441w, 1421w, 1372w, 1313w, 1255s, 1201s, 1168w, 1138s, 1057w, 1028s.
1H-NMR (500 MHz, CDCl3): δ 3.68 (2H, t, J = 5.5 Hz, -OCH2CH2N3), 3.95 (3H, s, -OCH3), 4.24 (2H,
t, J = 5.5 Hz, -OCH2CH2N3), 6.92 (1H, d, J = 8.0 Hz, ArH), 6.93–6.96 (1H, m, ArH), 7.03 (1H, dd,
J = 8.5, 1.5 Hz, ArH), 7.19 (1H, d, J = 2.0 Hz, ArH), 7.25 (1H, dd, J = 8.5, 1.5 Hz, ArH), 7.50 (1H, t,
J = 8.5 Hz, ArH), 7.53 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.87 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.93
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(1H, dd, J = 8.0, 1.5 Hz, ArH), 12.91 (1H, s, OH). 13C-NMR (500 MHz, CDCl3): δ 50.1, 56.1, 67.9, 111.2,
113.4, 118.2, 118.5, 118.7, 120.0, 123.1, 128.5, 129.5, 136.2, 145.4, 149.9, 150.5, 163.5, 193.5. LCMS (ES+)
m/z = 340.3 ([M + H]+, tR = 1.96 min). HRMS (ESI+) m/z = 340.1296 [M + H]+ found, C18H18N3O4+
required 340.1297.
(E)-3-(3-(2-Azidoethoxy)-4-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (78). A mixture of
benzaldehyde 75 (3.00 g, 13.6 mmol), acetophenone 10 (1.63 mL, 13.6 mmol) and KOH (4.57 g,
81.4 mmol) in absolute EtOH (100 mL) was reacted according to GP-D. The crude residue was purified
by flash column chromatography (SiO2, PE/EtOAc; 5:1) to afford chalcone 78 (2.72 g, 59%) as a bright
yellow powdery solid. m.p. 98–100 ◦C. TLC Rf = 0.33 (PE/EtOAc; 3:1). IR νmax (neat)/cm−1: 3009w
(C-H str), 2970w (C-H str), 2112m (N3 str), 2067w, 1738s (C=O str), 1634s, 1567s (C=C str), 1511s (C=C
str), 1490s, 1440m, 1374s, 1315m, 1266s, 1227s, 1204s, 1142s, 1024s. 1H-NMR (500 MHz, CDCl3): δ 3.66
(2H, t, J = 5.0 Hz, -OCH2CH2N3), 3.89 (3H, s, -OCH3), 4.22 (2H, t, J = 5.0 Hz, -OCH2CH2N3), 6.90 (1H, d,
J = 8.5 Hz, ArH), 6.91 (1H, t, J = 8.5 Hz, ArH), 7.00 (1H, dd, J = 8.5, 1.0 Hz, ArH), 7.19 (1H, d, J = 2.5 Hz,
ArH), 7.27 (1H, dd, J = 8.0, 2.0 Hz, ArH, overlain by CDCl3), 7.46 (1H, t, J = 7.5 Hz, ArH), 7.48 (1H, d,
J = 15.0 Hz, -CH=CHCO-), 7.82 (1H, d, J = 15.0 Hz, -CH=CHCO-), 7.90 (1H, dd, J = 8.0, 1.5 Hz, ArH),
12.95 (1H, s, OH). 13C-NMR (500 MHz, CDCl3): δ 50.1, 55.8, 68.2, 111.7, 113.4, 117.7, 118.4, 118.6,
119.9, 124.6, 127.3, 129.4, 136.1, 145.2, 147.9, 152.5, 163.4, 193.3. LCMS (ES+) m/z = 340.3 ([M + H]+,
tR = 1.97 min). HRMS (ESI+) m/z = 340.1301 [M + H]+ found, C18H18N3O4+ required 340.1297.
4′-(2-Azidoethoxy)-3-hydroxyflavone (79). A mixture of chalcone 61 (2.02 g, 6.53 mmol), 16% NaOH
(12.9 mL) and 15% H2O2 (6.47 mL) in MeOH (50 mL) was reacted according to GP-F. The crude residue
was purified by flash column chromatography (SiO2, 1% MeOH/CH2Cl2) to afford flavonol 79 (1.68 g,
80%) as an off-white fluffy solid. m.p. 158–160 ◦C. TLC Rf = 0.39 (0.5% MeOH/CH2Cl2). IR νmax
(neat)/cm−1: 3235w(br) (O-H str), 2957w (C-H str), 2942w (C-H str), 2140m (N3 str), 2091m, 1739w,
1604s (C=O str), 1574m (C=C str), 1512s (C=C str), 1478m, 1425m, 1406m, 1346m, 1254s, 1201s, 1182s,
1117s, 1107s, 1057s. 1H-NMR (500 MHz, CDCl3): δ 3.66 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 4.24 (2H,
t, J = 5.2 Hz, -OCH2CH2N3), 7.03 (1H, br s, OH), 7.07 (2H, d, J = 8.8 Hz, ArH), 7.41 (1H, t, J = 7.6 Hz,
ArH), 7.58 (1H, d, J = 8.4 Hz, ArH), 7.70 (1H, t, J = 8.4 Hz, ArH), 8.25 (3H, d, J = 8.8 Hz, ArH). 13C-NMR
(500 MHz, CDCl3): δ 50.1, 67.0, 114.6, 118.1, 120.7, 124.2, 124.4, 125.4, 129.6, 133.4, 137.7, 145.0, 155.2,
159.6, 173.1. LCMS (ES+) m/z = 324.1 ([M + H]+, tR = 1.66 min). These characterisation data are in
accordance with that previously reported in the literature [51].
4′-(2-Azidoethoxy)-3-hydroxy-7-methoxyflavone (80). A mixture of chalcone 74 (1.06 g, 3.12 mmol), 16%
NaOH (5.89 mL) and 15% H2O2 (2.95 mL) in MeOH (30 mL) was reacted according to GP-F. The crude
residue was purified by flash column chromatography (SiO2, 1% MeOH/CH2Cl2) to afford flavonol 80
(677 mg, 61%) as an off-white powdery solid. m.p. 172–174 ◦C. TLC Rf = 0.39 (1% MeOH/CH2Cl2). IR
νmax (neat)/cm−1: 3269w(br) (O-H str), 2932w (C-H str), 2116s (N3 str), 2073m, 1597s (C=O str), 1561s
(C=C str), 1504s (C=C str), 1451m, 1403m, 1256s, 1239s, 1203s, 1171s, 1114m, 1098m, 1050m, 1026m.
1H-NMR (500 MHz, CDCl3): δ 3.66 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.94 (3H, s, -OCH3), 4.23 (2H, t,
J = 5.2 Hz, -OCH2CH2N3), 6.94 (1H, d, J = 2.0 Hz, ArH), 6.98 (1H, dd, J = 8.8, 2.0 Hz, ArH), 7.04 (1H,
br s, OH), 7.05 (2H, d, J = 9.2 Hz, ArH), 8.12 (1H, d, J = 8.8 Hz, ArH), 8.21 (2H, d, J = 8.8 Hz, ArH).
13C-NMR (500 MHz, CDCl3): δ 50.1, 55.8, 67.0, 99.8, 114.5, 114.6, 114.7, 124.3, 126.6, 129.2, 137.4, 144.3,
157.1, 159.3, 164.1, 172.6. LCMS (ES+) m/z = 354.2 ([M + H]+, tR = 1.90 min). HRMS (ESI+) m/z =
354.1074 [M + H]+ found, C18H16O5N3+ required 354.1084.
4′-(2-Azidoethoxy)-3-hydroxy-3′-methoxyflavone (81). A mixture of chalcone 77 (519 mg, 1.53 mmol),
16% NaOH (2.95 mL) and 15% H2O2 (1.47 mL) in MeOH (20 mL) was reacted according to GP-F.
The crude residue was purified by flash column chromatography (SiO2, 1% MeOH/CH2Cl2) to afford
flavonol 81 (418 mg, 77%) as a pale yellow-white powdery solid. m.p. 118–120 ◦C. TLC Rf = 0.45
(0.5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3224w(br) (O-H str), 2924w (C-H str), 2125s (N3 str),
1614s (C=O str), 1567m (C=C str), 1514s (C=C str), 1481m, 1470m, 1409s, 1269s, 1202s, 1183m, 1146s,
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1121m, 1035m, 1006m. 1H-NMR (500 MHz, CDCl3): δ 3.71 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.99 (3H,
s, -OCH3), 4.29 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 7.01 (1H, br s, OH), 7.05 (1H, d, J = 9.2 Hz, ArH),
7.43 (1H, t, J = 7.2 Hz, ArH), 7.60 (1H, d, J = 8.4 Hz, ArH), 7.72 (1H, t, J = 8.4 Hz, ArH), 7.87–7.89 (2H,
m, ArH), 8.26 (1H, dd, J = 8.0, 1.2 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 50.1, 56.2, 67.9, 111.6,
113.3, 118.2, 120.6, 121.3, 124.5, 124.8, 125.4, 133.5, 137.9, 144.8, 149.5, 149.5, 155.3, 173.2. LCMS (ES+)
m/z = 354.2 ([M + H]+, tR = 1.86 min). HRMS (ESI+) m/z = 354.1095 [M + H]+ found, C18H16N3O5+
required 354.1090.
3′-(2-Azidoethoxy)-3-hydroxy-4′-methoxyflavone (82). A mixture of chalcone 78 (513 mg, 1.51 mmol),
16% NaOH (2.95 mL) and 15% H2O2 (1.47 mL) in MeOH (20 mL) was reacted according to GP-F.
The crude residue was purified by flash column chromatography (SiO2, 1% MeOH/CH2Cl2) to afford
flavonol 82 (419 mg, 78%) as a pale yellow-white powdery solid. m.p. 164–166 ◦C. TLC Rf = 0.31 (0.5%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3199m(br) (O-H str), 2974w (C-H str), 2942w (C-H str), 2105s
(N3 str), 1611s (C=O str), 1599m (C=O str), 1564s (C=C str), 1516s (C=C str), 1480s, 1463m, 1412s, 1350m,
1264s, 1203s, 1179s, 1141s, 1012s. 1H-NMR (500 MHz, CDCl3): δ 3.71 (2H, t, J = 5.2 Hz, -OCH2CH2N3),
3.97 (3H, s, -OCH3), 4.31 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 7.01 (1H, br s, OH), 7.06 (1H, d, J = 8.4 Hz,
ArH), 7.43 (1H, t, J = 7.6 Hz, ArH), 7.60 (1H, d, J = 8.4 Hz, ArH), 7.71 (1H, t, J = 8.4 Hz, ArH), 7.91 (1H,
d, J = 2.0 Hz, ArH), 7.96 (1H, dd, J = 8.8, 2.0 Hz, ArH), 8.26 (1H, dd, J = 8.0, 1.2 Hz, ArH). 13C-NMR
(500 MHz, CDCl3): δ 50.2, 56.0, 68.3, 111.7, 113.8, 118.2, 120.6, 122.6, 123.7, 124.5, 125.4, 133.5, 137.8,
144.8, 147.6, 151.6, 155.2, 173.1. LCMS (ES+) m/z = 354.2 ([M + H]+, tR = 1.86 min). HRMS (ESI+)
m/z = 354.1096 [M + H]+ found, C18H16N3O5+ required 354.1090.
6-(2-Bromoethoxy)flavone (83). A mixture of flavone 28 (1.02 g, 4.28 mmol), 1,2-dibromoethane (0.47 mL,
5.46 mmol) and anhydrous K2CO3 (782 mg, 5.66 mmol) in dry acetone (50 mL) was reacted according to
GP-I. The crude residue was purified by flash column chromatography (SiO2, CH2Cl2) to afford flavone
83 (328 mg, 22%) as a white powdery solid. m.p. 180–182 ◦C. TLC Rf = 0.33 (1% MeOH/CH2Cl2).
IR νmax (neat)/cm−1: 3026w (C-H str), 2938w (C-H str), 2887w (C-H str), 1637s (C=O str), 1617m,
1586m (C=C str), 1568m (C=C str), 1482m, 1468m, 1447s, 1358s, 1313w, 1254m, 1200m, 1084m, 1030m,
1017s. 1H-NMR (500 MHz, CDCl3): δ 3.69 (2H, t, J = 6.0 Hz, -OCH2CH2Br), 4.41 (2H, t, J = 6.0 Hz,
-OCH2CH2Br), 6.82 (1H, s, -C=CH), 7.34 (1H, dd, J = 9.2, 3.2 Hz, ArH), 7.50–7.54 (4H, m, ArH), 7.58
(1H, d, J = 3.2 Hz, ArH), 7.91–7.93 (2H, m, ArH). 13C-NMR (500 MHz, CDCl3): δ 28.9, 68.4, 105.9,
106.8, 119.8, 124.1, 124.5, 126.2, 129.0, 131.5, 131.7, 151.3, 155.4, 163.2, 178.1. LCMS (ES+) m/z = 347.0
([M + H]+, tR = 1.66 min). These characterisation data are in accordance with that previously reported
in the literature [54].
7-(2-Bromoethoxy)flavone (84). A mixture of flavone 29 (1.59 g, 6.67 mmol), 1,2-dibromoethane (0.71 mL,
8.19 mmol) and anhydrous K2CO3 (1.20 g, 8.68 mmol) in dry acetone (50 mL) was reacted according to
GP-I. The crude residue was purified by flash column chromatography (SiO2, 1% MeOH/CH2Cl2)
to afford flavone 84 (1.50 g, 65%) as a white powdery solid. m.p. 150–152 ◦C. TLC Rf = 0.22 (1%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3045w (C-H str), 2934w (C-H str), 2864w (C-H str), 1628s (C=O
str), 1604s, 1594s (C=C str), 1567m (C=C str), 1494m, 1439m, 1372s, 1356s, 1282s, 1250s, 1227s, 1171s,
1131m, 1089s, 1013m. 1H-NMR (500 MHz, CDCl3): δ 3.70 (2H, t, J = 6.0 Hz, -OCH2CH2Br), 4.41 (2H,
t, J = 6.0 Hz, -OCH2CH2Br), 6.76 (1H, s, -C=CH), 6.97 (1H, d, J = 2.4 Hz, ArH), 7.00 (1H, dd, J = 8.8,
2.4 Hz, ArH), 7.49–7.54 (3H, m, ArH), 7.88–7.91 (2H, m, ArH), 8.14 (1H, d, J = 8.8 Hz, ArH). 13C-NMR
(500 MHz, CDCl3): δ 28.3, 68.2, 101.3, 107.5, 114.4, 118.3, 126.1, 127.3, 129.0, 131.4, 131.7, 157.8, 162.4,
163.0, 177.7. LCMS (ES+) m/z = 347.0 ([M + H]+, tR = 1.69 min). These characterisation data are in
accordance with that previously reported in the literature [28].
6-(2-Azidoethoxy)flavone (85). A mixture of flavone 83 (824 mg, 2.39 mmol) and NaN3 (336 mg,
5.17 mmol) in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture was worked up
to afford flavone 85 (686 mg, 93%) as a white powdery solid and was used without further purification.
m.p. 138–140 ◦C. TLC Rf = 0.27 (1% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3073w (C-H str), 2930w
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(C-H str), 2107s (N3 str), 2063m, 1625s, 1616s (C=O str), 1603s, 1582s (C=C str), 1569s (C=C str), 1480s,
1455s, 1363s, 1291s, 1262m, 1242s, 1203s, 1130s, 1083m. 1H-NMR (500 MHz, CDCl3): δ 3.65 (2H, t,
J = 4.8 Hz, -OCH2CH2N3), 4.26 (2H, t, J = 4.8 Hz, -OCH2CH2N3), 6.81 (1H, s, -C=CH), 7.34 (1H, dd,
J = 8.8, 2.8 Hz, ArH), 7.51–7.54 (4H, m, ArH), 7.59 (1H, d, J = 2.8 Hz, ArH), 7.90–7.93 (2H, m, ArH).
13C-NMR (500 MHz, CDCl3): δ 50.0, 67.5, 105.6, 106.9, 119.8, 124.2, 124.5, 126.2, 129.0, 131.5, 131.8, 151.3,
155.5, 163.3, 178.1. LCMS (ES+) m/z = 308.2 ([M + H]+, tR = 1.68 min). HRMS (ESI+) m/z = 330.0836
[M + Na]+ found, C17H13O3N3Na+ required 330.0849.
7-(2-Azidoethoxy)flavone (86). A mixture of flavone 84 (1.03 g, 3.00 mmol) and NaN3 (444 mg, 6.83 mmol)
in dry DMF (20 mL) was reacted according to GP-J. The reaction mixture was worked up to afford
flavone 86 (838 mg, 91%) as an off-white powdery solid and was used without further purification.
m.p. 108–110 ◦C. TLC Rf = 0.23 (1% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3073w (C-H str), 2979w
(C-H str), 2926w (C-H str), 2105m (N3 str), 1631s (C=O str), 1601s, 1578m (C=C str), 1569m (C=C str),
1493w, 1447s, 1375m, 1358m, 1303m, 1244s, 1177s, 1130m, 1085s. 1H-NMR (500 MHz, CDCl3): δ 3.68
(2H, t, J = 5.0 Hz, -OCH2CH2N3), 4.26 (2H, t, J = 5.0 Hz, -OCH2CH2N3), 6.75 (1H, s, -C=CH), 6.97 (1H,
d, J = 2.0 Hz, ArH), 6.99 (1H, dd, J = 8.5, 2.0 Hz, ArH), 7.48–7.54 (3H, m, ArH), 7.88 (2H, dd, J = 8.0,
2.0 Hz, ArH), 8.13 (1H, d, J = 8.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.8, 67.4, 101.3, 107.5, 114.3,
118.2, 126.1, 127.2, 128.9, 131.4, 131.6, 157.7, 162.6, 163.0, 177.6. LCMS (ES+) m/z = 308.0 ([M + H]+,
tR = 4.43 min). These characterisation data are in accordance with that previously reported in the
literature [10].
4’-(2-Azidoethoxy)-7-methoxyflavone (87). To a stirred solution of chalcone 76 (1.02 g, 3.01 mmol) in
DMSO (20 mL) was added a catalytic amount of I2 (103 mg, 0.407 mmol). The reaction mixture was
heated at 130 ◦C with stirring for 24 h under a nitrogen atmosphere. The resulting mixture was allowed
to cool to room temperature and poured into H2O (50 mL). The aqueous solution was extracted
with CHCl3 (2 × 100 mL) and the combined organic layer was washed with H2O (2 × 50 mL), brine
(2 × 50 mL), dried over anhydrous MgSO4, filtered and the solvent removed under reduced pressure.
The crude residue was purified by flash column chromatography (SiO2, 1% MeOH/CH2Cl2) to afford
flavone 87 (924 mg, 91%) as a pale yellow-white powdery solid. m.p. 128–130 ◦C. TLC Rf = 0.35 (3%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2946w (C-H str), 2839w (C-H str), 2097s (N3 str), 1644s (C=O
str), 1626s, 1598s (C=C str), 1510s (C=C str), 1503s (C=C str), 1440s, 1376m, 1355s, 1247s, 1182s, 1164m,
1141w, 1091m, 1023m. 1H-NMR (500 MHz, CDCl3): δ 3.65 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 3.92 (3H, s,
-OCH3), 4.22 (2H, t, J = 5.2 Hz, -OCH2CH2N3), 6.66 (1H, s, -C=CH), 6.94 (1H, d, J = 2.4 Hz, ArH), 6.96
(1H, dd, J = 8.8, 2.4 Hz, ArH), 7.02 (2H, d, J = 9.2 Hz, ArH), 7.85 (2H, d, J = 9.2 Hz, ArH), 8.11 (1H, d,
J = 8.8 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 50.0, 55.8, 67.1, 100.3, 106.2, 114.2, 114.9, 117.7, 124.7,
126.9, 127.8, 157.8, 160.7, 162.7, 164.0, 177.7. LCMS (ES+) m/z = 338.2 ([M + H]+, tR = 1.84 min). HRMS
(ESI+) m/z = 338.1147 [M + H]+ found, C18H16N3O4+ required 338.1141.
4′-(2-Azidoethoxy)aurone (88). A mixture of chalcone 61 (403 mg, 1.30 mmol) and Hg(OAc)2 (440 mg,
1.38 mmol) in dry pyridine (15 mL) was reacted according to GP-K. The crude residue was purified by
flash column chromatography (SiO2, PE/EtOAc; 3:1) to afford aurone 88 (354 mg, 88%) as a bright
yellow powdery solid. m.p. 114–116 ◦C. TLC Rf = 0.37 (PE/EtOAc; 2:1). IR νmax (neat)/cm−1: 2945w
(C-H str), 2888w (C-H str), 2096s (N3 str), 2062m, 1699s (C=O str), 1649s, 1592s (C=C str), 1510m (C=C
str), 1474m, 1461m, 1395w, 1347m, 1301s, 1257s, 1177s, 1130m, 1111m, 1097w, 1048s, 1009w. 1H-NMR
(500 MHz, CDCl3): δ 3.65 (2H, t, J = 4.8 Hz, -OCH2CH2N3), 4.22 (2H, t, J = 4.8 Hz, -OCH2CH2N3), 6.89
(1H, s, -C=CH), 7.01 (2H, d, J = 8.8 Hz, ArH), 7.22 (1H, t, J = 7.6 Hz, ArH), 7.33 (1H, d, J = 8.4 Hz, ArH),
7.65 (1H, t, J = 8.4 Hz, ArH), 7.82 (1H, dd, J = 7.6, 0.4 Hz, ArH), 7.91 (2H, d, J = 8.8 Hz, ArH). 13C-NMR
(500 MHz, CDCl3): δ 50.0, 67.0, 112.9, 113.0, 115.0, 121.8, 123.3, 124.6, 125.7, 133.4, 136.6, 146.0, 159.6,
165.9, 184.6. LCMS (ES+) m/z = 308.2 ([M + H]+, tR = 1.73 min). HRMS (ESI+) m/z = 308.1035 [M + H]+
found, C17H14O3N3+ required 308.1035.
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4′-(2-Azidoethoxy)-6-methoxyaurone (89). A mixture of chalcone 76 (2.01 g, 5.91 mmol) and Hg(OAc)2
(1.95 g, 6.13 mmol) in dry pyridine (50 mL) was reacted according to GP-K. The crude residue was
purified by flash column chromatography (SiO2, 0.5% MeOH/CH2Cl2) to afford aurone 89 (1.91 g,
96%) as a bright yellow-orange powdery solid. m.p. 108–110 ◦C. TLC Rf = 0.36 (0.5% MeOH/CH2Cl2).
IR νmax (neat)/cm−1: 3008w (C-H str), 2970w (C-H str), 2092s (N3 str), 1694m (C=O str), 1652m, 1594s
(C=C str), 1570m (C=C str), 1512m (C=C str), 1443m, 1414w, 1349m, 1315w, 1271m, 1248s, 1185m, 1131s,
1110s, 1068w, 1035m. 1H-NMR (500 MHz, CDCl3): δ 3.63 (2H, t, J = 4.8 Hz, -OCH2CH2N3), 3.91 (3H, s,
-OCH3), 4.19 (2H, t, J = 4.8 Hz, -OCH2CH2N3), 6.72–6.74 (2H, m, ArH), 6.76 (1H, s, -C=CH), 6.97 (2H,
d, J = 8.8 Hz, ArH), 7.68 (1H, d, J = 8.8 Hz, ArH), 7.83 (2H, d, J = 8.8 Hz, ArH). 13C-NMR (500 MHz,
CDCl3): δ 50.0, 55.9, 66.9, 96.5, 111.7, 112.0, 114.9, 115.0, 125.6, 125.7, 133.1, 146.8, 159.3, 167.2, 168.2,
182.8. LCMS (ES+) m/z = 338.2 ([M + H]+, tR = 1.65 min). HRMS (ESI+) m/z = 338.1146 [M + H]+
found, C18H16N3O4+ required 338.1141.
3.3. Synthesis of Triazole-Bridged Flavonoid Dimers and Trimers
(E)-3-(3,4-Dimethoxyphenyl)-1-(3-methoxy-4-(2-(4-((2-methoxy-4-((E)-3-(4-methoxyphenyl)acryloyl))methyl)-
1H-1,2,3-triazol-1-yl)ethoxy)phenyl)prop-2-en-1-one (90). A mixture of alkyne chalcone 20 (254 mg,
0.789 mmol), azide chalcone 67 (305 mg, 0.796 mmol), CuSO4·5H2O (225 mg, 0.900 mmol) and sodium
ascorbate (389 mg, 1.97 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The
crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and
recrystallized from MeOH to afford triazole hybrid 90 (151 mg, 27%) as a pale yellow-brown powdery
solid. m.p. 108–110 ◦C. TLC Rf = 0.41 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2942w (C-H str),
2837w (C-H str), 1652m (C=O str), 1595m (C=C str), 1572m (C=C str), 1509s (C=C str), 1464m, 1420m,
1335w, 1307w, 1255s, 1195w, 1143s, 1021s. 1H-NMR (500 MHz, CDCl3): δ 3.86 (3H, s, -OCH3), 3.92
(3H, s, -OCH3), 3.94 (3H, s, -OCH3), 3.95 (3H, s, -OCH3), 3.96 (3H, s, -OCH3), 4.46 (2H, t, J = 5.2 Hz,
-OCH2CH2N-), 4.84 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.40 (2H, s, -OCH2CN-), 6.82 (1H, d, J = 8.0 Hz,
ArH), 6.90 (1H, d, J = 8.4 Hz, ArH), 6.93 (2H, d, J = 8.8 Hz, ArH), 7.14–7.17 (2H, m, ArH), 7.24 (1H, dd,
J = 8.4, 2.0 Hz, ArH), 7.37 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.41 (1H, d, J = 15.6 Hz, -CH=CHCO-),
7.57–7.62 (6H, m, ArH), 7.75 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.77 (1H, d, J = 15.6 Hz, -CH=CHCO-),
8.04 (1H, s, -CHN-). 13C-NMR (500 MHz, CDCl3): δ 49.8, 55.4, 56.0, 56.0, 62.9, 67.6, 110.2, 111.1, 111.1,
111.5, 112.3, 112.4, 114.4, 119.2, 119.4, 122.5, 122.6, 123.0, 124.7, 127.7, 127.9, 130.1, 132.1, 132.8, 143.7,
144.0, 144.5, 149.2, 149.5, 149.7, 151.2, 151.4, 151.6, 161.5, 188.6. LCMS (ES+) m/z = 706.2 ([M + H]+,
tR = 1.65 min). HRMS (ESI+) m/z = 728.2576 [M + Na]+ found, C40H39O9N3Na+ required 728.2579.
(E)-1-(3-Methoxy-4-((1-(2-(2-methoxy-4-((E)-3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-
triazol-4-yl)methoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (91). A mixture of alkyne chalcone 20
(234 mg, 0.727 mmol), azide chalcone 69 (303 mg, 0.732 mmol), CuSO4·5H2O (203 mg, 0.813 mmol) and
sodium ascorbate (361 mg, 1.82 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A.
The crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and
recrystallized from MeOH to afford triazole hybrid 91 (250 mg, 47%) as a pale yellow-white flaky solid.
m.p. 206–208 ◦C. TLC Rf = 0.44 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3150w (C-H str), 2942w
(C-H str), 1661m (C=O str), 1601s (C=C str), 1572s (C=C str), 1514s (C=C str), 1459m, 1416m, 1324s,
1295m, 1262s, 1228m, 1166s, 1150s, 1126s, 1053w, 1015s. 1H-NMR (500 MHz, CDCl3): δ 3.86 (3H, s,
-OCH3), 3.87 (3H, s, -OCH3), 3.91 (6H, s, 2 × -OCH3), 3.92 (3H, s, -OCH3), 3.95 (3H, s, -OCH3), 4.46
(2H, t, J = 5.2 Hz, -OCH2CH2N-), 4.84 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.40 (2H, s, -OCH2CN-), 6.15
(2H, s, ArH), 6.85 (1H, d, J = 8.4 Hz, ArH), 6.94 (2H, d, J = 8.8 Hz, ArH), 7.17 (1H, d, J = 8.8 Hz, ArH),
7.42 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.58–7.65 (6H, m, ArH), 7.78 (1H, d, J = 15.2 Hz, -CH=CHCO-),
7.85 (1H, d, J = 16.0 Hz, -CH=CHCO-), 8.05 (1H, s, -CHN-), 8.23 (1H, d, J = 16.0 Hz, -CH=CHCO-).
13C-NMR (500 MHz, CDCl3): δ 49.8, 55.4, 55.8, 55.9, 56.0, 62.9, 67.5, 90.5, 106.6, 111.1, 111.7, 112.3, 112.4,
114.4, 119.3, 121.6, 122.3, 122.6, 124.7, 127.8, 130.1, 132.1, 133.7, 135.6, 143.7, 143.9, 149.5, 149.5, 150.6,
151.6, 161.5, 161.7, 163.0, 188.6, 190.3. LCMS (ES+) m/z = 736.2 ([M + H]+, tR = 1.67 min). HRMS (ESI+)
m/z = 736.2892 [M + H]+ found, C41H42O10N3+ required 736.2865.
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(E)-1-(2-Hydroxy-4-methoxyphenyl)-3-(4-methoxy-3-((1-(2-(2-methoxy-4-((E)-3-(2,4,6-trimethoxyphenyl)acryl
oyl)phenoxy)ethyl)-1H-1,2,3- triazol-4-yl)methoxy)phenyl)prop-2-en-1-one (92). A mixture of alkyne
chalcone 4 (167 mg, 0.494 mmol), azide chalcone 69 (206 mg, 0.498 mmol), CuSO4·5H2O (140 mg,
0.560 mmol) and sodium ascorbate (253 mg, 1.28 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted
according to GP-A. The crude residue was purified by flash column chromatography (SiO2, 1%–5%
MeOH/CH2Cl2) and recrystallized from MeOH to afford triazole hybrid 92 (236 mg, 64%) as a bright
yellow flaky solid. m.p. 208–210 ◦C. TLC Rf = 0.48 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2931w
(C-H str), 2842w (C-H str), 1632m (C=O str), 1597m (C=C str), 1568s (C=C str), 1509s (C=C str), 1455w,
1419w, 1371m, 1318m, 1259s, 1232s, 1211s, 1153s, 1123s, 1021m, 1004m. 1H-NMR (500 MHz, CDCl3):
δ 3.86 (3H, s, -OCH3), 3.87 (3H, s, -OCH3), 3.91 (3H, s, -OCH3), 3.91 (9H, s, 3 × -OCH3), 4.45 (2H, t,
J = 4.8 Hz, -OCH2CH2N-), 4.84 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.38 (2H, s, -OCH2CN-), 6.14 (2H, s,
ArH), 6.46 (1H, d, J = 2.4 Hz, ArH), 6.50 (1H, dd, J = 8.8, 2.4 Hz, ArH), 6.81 (1H, d, J = 8.4 Hz, ArH),
6.89 (1H, d, J = 2.4 Hz, ArH), 7.21 (1H, dd, J = 8.0, 2.0 Hz, ArH), 7.45 (1H, d, J = 15.2 Hz, -CH=CHCO-),
7.46 (1H, d, J = 1.6 Hz, ArH), 7.55 (1H, dd, J = 8.4, 1.6 Hz, ArH), 7.61 (1H, d, J = 1.6 Hz, ArH), 7.77 (1H,
d, J = 15.6 Hz, -CH=CHCO-), 7.85 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.89 (1H, d, J = 8.8 Hz, ArH),
8.05 (1H, s, -CHN-), 8.23 (1H, d, J = 16.0 Hz, -CH=CHCO-), 13.55 (1H, s, OH). 13C-NMR (500 MHz,
CDCl3): δ 49.8, 55.4, 55.5, 55.8, 55.9, 56.0, 63.2, 67.6, 90.5, 101.0, 106.6, 107.6, 111.5, 111.6, 112.3, 113.0,
114.2, 118.4, 121.5, 122.3, 124.3, 124.7, 127.8, 131.3, 133.7, 135.6, 144.0, 144.1, 147.8, 149.4, 150.6, 152.0,
161.7, 163.0, 166.0, 166.6, 190.3, 191.8. LCMS (ES+) m/z = 752.2 ([M + H]+, tR = 1.74 min). HRMS (ESI+)
m/z = 752.2822 [M + H]+ found, C41H42O11N3+ required 752.2814.
(E)-1-(3-Methoxy-4-((1-(2-(2-methoxy-4-((E)-3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-tria
zol-4-yl)methoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (93). A mixture of alkyne chalcone 20
(235 mg, 0.729 mmol), azide chalcone 68 (303 mg, 0.733 mmol), CuSO4·5H2O (271 mg, 1.09 mmol) and
sodium ascorbate (414 mg, 2.09 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A.
The crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and
recrystallized from MeOH to afford triazole hybrid 93 (515 mg, 96%) as a pale yellow-green flaky solid.
m.p. 128–130 ◦C. TLC Rf = 0.30 (4% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2937w (C-H str), 2836w
(C-H str), 1652m (C=O str), 1595s (C=C str), 1572s (C=C str), 1510s (C=C str), 1494s, 1463s, 1415s,
1326w, 1255s, 1193w, 1148s, 1095s, 1021s. 1H-NMR (500 MHz, CDCl3): δ 3.86 (3H, s, -OCH3), 3.90
(3H, s, -OCH3), 3.92 (6H, s, 2 × -OCH3), 3.95 (6H, s, 2 × -OCH3), 4.47 (2H, t, J = 4.8 Hz, -OCH2CH2N-),
4.84 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.40 (2H, s, -OCH2CN-), 6.73 (1H, d, J = 8.8 Hz, ArH), 6.84 (1H,
d, J = 8.4 Hz, ArH), 6.94 (2H, d, J = 8.8 Hz, ArH), 7.17 (1H, d, J = 8.8 Hz, ArH), 7.39 (1H, d, J = 8.8
Hz, ArH), 7.42 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.54 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.59–7.64
(6H, m, ArH), 7.78 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.98 (1H, d, J = 16.0 Hz, -CH=CHCO-), 8.05
(1H, s, -CHN-). 13C-NMR (500 MHz, CDCl3): δ 49.7, 55.4, 56.0, 56.0, 56.1, 60.9, 61.4, 62.9, 67.5, 107.6,
111.1, 111.6, 112.3, 112.4, 114.4, 119.2, 120.8, 122.0, 122.5, 122.6, 123.9, 124.7, 127.7, 130.1, 132.1, 133.0,
139.7, 142.5, 143.7, 144.0, 149.5, 149.7, 151.1, 151.6, 153.8, 155.7, 161.5, 188.6, 189.0. LCMS (ES+) m/z
= 736.2 ([M + H]+, tR = 1.66 min). HRMS (ESI+) m/z = 736.2855 [M + H]+ found, C41H42O10N3+
required 736.2870.
(E)-1-(3-Methoxy-4-((1-(2-(2-methoxy-4-((E)-3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-tria
zol-4-yl)methoxy)phenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (94). A mixture of alkyne chalcone 22
(217 mg, 0.734 mmol), azide chalcone 69 (305 mg, 0.737 mmol), CuSO4·5H2O (214 mg, 0.857 mmol) and
sodium ascorbate (365 mg, 1.84 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A.
The crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and
recrystallized from MeOH to afford triazole hybrid 94 (367 mg, 70%) as a bright yellow flaky solid.
m.p. 138–140 ◦C. TLC Rf = 0.31 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2941w (C-H str), 2838w
(C-H str), 1646m (C=O str), 1596m (C=C str), 1566s (C=C str), 1512m (C=C str), 1470m, 1457m, 1414m,
1338w, 1321m, 1257s, 1198m, 1155s, 1146s, 1118s, 1027m. 1H-NMR (500 MHz, CDCl3): δ 3.77 (3H, s,
-NCH3), 3.86 (3H, s, -OCH3), 3.91 (6H, s, 2 × -OCH3), 3.91 (3H, s, -OCH3), 3.94 (3H, s, -OCH3), 4.45
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(2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.83 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.38 (2H, s, -OCH2CN-), 6.14
(2H, s, ArH), 6.21–6.23 (1H, m, ArH), 6.80–6.86 (3H, m, ArH), 7.16 (1H, d, J = 8.8 Hz, ArH), 7.29 (1H, d,
J = 15.6 Hz, -CH=CHCO-), 7.57–7.63 (4H, m, ArH), 7.79 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.85 (1H,
d, J = 16.0 Hz, -CH=CHCO-), 8.05 (1H, s, -CHN-), 8.23 (1H, d, J = 15.6 Hz, -CH=CHCO-). 13C-NMR
(500 MHz, CDCl3): δ 34.4, 49.7, 55.4, 55.8, 55.9, 56.0, 62.8, 67.5, 90.5, 106.5, 109.6, 111.1, 111.7, 112.1,
112.3, 112.4, 116.3, 121.5, 122.3, 122.3, 124.7, 127.6, 130.3, 131.6, 132.4, 133.7, 135.6, 143.7, 149.4, 149.5,
150.6, 151.4, 161.6, 163.0, 188.1, 190.3. LCMS (ES+) m/z = 709.3 ([M + H]+, tR = 1.63 min). HRMS (ESI+)
m/z = 709.2854 [M + H]+ found, C39H41O9N4+ required 709.2868.
(E)-1-(3-Methoxy-4-((1-(2-(2-methoxy-4-((E)-3-(1-methyl-1H-pyrrol-2-yl)acryloyl)phenoxy)ethyl)-1H-1,2,3-tria
zol-4-yl)methoxy)phenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (95). A mixture of alkyne chalcone 22
(271 mg, 0.918 mmol), azide chalcone 70 (301 mg, 0.924 mmol), CuSO4·5H2O (316 g, 1.26 mmol) and
sodium ascorbate (499 mg, 2.52 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A.
The crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2)
and recrystallized from MeOH to afford triazole hybrid 95 (555 mg, 97%) as a dark yellow-brown
flaky solid. m.p. 118–120 ◦C. TLC Rf = 0.38 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2941w (C-H
str), 2844w (C-H str), 1644m (C=O str), 1594m (C=C str), 1564s (C=C str), 1511m (C=C str), 1480m,
1412m, 1381w, 1330m, 1258s, 1196m, 1153s, 1129m, 1055w, 1025m. 1H-NMR (500 MHz, CDCl3): δ 3.76
(3H, s, -NCH3), 3.77 (3H, s, -NCH3), 3.92 (3H, s, -OCH3), 3.95 (3H, s, -OCH3), 4.46 (2H, t, J = 4.8 Hz,
-OCH2CH2N-), 4.84 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.39 (2H, s, -OCH2CN-), 6.22–6.24 (2H, m,
ArH), 6.82–6.86 (5H, m, ArH), 7.15 (1H, d, J = 8.0 Hz, ArH), 7.27 (1H, d, J = 15.2 Hz, -CH=CHCO-,
overlain by CDCl3), 7.29 (1H, d, J = 14.0 Hz, -CH=CHCO-), 7.57–7.62 (4H, m, ArH), 7.79 (2H, d,
J = 14.8 Hz, 2 × -CH=CHCO-), 8.04 (1H, s, -CHN-). 13C-NMR (500 MHz, CDCl3): δ 34.4, 49.7, 55.9,
56.0, 62.9, 67.5, 109.6, 109.7, 111.1, 111.4, 112.1, 112.2, 112.3, 112.4, 116.2, 116.3, 122.1, 122.3, 124.7, 127.6,
127.7, 130.3, 130.3, 131.6, 131.8, 132.4, 133.1, 143.7, 149.4, 149.6, 150.9, 151.4, 188.0, 188.1. LCMS (ES+)
m/z = 622.3 ([M + H]+, tR = 1.62 min). HRMS (ESI+) m/z = 622.2648 [M + H]+ found, C35H36O6N5+
required 622.2660.
(E)-1-(2-Hydroxyphenyl)-3-(4-(2-(4-((2-((E)-3-(1-methyl-1H-pyrrol-2-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-
triazol-1-yl)ethoxy)phenyl)prop-2-en-1-one (96). A mixture of alkyne chalcone 23 (337 mg, 1.27 mmol),
azide chalcone 61 (400 mg, 1.29 mmol), CuSO4·5H2O (429 mg, 1.72 mmol) and sodium ascorbate
(641 mg, 3.23 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue
was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole
hybrid 96 (399 mg, 55%) as a bright yellow-orange powdery solid. m.p. 98–100 ◦C. TLC Rf = 0.40 (3%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2933w (C-H str), 2884w (C-H str), 1635m (C=O str), 1597m
(C=C str), 1562s (C=C str), 1509m (C=C str), 1480m, 1447m, 1329m, 1286m, 1268m, 1233m, 1202s, 1174s,
1156s, 1113w, 1055m, 1025s. 1H-NMR (500 MHz, CDCl3): δ 3.65 (3H, s, -NCH3), 4.32 (2H, t, J = 5.2 Hz,
-OCH2CH2N-), 4.65 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.33 (2H, s, -OCH2CN-), 6.16–6.18 (1H, m, ArH),
6.63 (1H, dd, J = 4.0, 1.2 Hz, ArH), 6.76 (1H, t, J = 2.0 Hz, ArH), 6.85 (2H, d, J = 8.8 Hz, ArH), 6.95
(1H, t, J = 8.0 Hz, ArH), 7.03 (1H, dd, J = 8.4, 0.8 Hz, ArH), 7.08 (1H, d, J = 7.6 Hz, ArH), 7.12 (1H, d,
J = 8.4 Hz, ArH), 7.16 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.44–7.59 (4H, m, ArH), 7.54 (1H, d, J = 15.6
Hz, -CH=CHCO-), 7.60 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.66 (1H, dd, J = 8.0, 2.0 Hz, ArH), 7.76 (1H,
s, -CHN-), 7.86 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.93 (1H, dd, J = 8.4, 1.6 Hz, ArH), 12.89 (1H, s, OH).
13C-NMR (500 MHz, CDCl3): δ 34.3, 49.5, 63.0, 66.2, 109.6, 112.4, 113.0, 114.9, 118.2, 118.5, 118.8, 120.0,
121.4, 122.2, 123.9, 127.7, 128.2, 129.5, 130.0, 130.1, 130.5, 130.6, 132.7, 136.2, 144.1, 144.8, 156.5, 159.9,
163.5, 191.9, 193.5. LCMS (ES+) m/z = 575.3 ([M + H]+, tR = 1.72 min). HRMS (ESI+) m/z = 575.2266
[M + H]+ found, C34H31O5N4+ required 575.2289.
(E)-3-(Ferrocenyl)-1-(4-((1-(2-(4-((E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl)phenoxy)ethyl)-1H-1,2,3-triaz
ol-4-yl)methoxy)-3-methoxyphenyl)prop-2-en-1-one (97). A mixture of alkyne chalcone 25 (301 mg,
0.753 mmol), azide chalcone 61 (235 mg, 0.760 mmol), CuSO4·5H2O (225 mg, 0.900 mmol) and sodium
ascorbate (398 mg, 2.01 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The
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crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford
triazole hybrid 97 (427 mg, 80%) as a dark red-brown powdery solid. m.p. 178–180 ◦C. TLC Rf = 0.28
(2% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2937w (C-H str), 1740m (C=O str), 1651m, 1637s, 1596s
(C=C str), 1571s (C=C str), 1510s (C=C str), 1487m, 1444m, 1341w, 1300m, 1266s, 1203s, 1179s, 1159s,
1146s, 1048m, 1020s. 1H-NMR (500 MHz, CDCl3): δ 3.98 (3H, s, -OCH3), 4.16 (5H, s, -C5H5), 4.42 (2H, t,
J = 5.2 Hz, -OCH2CH2N-), 4.47 (2H, t, J = 2.0 Hz, -C5H4), 4.56 (2H, t, J = 2.0 Hz, -C5H4), 4.80 (2H, t,
J = 5.2 Hz, -OCH2CH2N-), 5.43 (2H, s, -OCH2CN-), 6.84 (2H, d, J = 8.8 Hz, ArH), 6.97 (1H, t, J = 8.0 Hz,
ArH), 7.04 (1H, dd, J = 8.4, 0.8 Hz, ArH), 7.12 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.12 (1H, d, J = 8.4 Hz,
ArH), 7.51 (1H, t, J = 8.4 Hz, ArH), 7.54–7.61 (3H, m, ArH), 7.59 (1H, d, J = 16.0 Hz, -CH=CHCO-),
7.64 (1H, d, J = 1.6 Hz, ArH), 7.74 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.86 (1H, s, -CHN-), 7.86 (1H, d,
J = 15.6 Hz, -CH=CHCO-), 7.97 (1H, dd, J = 8.0, 1.6 Hz, ArH), 12.90 (1H, s, OH). 13C-NMR (500 MHz,
CDCl3): δ 49.7, 56.1, 62.8, 66.3, 68.9, 69.7, 71.3, 79.2, 111.1, 112.3, 114.9, 118.3, 118.5, 118.6, 118.8, 120.0,
122.4, 124.3, 128.4, 129.6, 130.6, 132.3, 136.3, 143.8, 144.7, 146.1, 149.5, 151.2, 159.8, 163.6, 187.9, 193.6.
LCMS (ES+) m/z = 710.2 ([M + H]+, tR = 2.09 min). HRMS (ESI+) m/z = 710.1889 [M + H]+ found,
C40H36N3O6Fe+ required 710.1875.
(E)-3-((1-(2-(4-(3-(3,4-Dimethoxyphenyl)acryloyl)-2-methoxyphenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-
phenyl-4H-chromen-4-one (98). A mixture of alkyne flavone 30 (806 mg, 2.92 mmol), azide chalcone
67 (1.01 g, 2.64 mmol), CuSO4·5H2O (716 mg, 2.87 mmol) and sodium ascorbate (1.29 g, 6.51 mmol)
in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by
flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 98 (622 mg,
36%) as a pale yellow-green powdery solid. m.p. 102–104 ◦C. TLC Rf = 0.24 (3% MeOH/CH2Cl2).
IR νmax (neat)/cm−1: 2940w (C-H str), 2836w (C-H str), 1644m (C=O str), 1596m (C=C str), 1579m
(C=C str), 1510s (C=C str), 1467m, 1420w, 1398w, 1260s, 1237s, 1196m, 1146s, 1138s, 1022s. 1H-NMR
(500 MHz, CDCl3): δ 3.87 (3H, s, -OCH3), 3.94 (3H, s, -OCH3), 3.96 (3H, s, -OCH3), 4.38 (2H, t,
J = 5.2 Hz, -OCH2CH2N-), 4.74 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.32 (2H, s, -OCH2CN-), 6.84 (1H,
d, J = 8.4 Hz, ArH), 6.90 (1H, d, J = 8.4 Hz, ArH), 7.16 (1H, d, J = 1.6 Hz, ArH), 7.24 (1H, dd, J = 8.4,
1.6 Hz, ArH), 7.39 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.39–7.44 (4H, m, ArH), 7.50 (1H, d, J = 8.4 Hz,
ArH), 7.59 (1H, d, J = 1.6 Hz, ArH), 7.62 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.69 (1H, t, J = 8.4 Hz, ArH),
7.77 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.96 (1H, s, -CHN-), 7.97–8.00 (2H, m, ArH), 8.27 (1H, dd,
J = 8.0, 1.6 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.4, 56.0, 56.0, 65.1, 67.4, 110.2, 111.1, 111.5, 112.2,
118.1, 119.5, 122.4, 123.0, 124.1, 124.8, 125.3, 125.7, 127.9, 128.3, 128.7, 130.6, 130.7, 132.7, 133.5, 139.4,
143.9, 144.5, 149.2, 149.7, 151.3, 151.3, 155.3, 156.4, 175.0, 188.6. LCMS (ES+) m/z = 660.2 ([M + H]+,
tR = 1.64 min). HRMS (ESI+) m/z = 660.2325 [M + H]+ found, C38H34O8N3+ required 660.2340.
(E)-3-((1-(2-(2-Methoxy-4-(3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-
2-phenyl-4H-chromen-4-one (99). A mixture of alkyne flavone 30 (205 mg, 0.742 mmol), azide chalcone 68
(306 mg, 0.739 mmol), CuSO4·5H2O (204 mg, 0.818 mmol) and sodium ascorbate (365 mg, 1.84 mmol)
in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from MeOH to afford
triazole hybrid 99 (178 mg, 35%) as an off-white powdery solid. m.p. 120–122 ◦C. TLC Rf = 0.28 (5%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2941w (C-H str), 2838w (C-H str), 1740w, 1645s (C=O str),
1581s (C=C str), 1563m (C=C str), 1516w (C=C str), 1494s, 1466s, 1414m, 1403m, 1264s, 1238m, 1195m,
1148m, 1096s, 1039m, 1027m. 1H-NMR (500 MHz, CDCl3): δ 3.86 (3H, s, -OCH3), 3.90 (3H, s, -OCH3),
3.92 (3H, s, -OCH3), 3.95 (3H, s, -OCH3), 4.36 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 4.73 (2H, t, J = 5.2 Hz,
-OCH2CH2N-), 5.33 (2H, s, -OCH2CN-), 6.73 (1H, d, J = 8.8 Hz, ArH), 6.84 (1H, d, J = 8.0 Hz, ArH),
7.38–7.44 (5H, m, ArH), 7.50 (1H, d, J = 8.4 Hz, ArH), 7.55 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.59–7.62
(2H, m, ArH), 7.69 (1H, t, J = 8.4 Hz, ArH), 7.95 (1H, s, -CHN-), 7.96–7.99 (2H, m, ArH), 7.99 (1H, d,
J = 15.6 Hz, -CH=CHCO-), 8.28 (1H, dd, J = 8.0, 1.2 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.4,
55.9, 56.1, 60.9, 61.4, 65.1, 67.4, 107.6, 111.5, 112.2, 118.1, 120.9, 122.0, 122.4, 123.9, 124.1, 124.8, 125.3,
125.7, 128.3, 128.7, 130.6, 130.7, 132.8, 133.5, 139.4, 139.7, 142.5, 143.9, 149.6, 151.2, 153.7, 155.3, 155.7,
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156.4, 175.0, 189.0. LCMS (ES+) m/z = 690.2 ([M + H]+, tR = 1.95 min). HRMS (ESI+) m/z = 690.2425
[M + H]+ found, C39H36O9N3+ required 690.2446.
(E)-3-((1-(2-(2-Methoxy-4-(3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-
2-phenyl-4H-chromen-4-one (100). A mixture of alkyne flavone 30 (207 mg, 0.749 mmol), azide chalcone
69 (306 mg, 0.741 mmol), CuSO4·5H2O (203 mg, 0.814 mmol) and sodium ascorbate (369 mg,
1.86 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from
MeOH to afford triazole hybrid 100 (342 mg, 67%) as a white powdery solid. m.p. 172–174 ◦C. TLC Rf
= 0.30 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2941w (C-H str), 2843w (C-H str), 1737w, 1643s
(C=O str), 1599s (C=C str), 1575s (C=C str), 1515m (C=C str), 1465m, 1416m, 1322m, 1261m, 1231s,
1216m, 1192m, 1149s, 1125s, 1027s. 1H-NMR (500 MHz, CDCl3): δ 3.85 (3H, s, -OCH3), 3.88 (3H,
s, -OCH3), 3.92 (6H, s, 2 × -OCH3), 4.35 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 4.72 (2H, t, J = 5.2 Hz,
-OCH2CH2N-), 5.35 (2H, s, -OCH2CN-), 6.16 (2H, s, ArH), 6.84 (1H, d, J = 8.8 Hz, ArH), 7.38–7.44 (4H,
m, ArH), 7.50 (1H, d, J = 8.4 Hz, ArH), 7.60–7.62 (2H, m, ArH), 7.70 (1H, t, J = 8.8 Hz, ArH), 7.87
(1H, d, J = 16.0 Hz, -CH=CHCO-), 7.94 (1H, s -CHN-), 7.95–7.98 (2H, m, ArH), 8.25 (1H, d, J = 16.0
Hz, -CH=CHCO-), 8.29 (1H, dd, J = 8.4, 1.6 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.4, 55.4, 55.8,
55.8, 65.0, 67.3, 90.5, 106.5, 111.7, 112.3, 118.1, 121.6, 122.3, 124.1, 124.7, 125.2, 125.7, 128.2, 128.7, 130.6,
130.7, 133.5, 133.5, 135.6, 139.3, 143.8, 149.4, 150.7, 155.2, 156.4, 161.6, 163.0, 175.0, 190.4. LCMS (ES+)
m/z = 690.2 ([M + H]+, tR = 1.73 min). HRMS (ESI+) m/z = 690.2476 [M + H]+ found, C39H36O9N3+
required 690.2446.
(E)-6-((1-(2-(4-(3-(3,4-Dimethoxyphenyl)acryloyl)-2-methoxyphenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-
phenyl-4H-chromen-4-one (101). A mixture of alkyne flavone 31 (179 mg, 0.648 mmol), azide chalcone 67
(246 mg, 0.641 mmol), CuSO4·5H2O (188 mg, 0.753 mmol) and sodium ascorbate (322 mg, 1.63 mmol)
in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from MeOH to afford
triazole hybrid 101 (366 mg, 87%) as a bright orange crystalline solid. m.p. 128–130 ◦C. TLC Rf = 0.34
(5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2940w (C-H str), 2831w (C-H str), 1637s (C=O str), 1618m,
1595s (C=C str), 1571s (C=C str), 1510s (C=C str), 1481m, 1454s, 1419m, 1360s, 1257s, 1235m, 1198m,
1140s, 1023s. 1H-NMR (500 MHz, CDCl3): δ 3.92 (3H, s, -OCH3), 3.93 (3H, s, -OCH3), 3.94 (3H, s,
-OCH3), 4.47 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.86 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.29 (2H, s,
-OCH2CN-), 6.79 (1H, s, -C=CH), 6.85 (1H, d, J = 8.8 Hz, ArH), 6.89 (1H, d, J = 8.4 Hz, ArH), 7.14 (1H,
d, J = 1.6 Hz, ArH), 7.22 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.33 (1H, dd, J = 9.2, 3.2 Hz, ArH), 7.36 (1H, d,
J = 15.2 Hz, -CH=CHCO-), 7.49–7.52 (4H, m, ArH), 7.59–7.61 (2H, m, ArH), 7.71 (1H, d, J = 3.2 Hz,
ArH), 7.73 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.88–7.91 (2H, m, ArH), 8.04 (1H, s, -CHN-). 13C-NMR
(500 MHz, CDCl3): δ 49.7, 55.9, 56.0, 62.3, 67.5, 106.3, 106.7, 110.1, 111.1, 111.5, 112.3, 119.4, 119.7, 122.5,
123.0, 123.9, 124.5, 124.6, 126.2, 127.8, 129.0, 131.5, 131.7, 132.7, 143.3, 144.5, 149.2, 149.7, 151.2, 151.2,
151.3, 155.5, 163.2, 178.1, 188.5. LCMS (ES+) m/z = 660.2 ([M + H]+, tR = 1.81 min). HRMS (ESI+)
m/z = 682.2153 [M + Na]+ found, C38H33O8N3Na+ required 682.2160.
(E)-6-((1-(2-(2-Methoxy-4-(3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-
2-phenyl-4H-chromen-4-one (102). A mixture of alkyne flavone 31 (211 mg, 0.763 mmol), azide chalcone
69 (317 mg, 0.767 mmol), CuSO4·5H2O (211 mg, 0.843 mmol) and sodium ascorbate (382 mg,
1.93 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue
was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized
from MeOH to afford triazole hybrid 102 (397 mg, 75%) as a bright yellow-orange flaky solid.
m.p. 128–130 ◦C. TLC Rf = 0.25 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2941w (C-H str), 2838w
(C-H str), 1739w, 1640s (C=O str), 1598s (C=C str), 1569s (C=C str), 1517m (C=C str), 1455s, 1363m,
1320m, 1279m, 1261m, 1201s, 1154s, 1122s, 1035s, 1025s. 1H-NMR (500 MHz, CDCl3): δ 3.84 (3H, s,
-OCH3), 3.89 (6H, s, 2 × -OCH3), 3.92 (3H, s, -OCH3), 4.45 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.85 (2H, t,
J = 4.8 Hz, -OCH2CH2N-), 5.28 (2H, s, -OCH2CN-), 6.12 (2H, s, ArH), 6.79 (1H, s, -C=CH), 6.84 (1H,
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d, J = 8.4 Hz, ArH), 7.33 (1H, dd, J = 9.2, 3.2 Hz, ArH), 7.48–7.51 (4H, m, ArH), 7.57 (1H, dd, J = 8.0,
1.6 Hz, ArH), 7.61 (1H, d, J = 1.6 Hz, ArH), 7.71 (1H, d, J = 2.8 Hz, ArH), 7.84 (1H, d, J = 16.0 Hz,
-CH=CHCO-), 7.88–7.91 (2H, m, ArH), 8.06 (1H, s, -CHN-), 8.21 (1H, d, J = 15.6 Hz, -CH=CHCO-).
13C-NMR (500 MHz, CDCl3): δ 49.7, 55.3, 55.7, 55.9, 62.3, 67.5, 90.5, 106.2, 106.5, 106.7, 111.6, 112.4,
119.6, 121.4, 122.3, 123.9, 124.4, 124.6, 126.2, 128.9, 131.5, 131.7, 133.6, 135.5, 143.3, 149.4, 150.6, 151.2,
155.6, 161.6, 163.0, 163.2, 178.1, 190.3. LCMS (ES+) m/z = 690.3 ([M + H]+, tR = 1.88 min). HRMS (ESI+)
m/z = 690.2426 [M + H]+ found, C39H36O9N3+ required 690.2446.
(E)-6-((1-(2-(2-Methoxy-4-(3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)
-2-phenyl-4H-chromen-4-one (103). A mixture of alkyne flavone 31 (201 mg, 0.729 mmol), azide chalcone
68 (304 mg, 0.735 mmol), CuSO4·5H2O (208 mg, 0.831 mmol) and sodium ascorbate (383 mg,
1.93 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from
MeOH to afford triazole hybrid 103 (382 mg, 76%) as a pale yellow flaky solid. m.p. 138–140 ◦C. TLC
Rf = 0.32 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2939w (C-H str), 2839w (C-H str), 1740w, 1640s
(C=O str), 1619m, 1593m (C=C str), 1573s (C=C str), 1516m (C=C str), 1495m, 1482m, 1455s, 1415m,
1360s, 1259s, 1200m, 1157m, 1095s, 1026s. 1H-NMR (500 MHz, CDCl3): δ 3.89 (3H, s, -OCH3), 3.90 (3H,
s, -OCH3), 3.93 (3H, s, -OCH3), 3.94 (3H, s, -OCH3), 4.47 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.86 (2H, t,
J = 4.8 Hz, -OCH2CH2N-), 5.29 (2H, s, -OCH2CN-), 6.72 (1H, d, J = 8.8 Hz, ArH), 6.80 (1H, s, -C=CH),
6.86 (1H, d, J = 8.0 Hz, ArH), 7.34 (1H, dd, J = 9.2, 3.2 Hz, ArH), 7.37 (1H, d, J = 8.8 Hz, ArH), 7.49–7.52
(4H, m, ArH), 7.53 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.58–7.61 (2H, m, ArH), 7.71 (1H, d, J = 3.2 Hz,
ArH), 7.89–7.92 (2H, m, ArH), 7.96 (1H, d, J = 16.0 Hz, -CH=CHCO-), 8.05 (1H, s, -CHN-). 13C-NMR
(500 MHz, CDCl3): δ 49.7, 56.0, 56.0, 60.9, 61.3, 62.3, 67.5, 106.3, 106.8, 107.5, 111.5, 112.3, 119.7, 120.8,
122.0, 122.4, 123.8, 123.9, 124.5, 124.6, 126.2, 129.0, 131.5, 131.7, 132.8, 139.6, 142.4, 143.3, 149.6, 151.1,
151.2, 153.7, 155.6, 155.7, 163.2, 178.1, 188.9. LCMS (ES+) m/z = 690.2 ([M + H]+, tR = 1.94 min). HRMS
(ESI+) m/z = 690.2452 [M + H]+ found, C39H36N3O9+ required 690.2452.
(E)-7-((1-(2-(2-Methoxy-4-(3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)
-2-phenyl-4H-chromen-4-one (104). A mixture of alkyne flavone 32 (202 mg, 0.730 mmol), azide chalcone
69 (304 mg, 0.735 mmol), CuSO4·5H2O (218 mg, 0.872 mmol) and sodium ascorbate (386 mg,
1.95 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue
was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized
from MeOH to afford triazole hybrid 104 (324 mg, 64%) as a pale yellow-white powdery solid.
m.p. 168–170 ◦C. TLC Rf = 0.25 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2941w (C-H str), 2841w
(C-H str), 1736w, 1634s (C=O str), 1599s (C=C str), 1566s (C=C str), 1512m (C=C str), 1451m, 1441m,
1336s, 1302w, 1279m, 1261m, 1204m, 1175m, 1160w, 1122s, 1092w, 1053w, 1037m, 1016w. 1H-NMR
(500 MHz, CDCl3): δ 3.87 (3H, s, -OCH3), 3.91 (6H, s, 2 × -OCH3), 3.93 (3H, s, -OCH3), 4.48 (2H, t,
J = 5.2 Hz, -OCH2CH2N-), 4.87 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.35 (2H, s, -OCH2CN-), 6.14 (2H,
s, ArH), 6.77 (1H, s, -C=CH), 6.86 (1H, d, J = 8.0 Hz, ArH), 7.06 (1H, dd, J = 8.8, 2.0 Hz, ArH), 7.14
(1H, d, J = 2.0 Hz, ArH), 7.49–7.53 (3H, m, ArH), 7.59 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.63 (1H, d,
J = 1.6 Hz, ArH), 7.84 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.90–7.92 (2H, m, ArH), 8.07 (1H, s, -CHN-),
8.15 (1H, d, J = 8.8 Hz, ArH), 8.23 (1H, d, J = 16.0 Hz, -CH=CHCO-). 13C-NMR (500 MHz, CDCl3): δ
49.8, 55.3, 55.7, 55.8, 62.3, 67.4, 90.4, 101.4, 106.4, 107.3, 111.6, 112.4, 114.8, 118.0, 121.3, 122.3, 124.7,
126.1, 127.0, 128.9, 131.4, 131.6, 133.6, 135.6, 143.0, 149.4, 150.5, 157.8, 161.6, 162.6, 163.0, 163.1, 177.7,
190.2. LCMS (ES+) m/z = 690.2 ([M + H]+, tR = 1.70 min). HRMS (ESI+) m/z = 690.2471 [M + H]+
found, C39H36O9N3+ required 690.2446.
(E)-2-(4-(2-(4-((2-(3-(Ferrocenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-hydroxy-7-
methoxy-4H-chromen-4-one (105). A mixture of alkyne chalcone 26 (310 mg, 0.838 mmol), azide flavonol
80 (296 mg, 0.838 mmol), CuSO4·5H2O (273 mg, 1.09 mmol) and sodium ascorbate (496 mg, 2.50 mmol)
in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 105 (238 mg, 40%) as
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a dark red powdery solid. m.p. 118–120 ◦C. TLC Rf = 0.44 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1:
3340w (O-H str), 3088w (C-H str), 2929w (C-H str), 1735m (C=O str), 1597s (C=C str), 1541m (C=C str),
1506m (C=C str), 1484m, 1449m, 1403m, 1235s, 1206s, 1171s, 1117m, 1106m, 1044w, 1025s. 1H-NMR
(500 MHz, CDCl3): δ 3.96 (3H, s, -OCH3), 4.12 (5H, s, -C5H5), 4.35 (2H, t, J = 4.5 Hz, -OCH2CH2N-),
4.43 (2H, t, J = 1.5 Hz, -C5H4), 4.48 (2H, t, J = 1.5 Hz, -C5H4), 4.67 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 5.33
(2H, br s, -OCH2CN-), 6.95–6.97 (4H, m, ArH and OH), 6.96 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.01 (1H,
dd, J = 9.0, 2.0 Hz, ArH), 7.09 (1H, t, J = 7.5 Hz, ArH), 7.14 (1H, d, J = 8.5 Hz, ArH), 7.46 (1H, dd, J = 7.5,
1.0 Hz, ArH), 7.50 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.60 (1H, dd, J = 7.5, 1.5 Hz, ArH), 7.77 (1H, br s,
-CHN-), 8.14 (1H, d, J = 9.0 Hz, ArH), 8.19 (2H, d, J = 8.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.6,
55.8, 63.0, 66.1, 68.9, 69.8, 71.3, 79.0, 99.9, 113.1, 114.5, 114.6, 114.7, 121.4, 124.0, 124.7, 126.7, 129.3, 130.1,
130.2, 132.4, 137.4, 144.1, 145.5, 156.3, 157.2, 158.8, 164.2, 172.6, 192.3. LCMS (ES+) m/z = 724.2 ([M + H]+,
tR = 2.01 min). HRMS (ESI+) m/z = 724.1711 [M + H]+ found, C40H34N3O7Fe+ required 724.1746.
(E)-2-(4-(2-(4-((4-(3-(Ferrocenyl)acryloyl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-
hydroxy-4H-chromen-4-one (106). A mixture of alkyne chalcone 25 (308 mg, 0.769 mmol), azide flavonol
79 (252 mg, 0.779 mmol), CuSO4·5H2O (209 mg, 0.835 mmol) and sodium ascorbate (395 mg,
1.99 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 106
(212 mg, 38%) as a dark-red powdery solid. m.p. 158–160 ◦C. TLC Rf = 0.26 (3% MeOH/CH2Cl2).
IR νmax (neat)/cm−1: 3429w (O-H str), 2943w (C-H str), 2873w (C-H str), 1735m (C=O str), 1645w,
1596s (C=C str), 1568s (C=C str), 1509s (C=C str), 1469m, 1418m, 1409m, 1348w, 1292w, 1254s, 1200w,
1180m, 1151m, 1108m, 1027m. 1H-NMR (500 MHz, CDCl3): δ 3.97 (3H, s, -OCH3), 4.17 (5H, s, -C5H5),
4.46–4.48 (4H, m, -C5H4 and -OCH2CH2N-), 4.57 (2H, t, J = 2.0 Hz, -C5H4), 4.83 (2H, t, J = 5.0 Hz,
-OCH2CH2N-), 5.43 (2H, s, -OCH2CN-), 6.94 (1H, br s, OH), 6.98 (2H, d, J = 9.0 Hz, ArH), 7.12 (1H, d,
J = 15.0 Hz, -CH=CHCO-), 7.15 (1H, d, J = 8.5 Hz, ArH), 7.43 (1H, t, J = 8.0 Hz, ArH), 7.57 (1H, dd,
J = 8.0, 1.5 Hz, ArH), 7.59 (1H, d, J = 8.5 Hz, ArH), 7.63 (1H, d, J = 2.0 Hz, ArH), 7.71 (1H, t, J = 8.0 Hz,
ArH), 7.73 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.90 (1H, br s, -CHN-), 8.22 (2H, d, J = 9.0 Hz, ArH), 8.25
(1H, dd, J = 8.0, 1.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.7, 56.1, 62.9, 66.3, 68.9, 69.7, 71.2, 79.3,
111.2, 112.3, 114.5, 118.2, 118.5, 120.7, 122.4, 124.3, 124.5, 124.6, 125.4, 129.6, 132.3, 133.5, 137.8, 143.8,
144.7, 146.0, 149.5, 151.3, 155.2, 159.0, 173.2, 187.9. LCMS (ES+) m/z = 724.2 ([M + H]+, tR = 2.04 min).
HRMS (ESI+) m/z = 724.1723 [M + H]+ found, C40H34N3O7Fe+ required 724.1746.
(E)-2-(3-(2-(4-((4-Bromo-2-(3-(1-methyl-1H-indol-3-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-ethoxy)
-4-methoxyphenyl)-3-hydroxy-4H-chromen-4-one (107). A mixture of alkyne chalcone 21 (339 mg,
0.859 mmol), azide flavonol 82 (301 mg, 0.853 mmol), CuSO4·5H2O (542 mg, 2.17 mmol) and sodium
ascorbate (202 mg, 1.02 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The
crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and
recrystallized from MeOH to afford triazole hybrid 107 (258 mg, 40%) as a brown powdery solid. m.p.
158–160 ◦C. TLC Rf = 0.44 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3351w (O-H str), 2920m (C-H
str), 2852w (C-H str), 1640m (C=O str), 1589s (C=C str), 1559m (C=C str), 1514m (C=C str), 1492m,
1471m, 1397m, 1374m, 1333w, 1269s, 1204m, 1180m, 1130s, 1074w, 1047m, 1020m. 1H-NMR (500 MHz,
CDCl3): δ 3.64 (3H, s, -NCH3), 3.83 (3H, s, -OCH3), 4.02 (2H, t, J = 4.5 Hz, -OCH2CH2N-), 4.49 (2H, t,
J = 4.5 Hz, -OCH2CH2N-), 5.36 (2H, br s, -OCH2CN-), 6.96 (1H, d, J = 9.0 Hz, ArH), 7.02 (1H, br s, OH),
7.07 (1H, d, J = 8.5 Hz, ArH), 7.10–7.13 (1H, m, ArH), 7.18 (1H, s, ArH), 7.23 (2H, d, J = 3.5 Hz, ArH),
7.38 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.45 (1H, t, J = 7.5 Hz, ArH), 7.50 (1H, d, J = 1.5 Hz, ArH), 7.53
(1H, d, J = 7.5 Hz, ArH), 7.56 (1H, dd, J = 8.5, 2.5 Hz, ArH), 7.60 (1H, d, J = 8.5 Hz, ArH), 7.73 (1H, t,
J = 7.0 Hz, ArH), 7.77 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.83 (1H, d, J = 2.5 Hz, ArH), 7.90 (1H, dd,
J = 8.5, 1.5 Hz, ArH), 8.06 (1H, br s, -CHN-), 8.27 (1H, d, J = 8.0 Hz, ArH). 13C-NMR (500 MHz, CDCl3):
δ 33.0, 49.5, 55.9, 63.5, 67.1, 109.9, 111.4, 112.6, 113.2, 114.0, 114.8, 118.1, 120.5, 120.6, 121.4, 121.6, 122.6,
123.0, 123.3, 123.7, 124.6, 124.8, 125.4, 125.7, 131.9, 133.3, 133.6, 134.8, 134.9, 137.7, 137.8, 138.0, 144.5,
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146.9, 151.3, 155.1, 155.8, 173.0, 190.5. LCMS (ES+) m/z = 749.2 ([M + H]+, tR = 1.99 min). HRMS (ESI+)
m/z = 769.1232 [M + Na]+ found, C39H31O7N4BrNa+ required 769.1268.
(E)-2-(4-(2-(4-((4-Bromo-2-(3-(furan-2-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-3-methoxyph
enyl)-3-hydroxy-4H-chromen-4-one (108). A mixture of alkyne chalcone 24 (289 mg, 0.872 mmol), azide
flavonol 81 (304 mg, 0.860 mmol), CuSO4·5H2O (234 mg, 0.936 mmol) and sodium ascorbate (476 mg,
2.40 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from
MeOH to afford triazole hybrid 108 (245 mg, 42%) as a dark yellow-brown powdery solid. m.p.
118–120 ◦C. TLC Rf = 0.41 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3275w (O-H str), 3110w (C-H
str), 2926w (C-H str), 1650m (C=O str), 1598s (C=C str), 1549m (C=C str), 1515s (C=C str), 1481s, 1422w,
1398m, 1267s, 1232m, 1207s, 1177m, 1145s, 1111m, 1041m, 1017m, 1008m. 1H-NMR (500 MHz, CDCl3):
δ 3.90 (3H, s, -OCH3), 4.43 (2H, t, J = 4.0 Hz, -OCH2CH2N-), 4.75 (2H, t, J = 4.0 Hz, -OCH2CH2N-),
5.33 (2H, br s, -OCH2CN-), 6.47 (1H, d, J = 1.5 Hz, ArH), 6.64 (1H, d, J = 3.0 Hz, ArH), 6.89 (1H, d,
J = 8.5 Hz, ArH), 7.01 (1H, s, ArH), 7.06–7.08 (1H, m, ArH), 7.25 (1H, d, J = 16.0 Hz, -CH=CHCO-,
overlain by CDCl3), 7.36 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.44 (1H, t, J = 7.5 Hz, ArH), 7.52 (1H, s,
ArH), 7.54 (1H, d, J = 6.5 Hz, ArH), 7.61 (1H, d, J = 8.5 Hz, ArH), 7.72 (1H, d, J = 7.0 Hz, ArH), 7.74 (1H,
d, J = 2.0 Hz, ArH), 7.82 (1H, d, J = 8.5 Hz, ArH), 7.84 (1H, s, -CHN-), 8.09 (1H, br s, OH), 8.26 (1H, d,
J = 7.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.9, 55.8, 63.2, 67.5, 111.4, 112.7, 113.6, 113.9, 115.1,
116.1, 118.2, 120.6, 121.1, 124.0, 124.5, 125.2, 125.4, 129.6, 131.1, 133.0, 133.5, 135.4, 137.9, 144.6, 145.0,
148.7, 149.4, 151.4, 155.2, 155.7, 173.1, 190.2. LCMS (ES+) m/z = 686.2 ([M + H]+, tR = 2.00 min). HRMS
(ESI+) m/z = 684.0955 [M + H]+ found, C34H27O8N3Br+ required 684.0976.
6-(2-(4-(((4-Oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-2-phenyl-4H-chromen-
4-one (109). A mixture of alkyne flavone 30 (277 mg, 1.00 mmol), azide flavone 85 (307 mg, 0.998 mmol),
CuSO4·5H2O (303 mg, 1.21 mmol) and sodium ascorbate (492 mg, 2.48 mmol) in t-BuOH/H2O
(1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column
chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 109 (534 mg, 92%) as a white
powdery solid. m.p. 234–236 ◦C. TLC Rf = 0.36 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3145w
(C-H str), 2940w (C-H str), 1736w, 1643s (C=O str), 1627s, 1600m, 1570m (C=C str), 1561m (C=C str),
1482m, 1470m, 1455s, 1398m, 1361s, 1293m, 1197s, 1187m, 1148m, 1087m, 1047m, 1026w. 1H-NMR (500
MHz, CDCl3): δ 4.41 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.73 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.34 (2H,
s, -OCH2CN-), 6.83 (1H, s, -C=CH), 7.25 (1H, dd, J = 9.2, 3.2 Hz, ArH, overlain by CDCl3), 7.41–7.46
(4H, m, ArH), 7.51–7.55 (5H, m, ArH), 7.58 (1H, d, J = 3.2 Hz, ArH), 7.70 (1H, t, J = 7.2 Hz, ArH), 7.81
(1H, s, -CHN-), 7.92–7.94 (2H, m, ArH), 8.01–8.04 (2H, m, ArH), 8.29 (1H, d, J = 7.2 Hz, ArH). 13C-NMR
(500 MHz, CDCl3): δ 49.4, 65.1, 66.7, 105.9, 106.9, 118.0, 119.9, 123.8, 124.1, 124.5, 124.8, 125.7, 126.2,
128.3, 128.7, 129.0, 130.7, 131.6, 131.7, 133.5, 139.5, 144.0, 151.4, 155.1, 155.3, 156.4, 163.3, 175.1, 178.0.
LCMS (ES+) m/z = 584.1 ([M + H]+, tR = 1.91 min). HRMS (ESI+) m/z = 606.1610 [M + Na]+ found,
C35H25O6N3Na+ required 606.1636.
3-Hydroxy-2-(4-(2-(4-(((4-oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)
-4H-chromen-4-one (110). A mixture of alkyne flavone 30 (272 mg, 0.984 mmol), azide flavonol 79
(311 mg, 0.961 mmol), CuSO4·5H2O (274 mg, 1.10 mmol) and sodium ascorbate (557 mg, 2.81 mmol) in
t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from MeOH to afford
triazole hybrid 110 (272 mg, 47%) as an off-white powdery solid. m.p. 148–150 ◦C. TLC Rf = 0.34 (5%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3254w(br) (O-H str), 2964w (C-H str), 1602s (C=O str), 1564m
(C=C str), 1549m (C=C str), 1509s (C=C str), 1481m, 1469s, 1427m, 1403s, 1282m, 1250s, 1198m, 1183s,
1150w, 1116m, 1109m, 1041m. 1H-NMR (500 MHz, CDCl3): δ 4.39 (2H, t, J = 5.5 Hz, -OCH2CH2N-),
4.73 (2H, t, J = 5.5 Hz, -OCH2CH2N-), 5.33 (2H, s, -OCH2CN-), 6.99 (3H, d, J = 9.0 Hz, ArH and OH),
7.41–7.46 (5H, m, ArH), 7.53 (1H, dd, J = 8.0, 0.5 Hz, ArH), 7.59 (1H, d, J = 8.0 Hz, ArH), 7.68–7.72 (2H,
m, ArH), 7.85 (1H, s, -CHN-), 8.01–8.03 (2H, m, ArH), 8.23 (2H, d, J = 9.0 Hz, ArH), 8.25 (1H, dd, J = 8.0,
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1.5 Hz, ArH), 8.29 (1H, dd, J = 8.0, 1.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.5, 65.1, 66.2, 114.5,
118.1, 118.2, 120.7, 124.1, 124.5, 124.5, 124.8, 125.0, 125.4, 125.7, 128.4, 128.7, 129.6, 130.7, 133.5, 133.6,
137.8, 139.5, 144.1, 144.8, 155.3, 155.3, 156.4, 159.1, 173.2, 175.1. LCMS (ES+) m/z = 600.0 ([M + H]+,
tR = 1.75 min). HRMS (ESI+) m/z = 600.1755 [M + H]+ found, C35H26O7N3+ required 600.1765.
3-Hydroxy-2-(4-((1-(2-(4-(3-hydroxy-4-oxo-4H-chromen-2-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)
phenyl)-4H-chromen-4-one (111). A mixture of alkyne flavonol 36 (273 mg, 0.933 mmol), azide flavonol
79 (310 mg, 0.958 mmol), CuSO4·5H2O (296 mg, 1.19 mmol) and sodium ascorbate (461 mg, 2.33 mmol)
in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from MeOH to afford
triazole hybrid 111 (82.7 mg, 14%) as a dark brown powdery solid. m.p. 218–220 ◦C. TLC Rf = 0.41
(5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3284w (O-H str), 3087w (C-H str), 2924w (C-H str), 1600s
(C=O str), 1563m (C=C str), 1543m (C=C str), 1508s (C=C str), 1491s, 1424s, 1409s, 1248s, 1209m, 1180s,
1108s, 1043m, 1014w. 1H-NMR (500 MHz, DMSO-d6): δ 4.53 (2H, t, J = 4.5 Hz, -OCH2CH2N-), 4.85
(2H, t, J = 4.5 Hz, -OCH2CH2N-), 5.29 (2H, s, -OCH2CN-), 7.11 (2H, d, J = 8.5 Hz, ArH), 7.25 (2H, d,
J = 8.5 Hz, ArH), 7.43–7.47 (2H, m, ArH), 7.71–7.80 (4H, m, ArH), 8.09 (2H, t, J = 6.5 Hz, ArH), 8.17 (2H,
d, J = 9.0 Hz, ArH), 8.21 (2H, d, J = 9.0 Hz, ArH), 8.39 (1H, s, -CHN-), 9.47 (1H, s, OH), 9.48 (1H, s, OH).
13C-NMR (500 MHz, DMSO-d6): δ 49.0, 61.1, 66.3, 114.6, 114.8, 115.4, 118.3, 121.3, 123.9, 124.1, 124.5,
124.7, 125.4, 129.4, 129.6, 133.4, 133.5, 138.2, 142.4, 145.3, 145.4, 154.4, 158.9, 159.1, 172.6. LCMS (ES+)
m/z = 616.1 ([M + H]+, tR = 1.68 min). HRMS (ESI+) m/z = 616.1722 [M + H]+ found, C35H26N3O8+
required 616.1720.
3-(4-Methoxyphenyl)-7-((1-(2-((4-oxo-2-phenyl-4H-chromen-6-yl)oxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)-
4H-chromen-4-one (112). A mixture of alkyne isoflavone 46 (280 mg, 0.914 mmol), azide flavone 85
(282 mg, 0.919 mmol), CuSO4·5H2O (279 mg, 1.12 mmol) and sodium ascorbate (503 mg, 2.54 mmol)
in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by
flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from MeOH to
afford triazole hybrid 112 (531 mg, 95%) as a white powdery solid. m.p. 234–236 ◦C. TLC Rf = (3%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3082w (C-H str), 2941w (C-H str), 1641s, 1625s (C=O str),
1608s, 1567s (C=C str), 1515s (C=C str), 1497w, 1483w, 1456s, 1443s, 1359s, 1292s, 1252s, 1204m, 1192m,
1185s, 1137w, 1099m, 1084m, 1047s, 1032s. 1H-NMR (500 MHz, CDCl3): δ 3.83 (3H, s, -OCH3), 4.50 (2H,
t, J = 4.8 Hz, -OCH2CH2N-), 4.86 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.36 (2H, s, -OCH2CN-), 6.82 (1H, s,
-C=CH), 6.95 (2H, d, J = 8.4 Hz, ArH), 7.01 (1H, d, J = 2.0 Hz, ArH), 7.07 (1H, dd, J = 8.8, 2.0 Hz, ArH),
7.18 (1H, dd, J = 8.8, 3.2 Hz, ArH), 7.48–7.56 (6H, m, ArH), 7.59 (1H, d, J = 3.2 Hz, ArH), 7.86 (1H,
s, -CHN-), 7.90–7.92 (3H, m, -C=CH and ArH), 8.22 (1H, d, J = 8.4 Hz, ArH). 13C-NMR (500 MHz,
CDCl3): δ 49.8, 55.3, 62.4, 66.8, 101.3, 106.2, 106.9, 113.9, 115.0, 118.8, 119.9, 123.4, 124.0, 124.1, 124.6,
124.9, 126.3, 127.9, 129.1, 130.1, 131.7, 143.3, 151.5, 152.1, 155.0, 157.7, 159.6, 162.3, 163.5, 175.8, 178.0.
LCMS (ES+) m/z = 614.2 ([M + H]+, tR = 1.94 min). HRMS (ESI+) m/z = 614.1942 [M + H]+ found,
C36H28N3O7+ required 614.1927.
(E)-7-Methoxy-3-(4-((1-(2-(2-methoxy-4-(3-(2,4,6-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-
4-yl)methoxy)phenyl)-4H-chromen-4-one (113). A mixture of alkyne isoflavone 45 (236 mg, 0.770 mmol),
azide chalcone 69 (308 mg, 0.744 mmol), CuSO4·5H2O (210 mg, 0.843 mmol) and sodium ascorbate
(363 mg, 1.83 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue
was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized
from MeOH/PE to afford triazole hybrid 113 (167 mg, 31%) as a pale yellow-orange powdery solid.
m.p. 118–120 ◦C. TLC Rf = 0.33 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2942w (C-H str), 2840w
(C-H str), 1637m (C=O str), 1595s (C=C str), 1559s (C=C str), 1511s (C=C str), 1438m, 1418m, 1336m,
1300m, 1244s, 1201m, 1153s, 1177s, 1118s, 1037s, 1024s. 1H-NMR (500 MHz, CDCl3): δ 3.86 (3H, s,
-OCH3), 3.90 (6H, s, 2 × -OCH3), 3.90 (3H, s, -OCH3), 3.93 (3H, s, -OCH3), 4.46 (2H, t, J = 5.2 Hz,
-OCH2CH2N-), 4.84 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.26 (2H, s, -OCH2CN-), 6.13 (2H, s, ArH), 6.83
(1H, d, J = 0.4 Hz, ArH), 6.84 (1H, d, J = 6.0 Hz, ArH), 6.97 (1H, dd, J = 8.8, 2.4 Hz, ArH), 7.04 (2H,
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d, J = 8.8 Hz, ArH), 7.48 (2H, d, J = 8.8 Hz, ArH), 7.58 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.62 (1H, d,
J = 2.0 Hz, ArH), 7.84 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.88 (1H, s, -CHN-), 8.02 (1H, s, -C=CH), 8.19
(1H, d, J = 8.8 Hz, ArH), 8.21 (1H, d, J = 15.6 Hz, -CH=CHCO-). 13C-NMR (500 MHz, CDCl3): δ 49.7,
55.0, 55.4, 55.8, 55.9, 62.1, 67.6, 90.5, 100.0, 106.6, 111.7, 112.5, 114.5, 114.8, 118.4, 121.6, 122.3, 122.9,
124.4, 127.7, 130.1, 133.7, 135.6, 144.3, 149.5, 150.7, 152.1, 157.9, 158.2, 158.3, 161.6, 163.0, 163.9, 175.7,
190.3. LCMS (ES+) m/z = 720.3 ([M + H]+, tR = 1.69 min). HRMS (ESI+) m/z = 720.2529 [M + H]+
found, C40H38O10N3+ required 720.2552.
(E)-7-((1-(2-(2-Methoxy-4-(3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-methoxy)-
3-(4-methoxyphenyl)-4H-chromen-4-one (114). A mixture of alkyne isoflavone 46 (226 mg, 0.738 mmol),
azide chalcone 68 (301 mg, 0.728 mmol), CuSO4·5H2O (204 mg, 0.818 mmol) and sodium ascorbate
(393 mg, 1.98 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue
was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized
from MeOH to afford triazole hybrid 114 (331 mg, 63%) as a pale yellow-green powdery solid.
m.p. 98–100 ◦C. TLC Rf = 0.39 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2937w (C-H str), 2838w
(C-H str), 1623s (C=O str), 1594s (C=C str), 1576s (C=C str), 1512s (C=C str), 1494s, 1463m, 1442m,
1416m, 1247s, 1196m, 1178m, 1094s, 1027m. 1H-NMR (500 MHz, CDCl3): δ 3.83 (3H, s, -OCH3), 3.89
(3H, s, -OCH3), 3.91 (3H, s, -OCH3), 3.93 (3H, s, -OCH3), 3.95 (3H, s, -OCH3), 4.47 (2H, t, J = 4.8 Hz,
-OCH2CH2N-), 4.86 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.32 (2H, s, -OCH2CN-), 6.72 (1H, d, J = 8.4 Hz,
ArH), 6.85 (1H, d, J = 8.4 Hz, ArH), 6.95 (2H, d, J = 8.8 Hz, ArH), 7.01 (1H, d, J = 2.0 Hz, ArH), 7.04
(1H, dd, J = 8.8, 2.0 Hz, ArH), 7.38 (1H, d, J = 8.8 Hz, ArH), 7.49 (2H, d, J = 8.8 Hz, ArH), 7.53 (1H, d,
J = 15.6 Hz, -CH=CHCO-), 7.60 (1H, d, J = 8.4, 1.6 Hz, ArH), 7.62 (1H, d, J = 0.8 Hz, ArH), 7.90 (1H,
s, -C=CH), 7.98 (1H, d, J = 16.0 Hz, -CH=CHCO-), 8.06 (1H, s, -CHN-), 8.20 (1H, d, J = 9.2 Hz, ArH).
13C-NMR (500 MHz, CDCl3): δ 49.8, 55.3, 56.0, 56.0, 60.9, 61.4, 62.4, 67.5, 101.2, 107.6, 111.5, 112.4,
113.9, 114.8, 118.7, 120.7, 122.0, 122.4, 123.9, 124.1, 124.7, 124.8, 127.9, 130.1, 133.0, 139.7, 142.4, 143.1,
149.6, 151.0, 152.1, 153.7, 155.7, 157.7, 159.5, 162.4, 175.7, 188.9. LCMS (ES+) m/z = 720.3 ([M + H]+,
tR = 1.84 min). HRMS (ESI+) m/z = 720.2533 [M + H]+ found, C40H38O10N3+ required 720.2552.
3-Hydroxy-2-(4-(2-(4-(((3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-etho
xy)phenyl)-4H-chromen-4-one (115). A mixture of alkyne isoflavone 46 (183 mg, 0.597 mmol), azide
flavonol 79 (189 mg, 0.585 mmol), CuSO4·5H2O (271 mg, 1.09 mmol) and sodium ascorbate (493 mg,
2.49 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from
MeOH to afford triazole hybrid 115 (42.9 mg, 12%) as a yellow-green powdery solid. m.p. 252–254 ◦C.
TLC Rf = 0.30 (3% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3371w(br) (O-H str), 3064w (C-H str),
2928w (C-H str), 1640m, 1626m (C=O str), 1601s, 1563m (C=C str), 1512m (C=C str), 1484w, 1444m,
1409m, 1290w, 1247s, 1201m, 1183m, 1121m, 1049m, 1027m. 1H-NMR (500 MHz, CDCl3): δ 3.83 (3H,
s, -OCH3), 4.48 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 4.86 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 5.36 (2H, s,
-OCH2CN-), 6.92 (2H, d, J = 9.0 Hz, ArH), 6.97 (3H, d, J = 9.0 Hz, ArH and OH), 7.00 (1H, d, J = 1.5 Hz,
ArH), 7.07 (1H, dd, J = 8.5, 2.0 Hz, ArH), 7.42 (1H, t, J = 7.5 Hz, ArH), 7.47 (2H, d, J = 8.5 Hz, ArH), 7.57
(1H, d, J = 8.0 Hz, ArH), 7.70 (1H, t, J = 8.5 Hz, ArH), 7.89 (2H, s, -C=CH and -CHN-), 8.21–8.25 (4H, m,
ArH). 13C-NMR (500 MHz, CDCl3): δ 49.8, 55.3, 62.4, 66.3, 101.3, 113.9, 114.5, 115.0, 118.2, 118.8, 120.6,
124.1, 124.5, 124.7, 124.9, 125.4, 127.9, 129.6, 130.0, 133.5, 137.8, 144.6, 152.1, 155.3, 157.7, 159.0, 159.5,
162.3, 173.2, 175.8. LCMS (ES+) m/z = 630.2 ([M + H]+, tR = 1.77 min). HRMS (ESI+) m/z = 630.1861
[M + H]+ found, C36H28O8N3+ required 630.1871.
2-((Z)-4-(2-(4-((2-Methoxy-4-((E)-3-(4-methoxyphenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-etho
xy)benzylidene)benzofuran-3(2H)-one (116). A mixture of alkyne chalcone 20 (192 mg, 0.595 mmol), azide
aurone 88 (187 mg, 0.609 mmol), CuSO4·5H2O (289 mg, 1.16 mmol) and sodium ascorbate (548 mg,
2.77 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from
MeOH to afford triazole hybrid 116 (148 mg, 40%) as a bright yellow powdery solid. m.p. 128–130 ◦C.
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TLC Rf = 0.33 (3% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2941w (C-H str), 2835w (C-H str), 1695m
(C=O str), 1647m, 1590s (C=C str), 1571s (C=C str), 1509s (C=C str), 1461m, 1422m, 1296m, 1250s,
1174s, 1147s, 1128s, 1110s, 1098m, 1025s. 1H-NMR (500 MHz, CDCl3): δ 3.85 (3H, s, -OCH3), 3.97 (3H,
s, -OCH3), 4.43 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 4.80 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 5.42 (2H, s,
-OCH2CN-), 6.83 (1H, s, -C=CH), 6.89 (2H, d, J = 9.0 Hz, ArH), 6.91 (2H, d, J = 9.0 Hz, ArH), 7.12 (1H,
d, J = 8.0 Hz, ArH), 7.22 (1H, t, J = 8.0 Hz, ArH), 7.33 (1H, d, J = 8.0 Hz, ArH), 7.39 (1H, d, J = 15.5 Hz,
-CH=CHCO-), 7.56 (2H, d, J = 8.5 Hz, ArH), 7.60 (1H, dd, J = 8.5, 2.0 Hz, ArH), 7.64–7.67 (2H, m, ArH),
7.77 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.79–7.81 (1H, m, ArH), 7.86 (2H, d, J = 9.0 Hz, ArH), 7.87 (1H,
br s, -CHN-). 13C-NMR (500 MHz, CDCl3): δ 49.7, 55.4, 56.1, 62.9, 66.3, 111.1, 112.3, 112.6, 112.9, 114.3,
114.9, 119.1, 121.8, 122.6, 123.3, 124.3, 124.6, 126.1, 127.7, 130.1, 132.2, 133.1, 133.4, 136.6, 144.0, 146.1,
149.6, 151.4, 158.9, 161.5, 165.9, 184.5, 188.6. LCMS (ES+) m/z = 630.0 ([M + H]+, tR = 1.72 min). HRMS
(ESI+) m/z = 630.2217 [M + H]+ found, C37H32O7N3+ required 630.2235.
2-((Z)-4-(2-(4-((2-((E)-3-(Ferrocenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)benzylidene)benzo
furan-3(2H)-one (117). A mixture of alkyne chalcone 26 (286 mg, 0.772 mmol), azide aurone 88 (248 mg,
0.806 mmol), CuSO4·5H2O (236 mg, 0.943 mmol) and sodium ascorbate (426 mg, 2.15 mmol) in
t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 117 (409 mg, 78%) as
a dark red-purple microcrystalline solid. m.p. 108–110 ◦C. TLC Rf = 0.48 (3% MeOH/CH2Cl2). IR νmax
(neat)/cm−1: 3090w (C-H str), 1699m (C=O str), 1646m, 1594s (C=C str), 1569m (C=C str), 1509s (C=C
str), 1476w, 1459m, 1347w, 1297m, 1247m, 1208m, 1178s, 1127s, 1109s, 1097s, 1044m, 1025m, 1001w.
1H-NMR (500 MHz, CDCl3): δ 4.11 (5H, s, -C5H5), 4.32 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 4.42 (2H, t,
J = 2.0 Hz, -C5H4), 4.47 (2H, t, J = 2.0 Hz, -C5H4), 4.65 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.32 (2H, s,
-OCH2CN-), 6.85 (1H, s, -C=CH), 6.88 (2H, d, J = 8.8 Hz, ArH), 6.95 (1H, d, J = 15.6 Hz, -CH=CHCO-),
7.08 (1H, t, J = 7.6 Hz, ArH), 7.13 (1H, d, J = 8.4 Hz, ArH), 7.22 (1H, t, J = 7.6 Hz, ArH), 7.34 (1H, d,
J = 8.4 Hz, ArH), 7.44–7.46 (1H, m, ArH), 7.49 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.60 (1H, dd, J = 7.6,
1.6 Hz, ArH), 7.65 (1H, t, J = 8.4 Hz, ArH), 7.74 (1H, s, -CHN-), 7.81 (1H, dd, J = 7.6, 0.8 Hz, ArH), 7.86
(2H, d, J = 8.8 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.5, 62.9, 66.1, 68.9, 69.8, 71.2, 79.0, 112.8,
112.9, 113.1, 115.0, 121.4, 121.8, 123.3, 123.9, 124.6, 124.7, 125.9, 130.1, 130.2, 132.4, 133.4, 136.6, 144.1,
145.4, 146.0, 156.3, 159.0, 165.8, 184.5, 192.3. LCMS (ES+) m/z = 678.2 ([M + H]+, tR = 2.11 min). HRMS
(ESI+) m/z = 678.1677 [M + H]+ found, C39H32N3O5Fe+ required 678.1691.
6-Methoxy-2-((Z)-4-(2-(4-((2-methoxy-5-((E)-3-(1-methyl-1H-pyrrol-2-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-
triazol-1-yl)ethoxy)benzylidene)benzofuran-3(2H)-one (118). A mixture of alkyne chalcone 22 (265 mg,
0.898 mmol), azide aurone 89 (304 mg, 0.900 mmol), CuSO4·5H2O (264 mg, 1.06 mmol) and sodium
ascorbate (474 mg, 2.39 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude
residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford
triazole hybrid 118 (270 mg, 48%) as a bright yellow powdery solid. m.p. 138–140 ◦C. TLC Rf = 0.46
(5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2934w (C-H str), 2884w (C-H str), 1700m (C=O str),
1656m, 1638m, 1596s (C=C str), 1562s (C=C str), 1510m (C=C str), 1483m, 1412m, 1330m, 1267s, 1198m,
1152s, 1132s, 1099s, 1056m, 1042s, 1022s. 1H-NMR (500 MHz, CDCl3): δ 3.74 (3H, s, -NCH3), 3.94
(3H, s, -OCH3), 3.96 (3H, s, -OCH3), 4.42 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.79 (2H, t, J = 4.8 Hz,
-OCH2CH2N-), 5.41 (2H, s, -OCH2CN-), 6.19–6.21 (1H, m, ArH), 6.74–6.80 (4H, m, ArH), 6.78 (1H,
s, -C=CH), 6.87 (2H, d, J = 8.8 Hz, ArH), 7.11 (1H, d, J = 8.4 Hz, ArH), 7.27 (1H, d, J = 15.2 Hz,
-CH=CHCO-, overlain by CDCl3), 7.58 (1H, dd, J = 8.4, 1.6 Hz, ArH), 7.64 (1H, d, J = 2.0 Hz, ArH), 7.69
(1H, d, J = 8.8 Hz, ArH), 7.78 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.82 (2H, d, J = 8.8 Hz, ArH), 7.87 (1H,
s, -CHN-). 13C-NMR (500 MHz, CDCl3): δ 34.3, 49.7, 56.0, 56.0, 62.8, 66.2, 96.6, 109.6, 111.0, 111.4, 112.0,
112.1, 112.3, 114.8, 114.9, 116.2, 122.3, 124.3, 125.6, 126.1, 127.6, 130.2, 131.6, 132.4, 133.1, 143.8, 147.0,
149.4, 151.2, 158.6, 167.2, 168.2, 182.8, 188.0. LCMS (ES+) m/z = 633.3 ([M + H]+, tR = 1.94 min). HRMS
(ESI+) m/z = 633.2352 [M + H]+ found, C36H33N4O7+ required 633.2349.
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2-((Z)-4-(2-(4-((4-Bromo-2-((E)-3-(1-methyl-1H-indol-3-yl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)eth
oxy)benzylidene)benzofuran-3(2H)-one (119). A mixture of alkyne chalcone 21 (308 mg, 0.781 mmol),
azide aurone 88 (239 mg, 0.779 mmol), CuSO4·5H2O (261 mg, 1.04 mmol) and sodium ascorbate
(397 mg, 2.00 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue
was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized
from MeOH to afford triazole hybrid 119 (117 mg, 21%) as a pale yellow-brown powdery solid.
m.p. 138–140 ◦C. TLC Rf = 0.44 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2930w (C-H str), 1699m
(C=O str), 1644m, 1590s (C=C str), 1525m (C=C str), 1508m (C=C str), 1460m, 1395w, 1373m, 1249m,
1177s, 1126m, 1096w, 1045w. 1H-NMR (500 MHz, CDCl3): δ 3.74 (3H, s, -NCH3), 4.03 (2H, t, J = 5.2 Hz,
-OCH2CH2N-), 4.37 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.32 (2H, s, -OCH2CN-), 6.71 (2H, d, J = 8.8 Hz,
ArH), 6.82 (1H, s, -C=CH), 7.04 (1H, d, J = 8.8 Hz, ArH), 7.16–7.21 (1H, m, ArH), 7.23 (1H, t, J = 7.6 Hz,
ArH), 7.29–7.30 (2H, m, ArH), 7.33–7.35 (2H, m, ArH), 7.38 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.54
(1H, dd, J = 8.8, 2.4 Hz, ArH), 7.64–7.69 (2H, m, ArH), 7.73 (1H, s, -CHN-), 7.77 (2H, d, J = 8.8 ArH),
7.80–7.82 (2H, m, ArH), 7.85 (1H, d, J = 15.6 Hz, -CH=CHCO-). 13C-NMR (500 MHz, CDCl3): δ 33.2,
49.2, 63.3, 65.7, 110.0, 112.7, 112.7, 112.9, 114.0, 114.7, 114.9, 120.6, 121.7, 121.7, 121.8, 123.1, 123.4,
124.1, 124.6, 125.7, 125.8, 132.0, 133.1, 133.2, 134.8, 135.0, 136.7, 138.1, 138.1, 143.7, 146.0, 155.5, 158.8,
165.8, 184.5, 190.8. LCMS (ES+) m/z = 703.1 ([M + H]+, tR = 5.05 min). HRMS (ESI+) m/z = 723.1189
[M + Na]+ found, C38H29O5N4BrNa+ required 723.1214.
(Z)-3-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-meth
oxy)-2-phenyl-4H-chromen-4-one (120). A mixture of alkyne flavone 30 (250 mg, 0.906 mmol), azide
aurone 89 (316 mg, 0.936 mmol), CuSO4·5H2O (284 mg, 1.14 mmol) and sodium ascorbate (447 mg,
2.26 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue
was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized
from MeOH to afford triazole hybrid 120 (351 mg, 63%) as a pale yellow-white powdery solid.
m.p. 186–188 ◦C. TLC Rf = 0.38 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3056w (C-H str), 1698m
(C=O str), 1654w, 1608s, 1595s (C=C str), 1509m (C=C str), 1470m, 1434m, 1397m, 1342m, 1272s, 1245s,
1198s, 1176m, 1147m, 1128s, 1109s, 1091s, 1042m. 1H-NMR (500 MHz, CDCl3): δ 3.93 (3H, s, -OCH3),
4.35 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 4.71 (2H, t, J = 4.5 Hz, -OCH2CH2N-), 5.33 (2H, s, -OCH2CN-),
6.74–6.77 (3H, m, ArH and -C=CH), 6.90 (2H, d, J = 9.0 Hz, ArH), 7.40–7.45 (4H, m, ArH), 7.52 (1H, dd,
J = 8.5, 0.5 Hz, ArH), 7.69 (1H, t, J = 8.5 Hz, ArH), 7.70 (1H, d, J = 8.5 Hz, ArH), 7.83 (2H, d, J = 9.0 Hz,
ArH), 7.83 (1H, s, -CHN-), 8.01–8.03 (2H, m, ArH), 8.28 (1H, dd, J = 8.0, 1.5 Hz, ArH). 13C-NMR
(500 MHz, CDCl3): δ 49.5, 56.0, 65.1, 66.2, 96.6, 111.5, 112.0, 114.9, 115.0, 118.1, 124.1, 124.8, 124.9, 125.7,
126.1, 128.3, 128.7, 130.7, 133.1, 133.5, 139.5, 144.0, 147.0, 155.3, 156.4, 158.8, 167.3, 168.3, 175.1, 182.8.
LCMS (ES+) m/z = 614.2 ([M + H]+, tR = 1.91 min). HRMS (ESI+) m/z = 614.1926 [M + H]+ found,
C36H28N3O7+ required 614.1927.
(Z)-6-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)meth
oxy)-2-phenyl-4H-chromen-4-one (121). A mixture of alkyne flavone 31 (249 mg, 0.900 mmol), azide
aurone 89 (309 mg, 0.916 mmol), CuSO4·5H2O (247 mg, 0.989 mmol) and sodium ascorbate (482 mg,
2.43 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from
MeOH to afford triazole hybrid 121 (269 mg, 49%) as a bright yellow-orange powdery solid.
m.p. 148–150 ◦C. TLC Rf = 0.30 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3065w (C-H str),
2925w (C-H str), 1695m (C=O str), 1640s, 1594s (C=C str), 1568s (C=C str), 1510m (C=C str), 1496m,
1481m, 1454s, 1442s, 1360m, 1270m, 1250s, 1181s, 1131s, 1110s, 1095s, 1043m, 1027m. 1H-NMR
(500 MHz, CDCl3): δ 3.92 (3H, s, -OCH3), 4.43 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.82 (2H, t, J = 4.8 Hz,
-OCH2CH2N-), 5.30 (2H, s, -OCH2CN-), 6.72–6.74 (2H, m, ArH), 6.75 (1H, s, -C=CH), 6.79 (1H, s,
-C=CH), 6.89 (2H, d, J = 8.8 Hz, ArH), 7.33 (1H, dd, J = 9.2, 3.2 Hz, ArH), 7.48–7.52 (4H, m, ArH), 7.68
(1H, d, J = 9.2 Hz, ArH), 7.71 (1H, d, J = 3.2 Hz, ArH), 7.80 (2H, d, J = 8.8 Hz, ArH), 7.88–7.90 (3H, m,
ArH and -CHN-). 13C-NMR (500 MHz, CDCl3): δ 49.7, 56.0, 62.2, 66.3, 96.5, 106.4, 106.8, 111.4, 112.0,
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114.8, 114.9, 120.0, 123.9, 124.2, 124.5, 125.7, 126.1, 126.2, 129.0, 131.5, 131.7, 133.1, 143.4, 146.9, 151.2,
155.4, 158.7, 163.2, 167.2, 168.2, 178.1, 182.8. LCMS (ES+) m/z = 614.2 ([M + H]+, tR = 1.77 min). HRMS
(ESI+) m/z = 614.1906 [M + H]+ found, C36H28O7N3+ required 614.1922.
(Z)-3-Hydroxy-2-(4-((1-(2-(4-((3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)
methoxy)phenyl)-4H-chromen-4-one (122). A mixture of alkyne flavonol 36 (391 mg, 1.34 mmol), azide
aurone 88 (408 mg, 1.33 mmol), CuSO4·5H2O (435 mg, 1.74 mmol) and sodium ascorbate (682 mg,
3.44 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from
MeOH to afford triazole hybrid 122 (335 mg, 42%) as a yellow-brown powdery solid. m.p. 208–210 ◦C.
TLC Rf = 0.32 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3300w (O-H str), 3073w (C-H str), 2951w
(C-H str), 1694m (C=O str), 1646w, 1604s, 1596s (C=C str), 1567w (C=C str), 1509s (C=C str), 1458w,
1426w, 1407w, 1299m, 1256s, 1178s, 1109s, 1051s. 1H-NMR (500 MHz, CDCl3): δ 4.46 (2H, t, J = 4.8 Hz,
-OCH2CH2N-), 4.84 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.34 (2H, s, -OCH2CN-), 6.82 (1H, s, -C=CH),
6.92 (2H, d, J = 8.8 Hz, ArH), 6.96 (1H, br s, OH), 7.15 (2H, d, J = 8.8 Hz, ArH), 7.22 (1H, t, J = 7.6 Hz,
ArH), 7.31 (1H, d, J = 8.4 Hz, ArH), 7.39 (1H, t, J = 7.6 Hz, ArH), 7.56 (1H, d, J = 8.8 Hz, ArH), 7.63–7.71
(2H, m, ArH), 7.80 (1H, d, J = 7.6 Hz, ArH), 7.86 (3H, d, J = 8.4 Hz, ArH and -CHN-), 8.21–8.25 (3H,
m, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.8, 62.1, 66.4, 112.6, 112.9, 114.9, 114.9, 118.1, 120.6, 121.8,
123.4, 124.1, 124.4, 124.6, 125.4, 126.1, 129.5, 133.0, 133.4, 136.5, 136.7, 137.7, 145.0, 146.1, 155.3, 157.4,
158.9, 159.5, 165.9, 173.1, 184.5. LCMS (ES+) m/z = 600.0 ([M + H]+, tR = 4.68 min). HRMS (ESI+) m/z
= 600.1751 [M + H]+ found, C35H26O7N3+ required 600.1765.
(Z)-2-(4-(2-(4-((3-((4,6-Dimethoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)phenyl)-3-hydroxy-7-methoxy-4H-chromen-4-one (123). A mixture of alkyne aurone 56 (192 mg,
0.571 mmol), azide flavonol 80 (210 mg, 0.595 mmol), CuSO4·5H2O (234 mg, 0.939 mmol) and
sodium ascorbate (362 mg, 1.83 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A.
The crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2)
and recrystallized from MeOH to afford triazole hybrid 123 (54.3 mg, 14%) as a pale yellow-brown
powdery solid. m.p. 178–180 ◦C. TLC Rf = 0.29 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3302w
(O-H str), 2939w (C-H str), 2845w (C-H str), 1692w, 1614s (C=O str), 1599s (C=C str), 1510m (C=C str),
1503m (C=C str), 1452m, 1403w, 1361w, 1346w, 1251m, 1215s, 1187w, 1156m, 1121w, 1092s, 1036w.
1H-NMR (500 MHz, CDCl3): δ 3.91 (3H, s, -OCH3), 3.92 (3H, s, -OCH3), 3.95 (3H, s, -OCH3), 4.46 (2H, t,
J = 4.5 Hz, -OCH2CH2N-), 4.83 (2H, t, J = 4.5 Hz, -OCH2CH2N-), 5.34 (2H, s, -OCH2CN-), 6.08 (1H, s,
ArH), 6.41 (1H, s, ArH), 6.70 (1H, s, -C=CH), 6.93–6.95 (4H, m, ArH and OH), 6.99–7.03 (2H, m, ArH),
7.34 (1H, t, J = 8.0 Hz, ArH), 7.40 (1H, d, J = 7.5 Hz, ArH), 7.55 (1H, s, ArH), 7.85 (1H, br s, -CHN-),
8.12 (1H, d, J = 9.0 Hz, ArH), 8.16 (2H, d, J = 8.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.8, 55.9,
56.2, 56.2, 62.2, 66.4, 89.3, 94.1, 99.9, 105.1, 110.3, 114.4, 114.6, 114.8, 116.2, 116.7, 121.9, 123.9, 124.5,
124.8, 126.7, 129.3, 129.8, 134.0, 137.4, 144.0, 148.0, 157.2, 158.3, 158.8, 159.3, 164.2, 169.1, 172.6, 180.6.
LCMS (ES+) m/z = 690.2 ([M + H]+, tR = 4.59 min). HRMS (ESI+) m/z = 690.2062 [M + H]+ found,
C38H32O10N3+ required 690.2082.
(Z)-7-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)-met
hoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (124). A mixture of alkyne isoflavone 46 (276 mg,
0.901 mmol), azide aurone 89 (301 mg, 0.892 mmol), CuSO4·5H2O (348 mg, 1.39 mmol) and sodium
ascorbate (496 mg, 2.50 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A.
The crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and
recrystallized from MeOH to afford triazole hybrid 124 (317 mg, 55%) as a bright yellow powdery
solid. m.p. 228–230 ◦C. TLC Rf = 0.43 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3085w (C-H str),
2935w (C-H str), 1705m (C=O str), 1651m, 1629s, 1596s (C=C str), 1567m (C=C str), 1510s (C=C str),
1441s, 1347m, 1295m, 1249s, 1202m, 1179s, 1147s, 1098s, 1020s. 1H-NMR (500 MHz, CDCl3): δ 3.83
(3H, s, -OCH3), 3.93 (3H, s, -OCH3), 4.44 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.83 (2H, t, J = 4.8 Hz,
-OCH2CH2N-), 5.34 (2H, s, -OCH2CN-), 6.74–6.77 (2H, m, ArH), 6.76 (1H, s, -C=CH), 6.88 (2H, d,
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J = 8.8 Hz, ArH), 6.93 (2H, d, J = 8.8 Hz, ArH), 6.97 (1H, d, J = 2.4 Hz, ArH), 7.06 (1H, dd, J = 8.8,
2.4 Hz, ArH), 7.47 (2H, d, J = 8.8 Hz, ArH), 7.69 (1H, d, J = 8.4 Hz, ArH), 7.82 (2H, d, J = 8.8 Hz,
ArH), 7.87 (1H, s, -CHN-), 7.89 (1H, s, -C=CH), 8.23 (1H, d, J = 8.8 Hz, ArH). 13C-NMR (500 MHz,
CDCl3): δ 49.8, 55.3, 56.0, 62.4, 66.3, 96.7, 101.3, 111.3, 112.1, 113.9, 114.8, 114.9, 118.8, 124.1, 124.2, 124.9,
125.7, 126.3, 127.9, 130.0, 133.1, 143.2, 147.0, 152.1, 157.7, 158.6, 159.5, 162.3, 167.3, 168.3, 175.8, 182.8.
LCMS (ES+) m/z = 644.2 ([M + H]+, tR = 1.86 min). HRMS (ESI+) m/z = 644.2011 [M + H]+ found,
C37H30O8N3+ required 644.2027.
4,6-Dimethoxy-2-((Z)-3-((1-(2-(4-(((Z)-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol
-4-yl)methoxy)benzylidene)benzofuran-3(2H)-one (125). A mixture of alkyne aurone 56 (303 mg,
0.902 mmol), azide aurone 88 (278 mg, 0.905 mmol), CuSO4·5H2O (263 mg, 1.05 mmol) and sodium
ascorbate (462 mg, 2.33 mmol) in t-BuOH/H2O (1:1, 20 mL) was reacted according to GP-A. The
crude residue was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and
recrystallized from MeOH to afford triazole hybrid 125 (491 mg, 85%) as a bright yellow-brown
powdery solid. m.p. 148–150 ◦C. TLC Rf = 0.36 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2942w
(C-H str), 2843w (C-H str), 1694m (C=O str), 1651m, 1587s (C=C str), 1508m (C=C str), 1458m, 1423w,
1345m, 1298m, 1251m, 1234m, 1214s, 1177s, 1154s, 1128s, 1091s, 1036m. 1H-NMR (500 MHz, CDCl3):
δ 3.90 (3H, s, -OCH3), 3.92 (3H, s, -OCH3), 4.42 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.81 (2H, t, J = 4.8 Hz,
-OCH2CH2N-), 5.31 (2H, s, -OCH2CN-), 6.09 (1H, d, J = 1.6 Hz, ArH), 6.40 (1H, d, J = 1.2 Hz, ArH),
6.68 (1H, s, -C=CH), 6.81 (1H, s, -C=CH), 6.88 (2H, d, J = 8.4 Hz, ArH), 7.00 (1H, dd, J = 8.0, 2.4 Hz,
ArH), 7.21 (1H, t, J = 7.6 Hz, ArH), 7.30–7.34 (2H, m, ArH), 7.39 (1H, d, J = 8.0 Hz, ArH), 7.54 (1H, s,
ArH), 7.64 (1H, t, J = 7.6 Hz, ArH), 7.79 (1H, d, J = 7.6 Hz, ArH), 7.82–7.85 (3H, m, ArH and -CHN-).
13C-NMR (500 MHz, CDCl3): δ 49.7, 56.2, 62.2, 66.3, 89.3, 94.1, 105.1, 110.3, 112.7, 112.9, 114.3, 114.8,
116.3, 116.6, 121.8, 123.3, 123.9, 124.5, 124.5, 126.0, 129.8, 133.0, 133.4, 133.9, 136.7, 144.3, 146.1, 148.0,
158.3, 158.9, 159.3, 165.9, 169.0, 180.6, 184.5. LCMS (ES+) m/z = 644.2 ([M + H]+, tR = 2.02 min). HRMS
(ESI+) m/z = 644.2006 [M + H]+ found, C37H30O8N3+ required 644.2027.
(E)-4-((1-(2-(4-(3-(2-Hydroxyphenyl)-3-oxoprop-1-en-1-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-
chromen-2-one (126). A mixture of alkyne coumarin 48 (207 mg, 1.03 mmol), azide chalcone 61 (302 mg,
0.975 mmol), CuSO4·5H2O (292 mg, 1.17 mmol) and sodium ascorbate (508 mg, 2.56 mmol) in
t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from MeOH to afford
triazole hybrid 126 (387 mg, 78%) as a bright yellow powdery solid. m.p. 194–196 ◦C. TLC Rf = 0.43
(5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3083w (C-H str), 2929w (C-H str), 1725s (C=O str), 1641m,
1625m, 1607m, 1560s (C=C str), 1511s (C=C str), 1489s, 1424m, 1382m, 1273m, 1249s, 1202s, 1175s,
1156s, 1107m, 1056m, 1030m. 1H-NMR (500 MHz, CDCl3): δ 4.47 (2H, t, J = 5.2 Hz, -OCH2CH2N-),
4.87 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.36 (2H, s, -OCH2CN-), 5.87 (1H, s, -C=CH), 6.91–6.97 (3H, m,
ArH), 7.03 (1H, d, J = 8.4 Hz, ArH), 7.23 (1H, t, J = 8.0 Hz, ArH), 7.31 (1H, d, J = 8.4 Hz, ArH), 7.48–7.54
(2H, m, ArH), 7.54 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.61 (2H, d, J = 8.4 Hz, ArH), 7.78 (1H, dd, J = 8.0,
1.6 Hz, ArH), 7.86 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.91 (1H, dd, J = 8.0, 1.2 Hz, ArH), 7.94 (1H, s,
-CHN-), 12.87 (1H, s, OH). 13C-NMR (500 MHz, CDCl3): δ 49.9, 62.5, 66.3, 91.2, 115.0, 115.4, 116.8, 118.4,
118.6, 118.8, 120.0, 123.1, 123.9, 124.7, 128.5, 129.5, 130.6, 132.6, 136.3, 141.6, 144.7, 153.3, 159.8, 162.6,
163.5, 164.9, 193.6. LCMS (ES+) m/z = 510.2 ([M + H]+, tR = 1.65 min). HRMS (ESI+) m/z = 510.1651
[M + H]+ found, C29H24O6N3+ required 510.1660.
4-((1-(2-(4-(3-Hydroxy-4-oxo-4H-chromen-2-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-
one (127). A mixture of alkyne coumarin 48 (186 mg, 0.931 mmol), azide flavonol 79 (302 mg,
0.933 mmol), CuSO4·5H2O (318 mg, 1.27 mmol) and sodium ascorbate (497 mg, 2.51 mmol) in
t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from MeOH to afford
triazole hybrid 127 (77.9 mg, 16%) as an off-white powdery solid. m.p. 228–230 ◦C. TLC Rf = 0.46
(5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3271w (O-H str), 3015w (C-H str), 2923w (C-H str), 1714s
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(C=O str), 1622m, 1603s, 1565s (C=C str), 1509m (C=C str), 1480m, 1470w, 1428m, 1406w, 1376w,
1262s, 1228m, 1177m, 1140w, 1106m, 1043m. 1H-NMR (500 MHz, CDCl3): δ 4.52 (2H, t, J = 5.0 Hz,
-OCH2CH2N-), 4.89 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 5.37 (2H, s, -OCH2CN-), 5.89 (1H, s, -C=CH),
6.97 (1H, br s, OH), 7.03 (2H, d, J = 9.0 Hz, ArH), 7.24 (1H, t, J = 8.0 Hz, ArH), 7.31 (1H, dd, J = 8.5,
1.0 Hz, ArH), 7.43 (1H, t, J = 8.0 Hz, ArH), 7.54 (1H, t, J = 8.5 Hz, ArH), 7.59 (1H, d, J = 8.5 Hz, ArH),
7.72 (1H, t, J = 8.5 Hz, ArH), 7.78 (1H, dd, J = 8.0, 1.5 Hz, ArH), 7.96 (1H, s, -CHN-), 8.23–8.27 (3H, m,
ArH). 13C-NMR (500 MHz, CDCl3): δ 49.9, 62.6, 66.3, 91.2, 114.5, 115.4, 116.8, 118.2, 120.7, 123.1, 123.9,
124.5, 124.7, 124.8, 125.4, 129.7, 132.5, 133.5, 137.8, 141.7, 144.6, 153.3, 155.3, 159.0, 162.6, 164.9, 173.2.
LCMS (ES+) m/z = 524.2 ([M + H]+, tR = 1.55 min). HRMS (ESI+) m/z = 524.1476 [M + H]+ found,
C29H22N3O7+ required 524.1458.
4-(2-(4-(((4-Oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-2H-chromen-2-one
(128). A mixture of alkyne flavone 30 (310 mg, 1.12 mmol), azide coumarin 58 (256 mg, 1.11 mmol),
CuSO4·5H2O (399 mg, 1.60 mmol) and sodium ascorbate (578 mg, 2.92 mmol) in t-BuOH/H2O
(1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash column
chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 128 (354 mg, 63%) as a
white fluffy solid. m.p. 268–270 ◦C. TLC Rf = 0.30 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3082w
(C-H str), 2926w (C-H str), 1723s (C=O str), 1626s, 1567m (C=C str), 1494w, 1465m, 1400w, 1385m,
1274m, 1239s, 1197s, 1182s, 1148s, 1140m, 1111m, 1058w, 1030w. 1H-NMR (500 MHz, CDCl3): δ 4.47
(2H, t, J = 5.0 Hz, -OCH2CH2N-), 4.85 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 5.31 (2H, s, -OCH2CN-), 5.65
(1H, s, -C=CH), 7.24 (1H, t, J = 7.5 Hz, ArH, overlain by CDCl3), 7.33 (1H, d, J = 8.5 Hz, ArH), 7.41–7.46
(4H, m, ArH), 7.51 (1H, d, J = 8.5 Hz, ArH), 7.55 (1H, t, J = 8.0 Hz, ArH), 7.68–7.73 (2H, m, ArH), 7.93
(1H, s, -CHN-), 8.02–8.04 (2H, m, ArH), 8.25 (1H, d, J = 7.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ
48.7, 65.2, 67.0, 91.1, 115.0, 116.8, 118.1, 122.9, 124.0, 124.2, 124.7, 124.9, 125.6, 128.4, 128.7, 130.7, 130.8,
132.8, 133.7, 139.7, 144.7, 153.3, 155.3, 156.3, 162.2, 164.6, 175.1. LCMS (ES+) m/z = 508.3 ([M + H]+,
tR = 1.81 min). HRMS (ESI+) m/z = 508.1506 [M + H]+ found, C29H22N3O6+ required 508.1509.
(Z)-4-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)meth
oxy)-2H-chromen-2-one (129). A mixture of alkyne coumarin 48 (181 mg, 0.902 mmol), azide aurone 89
(302 mg, 0.895 mmol), CuSO4·5H2O (250 mg, 1.00 mmol) and sodium ascorbate (459 mg, 2.32 mmol) in
t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and recrystallized from MeOH to afford
triazole hybrid 129 (253 mg, 53%) as a bright yellow-orange microcrystalline solid. m.p. 138–140 ◦C.
TLC Rf = 0.40 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3077w (C-H str), 2926w (C-H str), 1719s
(C=O str), 1650m, 1623m, 1593s (C=C str), 1565m (C=C str), 1511m (C=C str), 1442m, 1399m, 1269m,
1247s, 1182s, 1130s, 1096s, 1042m, 1019m. 1H-NMR (500 MHz, CDCl3): δ 3.94 (3H, s, -OCH3), 4.48
(2H, t, J = 4.5 Hz, -OCH2CH2N-), 4.87 (2H, t, J = 4.5 Hz, -OCH2CH2N-), 5.36 (2H, s, -OCH2CN-), 5.88
(1H, s, -C=CH), 6.75–6.78 (2H, m, ArH), 6.76 (1H, s, -C=CH), 6.94 (2H, d, J = 9.0 Hz, ArH), 7.23 (1H, t,
J = 8.0 Hz, ArH), 7.31 (1H, dd, J = 8.5, 1.0 Hz, ArH), 7.53 (1H, t, J = 8.5 Hz, ArH), 7.71 (1H, d, J = 9.0 Hz,
ArH), 7.77 (1H, dd, J = 8.0, 1.5 Hz, ArH), 7.84 (2H, d, J = 8.5 Hz, ArH), 7.95 (1H, s, -CHN-). 13C-NMR
(500 MHz, CDCl3): δ 49.9, 56.0, 62.5, 66.3, 91.2, 96.6, 111.3, 112.1, 114.8, 115.0, 115.4, 116.8, 123.1, 123.9,
124.7, 125.8, 126.3, 132.5, 133.1, 141.6, 147.1, 153.3, 158.6, 162.6, 164.9, 167.3, 168.3, 182.8. LCMS (ES+)
m/z = 538.2 ([M + H]+, tR = 1.78 min). HRMS (ESI+) m/z = 538.1617 [M + H]+ found, C30H24N3O7+
required 538.1614.
4-(2-(4-(((3-(4-Methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-2H-chromen
-2-one (130). A mixture of alkyne isoflavone 46 (301 mg, 0.983 mmol), azide coumarin 58 (232 mg,
1.00 mmol), CuSO4·5H2O (288 mg, 1.15 mmol) and sodium ascorbate (503 mg, 2.54 mmol) in
t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 130 (363 mg, 69%)
as an off-white powdery solid. m.p. 208–210 ◦C. TLC Rf = 0.28 (5% MeOH/CH2Cl2). IR νmax
(neat)/cm−1: 3085w (C-H str), 2927w (C-H str), 1730s (C=O str), 1621s, 1566m (C=C str), 1513m (C=C
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str), 1495w, 1444m, 1379m, 1330w, 1279w, 1241s, 1198m, 1181s, 1144m, 1109m, 1031m. 1H-NMR
(500 MHz, CDCl3): δ 3.85 (3H, s, -OCH3), 4.58 (2H, t, J = 4.4 Hz, -OCH2CH2N-), 4.95 (2H, t, J = 4.4 Hz,
-OCH2CH2N-), 5.35 (2H, s, -OCH2CN-), 5.69 (1H, s, -C=CH), 6.97–6.99 (3H, m, ArH), 7.03 (1H, dd,
J = 8.8, 2.0 Hz, ArH), 7.23 (1H, d, J = 7.6 Hz, ArH), 7.31 (1H, d, J = 8.0 Hz, ArH), 7.50 (2H, d, J = 8.4 Hz,
ArH), 7.56 (1H, t, J = 8.0 Hz, ArH), 7.65 (1H, d, J = 8.0 Hz, ArH), 7.84 (1H, s, -CHN-), 7.90 (1H, s,
-C=CH), 8.20 (1H, d, J = 8.8 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.0, 55.3, 62.4, 67.0, 91.3, 101.2,
114.0, 114.8, 114.9, 117.0, 118.9, 120.2, 122.4, 123.5, 124.0, 124.1, 125.0, 128.0, 130.1, 132.9, 143.7, 152.1,
153.3, 157.7, 159.6, 162.2, 164.4, 175.7. LCMS (ES+) m/z = 538.0 ([M + H]+, tR = 4.19 min). HRMS (ESI+)
m/z = 538.1624 [M + H]+ found, C30H24N3O7+ required 538.1614.
(E)-4-((1-(2-(4-(3-Oxo-3-(2-(prop-2-yn-1-yloxy)phenyl)prop-1-en-1-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)
methoxy)-2H-chromen-2-one (131). A mixture of biflavonoid 126 (264 mg, 0.517 mmol), propargyl
bromide (0.130 mL, 1.46 mmol) and anhydrous K2CO3 (291 mg, 2.10 mmol) in dry acetone (50 mL) was
reacted according to GP-B. The crude residue was purified by flash column chromatography (SiO2,
1% MeOH/CH2Cl2) to afford alkyne biflavonoid 131 (229 mg, 81%) as a pale yellow-white powdery
solid. m.p. 164–166 ◦C. TLC Rf = 0.15 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3239w (C≡C-H
str), 3074w (C-H str), 2973w (C-H str), 2165w (C≡C str), 1723s (C=O str), 1651m, 1624m, 1600s (C=C
str), 1566m (C=C str), 1510m (C=C str), 1482w, 1452m, 1401s, 1372m, 1328m, 1231s, 1175w, 1105m,
1028m. 1H-NMR (500 MHz, CDCl3): δ 2.54 (1H, t, J = 2.0 Hz, -OCH2C≡CH), 4.45 (2H, t, J = 4.8 Hz,
-OCH2CH2N-), 4.79 (2H, d, J = 2.0 Hz, -OCH2C≡CH), 4.85 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.35 (2H,
s, -OCH2CN-), 5.87 (1H, s, -C=CH), 6.88 (2H, d, J = 8.8 Hz, ArH), 7.09–7.13 (2H, m, ArH), 7.23 (1H, t,
J = 7.6 Hz, ArH), 7.29 (1H, d, J = 13.2 Hz, -CH=CHCO-, overlain by CDCl3), 7.32 (1H, t, J = 4.4 Hz,
ArH), 7.49 (1H, t, J = 8.8 Hz, ArH), 7.53–7.58 (3H, m, ArH), 7.56 (1H, d, J = 15.6 Hz, -CH=CHCO-),
7.64 (1H, dd, J = 7.6, 1.2 Hz, ArH), 7.77 (1H, dd, J = 8.4, 0.8 Hz, ArH), 7.93 (1H, s, -CHN-). 13C-NMR
(500 MHz, CDCl3): δ 49.9, 56.4, 62.5, 66.3, 76.1, 78.1, 91.2, 113.3, 114.8, 115.4, 116.8, 121.8, 123.1, 123.9,
124.6, 125.6, 129.0, 130.0, 130.2, 130.5, 132.6, 132.6, 141.6, 142.7, 153.3, 155.8, 159.3, 162.5, 164.9, 192.5.
LCMS (ES+) m/z = 548.0 ([M + H]+, tR = 4.38 min). HRMS (ESI+) m/z = 548.1803 [M + H]+ found,
C32H26O6N3+ required 548.1816.
(Z)-2-(4-((1-(2-(4-((3-Oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)ph
enyl)-3-(prop-2-yn-1-yloxy)-4H-chromen-4-one (132). A mixture of biflavonoid 122 (212 mg, 0.354 mmol),
propargyl bromide (0.063 mL, 0.707 mmol) and anhydrous K2CO3 (153 mg, 1.11 mmol) in dry
acetone (20 mL) was reacted according to GP-B. The crude residue was purified by flash column
chromatography (SiO2, 1% MeOH/CH2Cl2) to afford alkyne biflavonoid 132 (168 mg, 74%) as a bright
yellow powdery solid. m.p. 150–152 ◦C. TLC Rf = 0.50 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1:
3233w (C≡C-H str), 2939w (C-H str), 2115w (C≡C str), 1697s (C=O str), 1635m, 1606s, 1598s (C=C
str), 1566m (C=C str), 1508s (C=C str), 1472m, 1395m, 1343w, 1301m, 1250s, 1198m, 1184s, 1148m,
1133w, 1047m, 1017w. 1H-NMR (500 MHz, CDCl3): δ 2.34 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 4.46 (2H, t,
J = 4.8 Hz, -OCH2CH2N-), 4.84 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.00 (2H, d, J = 2.4 Hz, -OCH2C≡CH),
5.33 (2H, s, -OCH2CN-), 6.83 (1H, s, -C=CH), 6.93 (2H, d, J = 8.8 Hz, ArH), 7.12 (2H, d, J = 9.2 Hz,
ArH), 7.22 (1H, t, J = 7.6 Hz, ArH), 7.31 (1H, d, J = 8.4 Hz, ArH), 7.38 (1H, t, J = 7.6 Hz, ArH), 7.51
(1H, d, J = 8.4 Hz, ArH), 7.63–7.69 (2H, m, ArH), 7.80 (1H, d, J = 7.6 Hz, ArH), 7.86 (2H, d, J = 6.8 Hz,
ArH), 7.87 (1H, s, -CHN-), 8.16 (2H, d, J = 8.8 Hz, ArH), 8.22 (1H, dd, J = 8.0, 1.6 Hz, ArH). 13C-NMR
(500 MHz, CDCl3): δ 49.8, 59.0, 62.0, 66.3, 76.0, 78.7, 112.6, 112.9, 114.6, 114.9, 117.9, 121.8, 123.4, 123.8,
123.9, 124.1, 124.6, 124.7, 125.7, 126.1, 130.7, 133.4, 136.7, 138.0, 146.1, 155.1, 156.4, 158.9, 160.1, 165.8,
174.7, 184.5. LCMS (ES+) m/z = 638.1 ([M + H]+, tr = 4.82 min). HRMS (ESI+) m/z = 638.1902 [M + H]+
found, C38H28O7N3+ required 638.1922.
(E)-1-(4-Methoxy-2-(prop-2-yn-1-yloxy)phenyl)-3-(4-methoxy-3-((1-(2-(2-methoxy-4-((E)-3-(2,4,6-trimethoxy
phenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)prop-2-en-1-one (133). A mixture of
biflavonoid 92 (111 mg, 0.148 mmol), propargyl bromide (0.050 mL, 0.561 mmol) and anhydrous
K2CO3 (113 mg, 0.815 mmol) in dry acetone (50 mL) was reacted according to GP-B. The crude
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residue was purified by flash column chromatography (SiO2, 1% MeOH/CH2Cl2) to afford alkyne
biflavonoid 133 (107 mg, 92%) as a bright yellow powdery solid. m.p. 170–172 ◦C. TLC Rf = 0.29 (5%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3286w (C≡C-H str), 3002w (C-H str), 2936w (C-H str), 2841w
(C-H str), 2160w (C≡C str), 1650m (C=O str), 1599s (C=C str), 1511m (C=C str), 1458m, 1441w, 1432w,
1418w, 1399w, 1377w, 1337m, 1321m, 1301m, 1259s, 1205w, 1159m, 1124m, 1027m. 1H-NMR (500 MHz,
CDCl3): δ 2.64 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 3.87 (6H, s, 2 × -OCH3), 3.89 (3H, s, -OCH3), 3.91
(9H, s, 3 × -OCH3), 4.45 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.83 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.84
(2H, d, J = 2.4 Hz, -OCH2C≡CH), 5.33 (2H, s, -OCH2CN-), 6.15 (2H, s, ArH), 6.61–6.63 (2H, m, ArH),
6.83 (1H, d, J = 8.0 Hz, ArH), 6.87 (1H, d, J = 8.0 Hz, ArH), 7.18 (1H, dd, J = 8.4, 2.0 Hz, ArH), 7.39
(1H, d, J = 1.6 Hz, ArH), 7.46 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.56–7.64 (2H, m, ArH), 7.61 (1H, d,
J = 16.0 Hz, -CH=CHCO-), 7.79 (1H, d, J = 9.2 Hz, ArH), 7.85 (1H, d, J = 15.6 Hz, -CH=CHCO-), 8.03
(1H, s, -CHN-), 8.23 (1H, d, J = 16.0 Hz, -CH=CHCO-). 13C-NMR (500 MHz, CDCl3): δ 49.7, 55.6, 55.8,
55.9, 55.9, 56.5, 63.1, 67.5, 76.3, 78.1, 90.5, 100.1, 106.4, 106.6, 111.5, 111.7, 112.4, 112.8, 121.6, 122.3,
122.8, 124.0, 124.6, 125.3, 128.5, 132.9, 133.7, 135.6, 142.1, 144.1, 147.7, 149.5, 150.6, 151.5, 158.2, 158.3,
161.6, 163.0, 163.8, 190.0, 190.3. LCMS (ES+) m/z = 790.3 ([M + H]+, tR = 4.71 min). HRMS (ESI+)
m/z = 790.2949 [M + H]+ found, C44H44O11N3+ required 790.2970.
2-(4-(2-(4-(((4-Oxo-2-phenyl-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-(prop-2-yn
-1-yloxy)-4H-chromen-4-one (134). A mixture of biflavonoid 110 (161 mg, 0.268 mmol), propargyl
bromide (0.045 mL, 0.500 mmol) and anhydrous K2CO3 (111 mg, 0.803 mmol) in dry acetone (20 mL)
was reacted according to GP-B. The crude residue was purified by flash column chromatography
(SiO2, 1% MeOH/CH2Cl2) to afford alkyne biflavonoid 134 (161 mg, 94%) as a pale yellow-white
powdery solid. m.p. 118–120 ◦C. TLC Rf = 0.34 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3233w
(C≡C-H str), 2939w (C-H str), 2116w (C≡C str), 1631s (C=O str), 1613s, 1600s, 1559m (C=C str), 1508m
(C=C str), 1467s, 1392s, 1287w, 1252m, 1239m, 1184s, 1146m, 1123w, 1109w, 1042w. 1H-NMR (500 MHz,
CDCl3): δ 2.33 (1H, t, J = 2.4 Hz, -OCH2C≡CH), 4.39 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 4.73 (2H, t,
J = 5.2 Hz, -OCH2CH2N-), 4.99 (2H, d, J = 2.4 Hz, -OCH2C≡CH), 5.33 (2H, s, -OCH2CN-) 6.97 (2H, d,
J = 9.2 Hz, ArH), 7.39–7.45 (5H, m, ArH), 7.53 (1H, d, J = 8.0 Hz, ArH), 7.54 (1H, d, J = 8.0 Hz, ArH),
7.67–7.72 (2H, m, ArH), 7.85 (1H, s, -CHN-), 8.02–8.04 (2H, m, ArH), 8.15 (2H, d, J = 9.2 Hz, ArH), 8.25
(1H, dd, J = 8.0, 1.2 Hz, ArH), 8.28 (1H, dd, J = 8.0, 1.2 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.5,
59.0, 65.1, 66.2, 76.1, 78.6, 114.3, 117.9, 118.1, 124.0, 124.1, 124.3, 124.7, 124.8, 124.9, 125.7, 128.3, 128.7,
130.7, 130.8, 133.4, 133.6, 138.1, 139.5, 144.1, 155.1, 155.3, 156.2, 156.4, 159.6, 174.7, 175.1. LCMS (ES+)
m/z = 638.1 ([M + H]+, tR = 4.70 min). HRMS (ESI+) m/z = 638.1905 [M + H]+ found, C38H28O7N3+
required 638.1922.
(E)-2-(4-(2-(4-((4-(3-(Ferrocenyl)acryloyl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-
(prop-2-yn-1-yloxy)-4H-chromen-4-one (135). A mixture of biflavonoid 106 (190 mg, 0.263 mmol),
propargyl bromide (0.047 mL, 0.526 mmol) and anhydrous K2CO3 (127 mg, 0.920 mmol) in dry
acetone (20 mL) was reacted according to GP-B. The crude residue was purified by flash column
chromatography (SiO2, 1% MeOH/CH2Cl2) to afford alkyne biflavonoid 135 (95.5 mg, 48%) as a dark
red powdery solid. m.p. 108–110 ◦C. TLC Rf = 0.37 (5% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3292w
(C≡C-H str), 2937w (C-H str), 2245w (C≡C str), 1636m (C=O str), 1598s (C=C str), 1576s (C=C str),
1509s (C=C str), 1467m, 1419m, 1395m, 1349w, 1258s, 1198m, 1184m, 1150m, 1029w, 1000w. 1H-NMR
(500 MHz, CDCl3): δ 2.33 (1H, t, J = 2.5 Hz, -OCH2C≡CH), 3.96 (3H, s, -OCH3), 4.17 (5H, s, -C5H5),
4.45–4.47 (4H, m, -C5H4 and -OCH2CH2N-), 4.57 (2H, t, J = 2.0 Hz, -C5H4), 4.82 (2H, t, J = 5.0 Hz,
-OCH2CH2N-), 4.98 (2H, d, J = 2.5 Hz, -OCH2C≡CH), 5.42 (2H, s, -OCH2CN-), 6.96 (2H, d, J = 9.0 Hz,
ArH), 7.13 (1H, d, J = 15.5 Hz, -CH=CHCO-), 7.15 (1H, d, J = 8.5 Hz, ArH), 7.41 (1H, t, J = 8.5 Hz, ArH),
7.54 (1H, dd, J = 8.5, 0.5 Hz, ArH), 7.58 (1H, dd, J = 8.5, 2.0 Hz, ArH), 7.63 (1H, d, J = 2.0 Hz, ArH),
7.69 (1H, t, J = 8.5 Hz, ArH), 7.73 (1H, d, J = 15.0 Hz, -CH=CHCO-), 7.90 (1H, s, -CHN-), 8.14 (2H, d,
J = 9.0 Hz, ArH), 8.25 (1H, dd, J = 8.0, 1.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.7, 56.1, 59.0,
62.8, 66.2, 68.9, 69.7, 71.2, 76.1, 78.6, 79.3, 111.2, 112.3, 114.2, 117.9, 118.5, 122.4, 124.0, 124.3, 124.4, 124.7,
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125.7, 130.8, 132.3, 133.4, 138.1, 143.8, 146.0, 149.5, 151.3, 155.1, 156.1, 159.5, 174.7, 187.9. LCMS (ES+)
m/z = 762.1 ([M + H]+, tR = 4.88 min). HRMS (ESI+) m/z = 762.1878 [M + H]+ found, C43H36O7N3Fe+
required 762.1897.
(E)-4-((1-(2-(4-(3-Oxo-3-(2-((1-(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)
phenyl)prop-1-en-1-yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (136). A mixture of
alkyne biflavonoid 131 (205 mg, 0.375 mmol), azide flavone 86 (123 mg, 0.399 mmol), CuSO4·5H2O
(115 mg, 0.459 mmol) and sodium ascorbate (192 mg, 0.969 mmol) in t-BuOH/H2O (1:1, 40 mL) was
reacted according to GP-A. The crude residue was purified by flash column chromatography (SiO2,
1%–5% MeOH/CH2Cl2) to afford triazole hybrid 136 (214 mg, 67%) as a pale yellow-white powdery
solid. m.p. 78–80 ◦C. TLC Rf = 0.37 (7% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 3080w (C-H str),
2923w (C-H str), 1708s (C=O str), 1622s, 1597s (C=C str), 1567s (C=C str), 1509w (C=C str), 1493w,
1449m, 1356m, 1274w, 1237m, 1173m, 1139w, 1105w, 1043w, 1026w. 1H-NMR (500 MHz, CDCl3): δ
4.38 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 4.41 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 4.70 (2H, t, J = 5.2 Hz,
-OCH2CH2N-), 4.82 (2H, t, J = 5.2 Hz, -OCH2CH2N-), 5.34 (2H, s, -OCH2CN-), 5.34 (2H, s, -OCH2CN-),
5.85 (1H, s, -C=CH), 6.75 (1H, s, -C=CH), 6.77–6.80 (3H, m, ArH), 6.85 (1H, d, J = 2.4 Hz, ArH), 7.08 (1H,
t, J = 7.6 Hz, ArH), 7.14 (1H, d, J = 8.4 Hz, ArH), 7.20 (1H, t, J = 8.0 Hz, ArH), 7.26 (1H, d, J = 16.0 Hz,
-CH=CHCO-, overlain by CDCl3), 7.28 (1H, d, J = 4.0 Hz, ArH), 7.38 (2H, d, J = 8.4 Hz, ArH), 7.46–7.54
(5H, m, ArH), 7.50 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.62 (1H, dd, J = 8.8, 1.6 Hz, ArH), 7.74 (1H, dd,
J = 8.0, 1.2 Hz, ArH), 7.77 (1H, s, -CHN-), 7.89 (2H, dd, J = 7.6, 1.6 Hz, ArH), 7.96 (1H, s, -CHN-), 8.03
(1H, d, J = 8.8 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.4, 49.8, 62.5, 62.8, 66.2, 66.6, 91.2, 101.4,
107.5, 113.1, 114.1, 114.8, 115.4, 116.7, 118.5, 121.5, 123.1, 123.9, 124.0, 124.8, 125.7, 126.2, 127.3, 128.7,
129.1, 129.8, 130.1, 130.4, 131.6, 131.6, 132.5, 132.9, 141.6, 142.4, 144.1, 153.3, 156.5, 157.6, 159.3, 161.9,
162.5, 163.2, 164.9, 177.6, 192.6. LCMS (ES+) m/z = 855.3 ([M + H]+, tR = 4.57 min). HRMS (ESI+)
m/z = 855.2743 [M + H]+ found, C49H39O9N6+ required 855.2773.
(Z)-7-(2-(4-(((4-Oxo-2-(4-((1-(2-(4-((3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)-4H-chromen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
(137). A mixture of alkyne biflavonoid 132 (145 mg, 0.227 mmol), azide flavone 86 (73.5 mg,
0.239 mmol), CuSO4·5H2O (70.1 mg, 0.281 mmol) and sodium ascorbate (129 mg, 0.651 mmol) in
t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by flash
column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 137 (106 mg, 49%)
as a bright yellow powdery solid. m.p. 198–200 ◦C. TLC Rf = 0.33 (7% MeOH/CH2Cl2). IR νmax
(neat)/cm−1: 2931w (C-H str), 2874w (C-H str), 1698w, 1628s (C=O str), 1602s, 1594s (C=C str), 1508s
(C=C str), 1466m, 1449m, 1423w, 1396w, 1374m, 1299w, 1288w, 1249s, 1178s, 1148w, 1128w, 1110w,
1096w, 1041m. 1H-NMR (500 MHz, CDCl3): δ 4.44–4.46 (4H, m, 2 × -OCH2CH2N-), 4.78 (2H, t,
J = 4.8 Hz, -OCH2CH2N-), 4.83 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.28 (2H, s, -OCH2CN-), 5.33 (2H,
s, -OCH2CN-), 6.75 (1H, s, -C=CH), 6.81 (1H, s, -C=CH), 6.91–6.94 (4H, m, ArH), 7.04 (2H, d, J = 9.2
Hz, ArH), 7.21 (1H, d, J = 7.6 Hz, ArH), 7.30 (1H, d, J = 8.4 Hz, ArH), 7.37 (1H, d, J = 7.6 Hz, ArH),
7.47–7.53 (4H, m, ArH), 7.62–7.67 (2H, m, ArH), 7.79 (1H, d, J = 7.6 Hz, ArH), 7.84 (2H, d, J = 8.8 Hz,
ArH), 7.87–7.90 (3H, m, -CHN- and ArH), 7.94 (1H, s, -CHN-), 8.04 (2H, d, J = 8.8 Hz, ArH), 8.11 (1H,
d, J = 8.8 Hz, ArH), 8.23 (1H, dd, J = 8.0, 1.2 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.3, 49.7,
61.9, 65.0, 66.3, 66.7, 101.5, 107.6, 112.7, 112.9, 114.2, 114.7, 114.9, 117.9, 118.5, 121.8, 123.4, 123.6, 124.0,
124.1, 124.6, 124.7, 125.0, 125.6, 126.1, 126.2, 127.4, 129.0, 130.5, 131.5, 131.7, 133.4, 133.4, 136.7, 139.0,
143.7, 144.3, 146.1, 155.1, 156.1, 157.7, 159.0, 160.0, 162.1, 163.2, 165.9, 174.9, 177.7, 184.5. LCMS (ES+)
m/z = 945.4 ([M + H]+, tR = 4.89 min). HRMS (ESI+) m/z = 945.2851 [M + H]+ found, C55H41O10N6+
required 945.2879.
7-Methoxy-2-(4-(2-(4-((5-methoxy-2-((E)-3-(4-methoxy-3-((1-(2-(2-methoxy-4-((E)-3-(2,4,6-trimethoxyphenyl)
acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)
ethoxy)phenyl)-4H-chromen-4-one (138). A mixture of alkyne biflavonoid 133 (107 mg, 0.135 mmol),
azide flavone 87 (49.3 mg, 0.146 mmol), CuSO4·5H2O (66.0 mg, 0.264 mmol) and sodium ascorbate
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(72.8 mg, 0.367 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue
was purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole
hybrid 138 (8.00 mg, 5%) as a pale yellow-white powdery solid. m.p. 128–130 ◦C. TLC Rf = 0.19 (5%
MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2927w (C-H str), 2846w (C-H str), 1736w, 1627m (C=O str),
1600s (C=C str), 1510s (C=C str), 1454m, 1439m, 1423m, 1375w, 1355w, 1338w, 1258s, 1204m, 1162m,
1123s, 1023s. 1H-NMR (500 MHz, DMSO-d6): δ 3.76 (6H, s, 2 × -OCH3), 3.85 (6H, s, 2 × -OCH3), 3.90
(9H, s, 3 × -OCH3), 4.38 (2H, t, J = 4.4 Hz, -OCH2CH2N-), 4.50 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.71
(2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.82 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 5.24 (2H, s, -OCH2CN-), 5.38
(2H, s, -OCH2CN-), 6.29 (2H, s, ArH), 6.57–6.66 (1H, m, ArH), 6.81 (1H, s, -C=CH), 6.82–6.85 (1H, m,
ArH), 6.92–6.98 (3H, m, ArH), 7.02–7.11 (3H, m, ArH), 7.20 (1H, d, J = 8.8 Hz, ArH), 7.27 (1H, dd,
J = 5.6, 2.4 Hz, ArH), 7.47 (1H, d, J = 15.6 Hz, -CH=CHCO-), 7.48 (1H, d, J = 8.0 Hz, ArH), 7.54–7.64
(2H, m, ArH), 7.56 (1H, d, J = 15.2 Hz, -CH=CHCO-), 7.82 (1H, d, J = 16.0 Hz, -CH=CHCO-), 7.87–8.06
(3H, m, ArH and -CHN-), 8.02 (1H, d, J = 16.0 Hz, -CH=CHCO-), 8.28 (1H, d, J = 6.4 Hz, ArH), 8.31 (1H,
s, -CHN-). 13C-NMR (500 MHz, DMSO-d6): δ 48.9, 49.0, 55.5, 55.7, 56.0, 61.5, 61.7, 66.2, 67.1, 91.0, 99.8,
100.9, 105.1, 105.4, 106.6, 111.0, 111.3, 111.8, 112.0, 112.7, 114.5, 114.9, 114.9, 115.0, 115.0, 117.1, 120.2,
122.1, 123.8, 125.3, 126.1, 127.6, 127.9, 128.0, 132.0, 132.1, 134.4, 137.4, 141.4, 142.3, 142.7, 147.7, 148.9,
149.8, 151.0, 151.1, 157.4, 157.9, 158.6, 160.4, 161.3, 162.0, 163.2, 163.7, 176.3, 188.3, 189.1. LCMS (ES+)
m/z = 1128.0 ([M + H]+, tR = 1.87 min). HRMS (ESI+) m/z = 1127.4014 [M + H]+ found, C62H59O15N6+
required 1127.4033.
(Z)-3-((1-(2-(4-((6-Methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)met
hoxy)-2-(4-(2-(4-(((4-oxo-2-phenyl-4H-chr omen-3-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-4H-
chromen-4-one (139). A mixture of alkyne biflavonoid 134 (134 mg, 0.210 mmol), azide aurone 89
(83.5 mg, 0.248 mmol), CuSO4·5H2O (70.8 mg, 0.284 mmol) and sodium ascorbate (131 mg, 0.659 mmol)
in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was purified by
flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) to afford triazole hybrid 139 (73.9 mg,
36%) as a bright yellow powdery solid. m.p. 98–100 ◦C. TLC Rf = 0.39 (7% MeOH/CH2Cl2). IR νmax
(neat)/cm−1: 3001w (C-H str), 2929w (C-H str), 2874w (C-H str), 1693m (C=O str), 1632m, 1600s (C=C
str), 1509m (C=C str), 1466m, 1444w, 1395m, 1343w, 1248s, 1181s, 1146m, 1129m, 1110m, 1096w, 1044m.
1H-NMR (500 MHz, CDCl3): δ 3.93 (3H, s, -OCH3), 4.34–4.37 (4H, m, 2 × -OCH2CH2N-), 4.69–4.72
(4H, m, 2 × -OCH2CH2N-), 5.32 (4H, s, 2 × -OCH2CN-), 6.77 (1H, d, J = 5.6 Hz, ArH), 6.77 (1H, s,
-C=CH), 6.88 (2H, d, J = 8.8 Hz, ArH), 6.90 (2H, d, J = 8.8 Hz, ArH), 7.40–7.45 (6H, m, ArH), 7.51 (1H,
d, J = 3.6 Hz, ArH), 7.53 (1H, d, J = 3.6 Hz, ArH), 7.67–7.72 (3H, m, ArH), 7.81 (2H, d, J = 9.2 Hz,
ArH), 7.84 (1H, s, -CHN-), 7.88 (1H, s, -CHN-), 8.01–8.05 (4H, m, ArH), 8.27 (2H, dd, J = 8.0, 1.6 Hz,
ArH). 13C-NMR (500 MHz, CDCl3): δ 49.4, 49.5, 56.0, 64.9, 65.2, 66.2, 66.3, 96.6, 111.5, 112.1, 114.3,
114.9, 115.0, 118.0, 118.1, 124.0, 124.1, 124.1, 124.8, 124.8, 124.9, 125.0, 125.7, 125.7, 125.7, 126.1, 128.4,
128.7, 130.6, 130.7, 133.1, 133.4, 133.6, 139.0, 139.6, 144.0, 144.1, 147.0, 155.2, 155.3, 156.0, 156.4, 158.8,
159.5, 167.3, 168.3, 175.0, 175.1, 182.8. LCMS (ES+) m/z = 975.4 ([M + H]+, tR = 4.94 min). HRMS (ESI+)
m/z = 975.2956 [M + H]+ found, C56H43O11N6+ required 975.2984.
2-(4-(2-(4-((4-((E)-3-(Ferrocenyl)acryloyl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-3-
((1-(2-(4-(((Z)-6-methoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)metho
xy)-4H-chromen-4-one (140). A mixture of alkyne biflavonoid 135 (71.6 mg, 0.0940 mmol), azide
aurone 89 (38.1 mg, 0.113 mmol), CuSO4·5H2O (46.1 mg, 0.185 mmol) and sodium ascorbate (58.0 mg,
0.293 mmol) in t-BuOH/H2O (1:1, 40 mL) was reacted according to GP-A. The crude residue was
purified by flash column chromatography (SiO2, 1%–5% MeOH/CH2Cl2) and further purified
by preparative HPLC to afford triazole hybrid 140 (2.80 mg, 3%) as a bright red powdery solid.
m.p. 158–160 ◦C. TLC Rf = 0.35 (7% MeOH/CH2Cl2). IR νmax (neat)/cm−1: 2917w (C-H str), 2852w
(C-H str), 1737w, 1605s (C=O str), 1509m (C=C str), 1465m, 1443w, 1378w, 1353w, 1260s, 1198m, 1151m,
1133w, 1113w, 1042w, 1015w. 1H-NMR (500 MHz, CDCl3): δ 3.94 (3H, s, -OCH3), 3.96 (3H, s, -OCH3),
4.17 (5H, br s, -C5H5), 4.38 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 4.42 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 4.47
Molecules 2016, 21, 1230 55 of 59
(2H, br s, -C5H4), 4.57 (2H, br s, -C5H4), 4.73 (2H, t, J = 5.0 Hz, -OCH2CH2N-), 4.80 (2H, t, J = 4.5 Hz,
-OCH2CH2N-), 5.30 (2H, s, -OCH2CN-), 5.41 (2H, s, -OCH2CN-), 6.76–6.79 (2H, m, ArH and -C=CH),
6.77 (1H, d, J = 14.5 Hz, -CH=CHCO-), 6.89 (2H, d, J = 9.0 Hz, ArH), 6.90 (2H, d, J = 8.5 Hz, ArH),
7.14 (1H, d, J = 8.0 Hz, ArH), 7.43 (1H, t, J = 8.0 Hz, ArH), 7.53 (1H, d, J = 8.5 Hz, ArH), 7.58 (1H, d,
J = 8.2 Hz, ArH), 7.62 (1H, s, ArH), 7.70 (1H, t, J = 8.5 Hz, ArH), 7.70 (1H, d, J = 16.0 Hz, -CH=CHCO-),
7.71 (2H, d, J = 8.5 Hz, ArH), 7.84 (2H, d, J = 9.0 Hz, ArH), 7.89 (1H, s, -CHN-), 7.94 (1H, s, -CHN-),
8.05 (2H, d, J = 9.0 Hz, ArH), 8.27 (1H, dd, J = 8.0, 1.5 Hz, ArH). 13C-NMR (500 MHz, CDCl3): δ 49.6,
49.7, 56.1, 61.2, 62.8, 66.2, 66.3, 68.9, 69.8, 71.3, 79.3, 96.6, 111.2, 111.6, 111.8, 112.1, 112.3, 114.3, 114.3,
114.9, 118.0, 118.6, 121.3, 122.5, 122.5, 124.1, 124.1, 124.3, 124.4, 124.8, 125.1, 125.7, 125.7, 125.8, 130.6,
133.0, 133.2, 133.5, 138.3, 144.0, 146.0, 149.6, 151.4, 155.1, 157.4, 158.8, 159.5, 167.5, 167.7, 179.2, 182.9,
187.9. LCMS (ES+) m/z = 1098.8 ([M + H]+, tR = 2.02 min). HRMS (ESI+) m/z = 1099.2960 [M + H]+
found, C61H51FeN6O11+ required 1099.2921.
3.4. Biological Screening
3.4.1. Aβ Preparation
Aβ42 (1 mg) was purchased from Eurogentec Ltd. (Hampshire, UK) as a lyophilised powder.
The peptide was dissolved in trifluroacetic acid (TFA, 1 mL), sonicated in an ice-water bath for 60 s,
then the TFA removed in a vacuum desiccator. Ice cold 1,1,1,3,3,3-hexafluro-2-propanol (HFIP, 1 mL)
was added to re-suspend the lyophilised peptide. The sample was sonicated for 60 s at 0 ◦C, then
aliquoted into 20 µL portions. The HFIP was removed in the vacuum desiccator overnight and
the lyophilised samples were stored at −80 ◦C until use. The required concentration of Aβ42 was
prepared by dissolving the sample in dimethyl sulfoxide (DMSO) (5% of total solvent volume), then
adding sodium phosphate buffer (50 mM, pH 7.4). The solution was sonicated at 0 ◦C for 3 min, then
centrifuged at 13,400 rpm for 30 min at 0 ◦C to separate any aggregated species.
3.4.2. Thioflavin T (THT) Assay
ThT was purchased from AbCam (Cambridge, UK). Final concentrations of 10 µM Aβ42, 20 µM
ThT and 50 µM compound in sodium phosphate buffer (50 mM, pH 7.4) were used for all samples.
The assay samples (100 µL) were mixed in a black non-binding 96-well plate (Greiner Bio-One,
Stonehouse, UK) which was sealed (Nunc™ polyolefin acrylate film Nunc, ThermoFisher) and loaded
into the fluorescence plate reader (Tecan, Männedorf, Switzerland) at 37 ◦C. Fluorescence kinetics were
measured at 5 min reading intervals, with 15 s shaking before each read. The excitation and emission
wavelengths were 440 and 480 nm respectively.
4. Conclusions
Herein, we have described a highly modular branching-type strategy for the synthesis of
biologically interesting and rare triazole-linked flavonoid dimers and trimers by the varied combination
of readily-accessible flavonoid building blocks. Application of this strategy enabled concise and
highly step-efficient access to a structurally diverse library of 46 final compounds, with six different
biologically-relevant flavonoid structural subclasses (chalcone, flavonol, aurone, flavone, coumarin and
isoflavone) successfully incorporated into the library. Each library member features structural motifs
that are associated with biological activity (at least two flavonoid units and a 1,2,3-triazole linkage)
and many also incorporate additional potential biomolecular-interacting elements (for example,
hydrogen-bonding motifs). Many library compounds also feature groups that could provide synthetic
handles for further elaboration or diversification. The synthetic strategy could conceivably be applied
on a larger scale using a greater range of building blocks. However, this current strategy is limited to the
installation of one linker type between the flavonoid units. It may be possible to adapt the strategy to
allow for greater variation in the linker motif (for example, the use of an alternate type of building block
may allow the alkyl chain length to be varied and 1,5-triazole linkages could conceivably be accessed
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though ruthenium-mediated ‘click’ cycloaddition conditions). Such variety may be of value in the
context of biological screening; for example, previous studies of flavonoid dimers have suggested that
linker length variation had a significant effect upon biological activity [14,16]. Preliminary biological
screening of a representative sub-set of compounds has revealed that a selection of the triazole-linked
dimers exhibit moderate inhibitory activity against the aggregation of Aβ42, a process closely linked
with the development of Alzheimer’s disease. Such findings prompt for continued screening of the
entire library and further study of the active scaffolds identified. Milligram (typically multimilligram)
quantities of most final library compounds were isolated, which should provide ample material for
screening in a wider range of biological assays; the systematic modification of any compounds with
interesting properties should be facilitated by the conciseness and inherent modularity of the synthetic
strategy [55]. More detailed biological assessment of the compound library is currently ongoing and
notable results will be reported in due course.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/21/
9/1230/s1.
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